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AAV  Adeno-associated viral vector 
AF   Alexa fluor 
ATMP  Advanced therapy medicinal product 
BEBSS Birmingham Epidermolysis Bullosa Severity Score 
BM  Bone marrow 
BMSC  Bone marrow stem cells 
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DEXA  Dual-energy X-ray absorptiometry 
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DIF  Direct immunofluorescence 
DMEM Dulbecco’s modified eagle’s medium 
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dNTPs  Deoxynucleotides 
EB  Epidermolysis bullosa 
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EC  Extracellular matrix 
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EGF  Epidermal growth factor 
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FISH  Fluorescence in situ hybridisation 
FN  Fibronectin 
FSH  Follicle-stimulating hormone 
GCSF  Granulocyte-colony stimulating factor 
GLP  Good laboratory practice 
GS  Glycine substitution 
GSS  Global severity score 
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HB-EGF Heparin-Binding EGF-like Growth Factor 
HLA  Human leukocyte antigen 
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HPC  Haematopoetic progenitor cells 
IC  Intracellular 
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IL  Interleukin 
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MSC  Mesenchymal stromal (stem) cells 
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NC  Non collagenous 
NHS  Normal human skin 
NS  Not significant 
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qRT-PCR quantitative real-time reverse transcription PCR 
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RNA   Ribonucleic acid 
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SCC  Squamous cell carcinoma  
SD   Standard deviation 
SDS  Sodium dodecyl sulphate 
SEM  Standard error of the mean 
SFFV  Spleen focus forming envelope virus 
SLAM  Signalling lymphocyte activating molecule 
SOP  Standard Operating Procedure 
TBSA  Total body surface area 
TEAE   Treatment-emergent adverse event 
TEM  Transmission electron microscopy 
TGFβ-1 Transforming growth factor beta 1 
TNF-α  Tumour necrosis factor alpha 
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Epidermolysis bullosa (EB) is a group of inherited  mechanobullous disorders characterised by 
trauma induced blistering. One of the most severe subtypes is recessive dystrophic 
epidermolysis bullosa (RDEB). RDEB is due to loss of function mutations in the gene encoding 
type VII collagen (COL7A1), one of the main constituents of anchoring fibrils anchoring the 
basement membrane to the underlying dermis. There is no cure for this devastating condition 
although promising pre-clinical studies for strategies using genetic correction, protein 
replacement, cell therapy or drug therapies are underway.  Reconstitution of COL7A1 
expression in both keratinocyte and fibroblast cell populations has been demonstrated using ex 
vivo gene therapy and hypothesised to lead to new anchoring fibril formation and amelioration 
of disease phenotype. Feasibility of this approach had been demonstrated in pre-clinical studies 
using a retroviral vector, and this work details the development of a phase 1 clinical trial to 
graft an autologous gene corrected skin equivalent graft. Detailed analysis of a cohort of adult 
patients with RDEB was performed in order to identify suitable trial candidates. In addition, 
an alternative strategy using a lentiviral vector encoding codon-optimised COL7A1 developed 
in order to transduce fibroblasts to be administered intradermally was developed.  Expression 
and secretion of full-length de novo C7 was confirmed, with transduced cells exhibiting 
increased levels of protein expression despite only modest transduction efficiencies. This work 
details the journey and obstacles encountered in developing gene therapy clinical trials for 
RDEB, both through the development of a phase 1 study for an autologous gene corrected skin 
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My MD research period started in January 2012 and was completed in January 2015 and details 
only a segment of a long and challenging journey in the development of two phase I clinical 
trials of ex vivo gene therapy for RDEB. My three main goals were to  
• Characterise a UK patient cohort for GENEGRAFT clinical trial 
• Develop a clinical trial of autologous gene corrected fibroblasts for intradermal 
administration in adult patients with RDEB 
• Determine the challenges in developing gene therapy clinical trials for inherited 
skin disorders 
The first part of my thesis presents my work on the GENEGRAFT clinical trial (led by 
Professor Alain Hovnanian at INSERM in Paris) which is a phase I clinical trial awarded an 
FP7 grant in 2009. My role was to primarily characterise a UK patient cohort and preselect the 
most suitable patients for the trial. The trial sponsor was INSERM but KCL/GSTT was a 
clinical site for patient recruitment. At the time of commencing my research project there had 
only been one successful clinical trial of gene therapy in an inherited skin disorder (Mavilio et 
al, 2006). The details of this landmark study are detailed in Chapter 1, but one of the critical 
reasons for success was determined to be suitable patient selection. Patient selection for the 
GENEGRAFT study involved assessing the full UK cohort of patients at GSTT with RDEB 
and assessing according to molecular data and genotyping, immunofluorescence and western 
blot data analysis of amount of C7 expression, clinical features and in particular the presence 
of chronic wounds as well as the likely immune response to a COL7A1 genetically corrected 
skin graft.  
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The second part of my research project involved working with Professor Adrian Thrasher and 
Professor Waseem Qasim at the Institute of Child Health in order to :  
• Provide pre-clinical supportive data for a trial of intradermal allogeneic 
fibroblasts into unblistered skin with adults with RDEB 
• Develop trial documents and work for application to ethics and MHRA for the 
trial 
• Support clinical trial work and recruitment for other inherited skin disorders 
(Netherton syndrome) 
Our own groups have focused on cell therapy, mainly fibroblast therapy. The rationale is based 
on studies showing intradermal injections of normal fibroblasts in mice can generate new  C7 
and AFs at the dermal epidermal junction (Wong et al, 2007). The main limitations of this 
approach are that these foreign cells are rejected within a few weeks only and a more sustained 
engraftment would be preferred. A complementary approach would be the use of gene therapy 
to correct autologous fibroblasts which could then be administered locally intradermally. The 
team at ICH already had a SIN lentiviral vector construct that had been approved for use in the 
UK to treat other conditions such as Wiskott-Aldrich syndrome. Although viral vector titre was 
relatively low, the data showed a reasonable transduction efficiency (up to 20%) and yet led to 
increased levels of C7 in RDEB fibroblasts. In addition I led the initial development of the 
clinical trial protocol as well as the preparation of trial documents facilitating a speedy 







General Introduction and Aims of thesis 
1.1 Skin structure 
The skin constitutes the largest organ of the body and functions as a defensive barrier as well 
as acting as a homeostatic regulator of fluid, electrolytes and temperature. Full skin thickness 
varies between 0.5-4mm depending on the body area and consists of three distinct layers: the 
epidermis, dermis and subcutaneous fat.  
The epidermis is an ectodermally derived stratified squamous keratinising epithelium and the 
principal cells within the epidermis are keratinocytes. The epidermis is highly specialised 
epithelium that is subdivided into 4 layers including the innermost basal cell layer, spinous 
layer, granular layer and outermost stratum corneum. Basal keratinocytes committed to 
terminal differentiation migrate upwards and initiate the process of keratinisation.  The 
epidermis is consistently renewed every 3-4 weeks due to an ever-present supply of epidermal 
stem cells located within niche areas in the epidermis.  
The underlying dense connective tissue dermal layer account for majority of skin’s tensile 
strength and is composed of hair follicles, sweat glands, sebaceous glands and vascular 
networks embedded in a dense extracellular matrix (ECM). Collagens are the main structural 
component and provide a supporting scaffold for extracellular matrices of connective tissues. 
They are typically composed of a collagen triple helical domain which may be further sub-
divided according to their structural and functional characteristics (Shaw and Olsen, 1991). The 





Figure 1.1 Histological appearance of normal skin 
Normal human skin using hematoxylin and eosin staining, bar = 50 μm. The epidermis is composed of four layers 
as shown (the outermost cornified layer, the stratum corneum, the granular layer, spinous layer and the innermost 
proliferating basal layer).  
1.2 Cutaneous basement membrane zone 
The dermal-epidermal junction (DEJ) separates the epidermal and dermal layers. It is 
characterised by downward folds of epidermis called rete ridges which interdigitate with 
upward projections of the dermis called the dermal papillae. The DEJ consists of an extremely 
complex network of interconnecting intracellular and extracellular proteins, termed the 
cutaneous basement membrane zone, that has a typical morphological appearance at the 
ultrastructural level (Eady and Dunnill, 1994). Within this zone different macromolecules 










The basement membrane zone (BMZ) is only visualised via electron microscopy and consists 
of an electron dense zone named the lamina densa, and superiorly an electron lucent zone 
named the lamina lucida, above which lie the basal keratinocytes and keratin intermediate 
filaments. Keratin 5 and 14 are the predominantly expressed keratins within basal keratinocytes 
(Lane et al., 1992).  
The keratin intermediate filaments interact with two of the intracellular proteins found in the 
BMZ are Bullous Pemphigoid Antigen -1, BPAG1e  (also known as BP230) and plectin. BP230 
is an intracellular protein consisting of an N terminal head domain (plakin domain) and a C 
terminus possibly involved in binding keratin filaments (Tang et al., 1996).  More critical for 
hemidesmosome assembly is plectin. Plectin is a large 200-nm-long protein found in the 
innermost portion of hemidesmosomes. This directly links intermediate filaments (IF) to both 
β4 integrin and to the 180-kDa bullous pemphigoid antigen (Koster et al., 2003, Nievers et al., 
2000). At its C-terminus, plectin anchors IF. The N terminus harbours a highly conserved actin 
binding domain (ABD), followed by nine spectrin repeats (Sonnenberg and Liem, 2007) and 
binds to actin, β4 integrin and type XVII collagen (also known as Bullous Pemphigoid Antigen-
2), BPAG2 or BP180. Type XVII collagen is a transmembrane protein which is mostly 
composed of a large extracellular C-terminus domain that is made up of 15 collagenous 
domains. Another important component of the hemidesmosomal outer plaque is α6β4 integrin. 
The β4 subunit has an intracytoplasmic tail domain which interacts with the hemidesmosmal 
proteins BP230, plectin and the cytoplasmic domain of type XVII collagen. The 120 kDa 
extracellular domain forms part of the anchoring filaments and binds to the α6 integrin subunit 
and laminin-332 and crosses the lamina lucida to anchor into the lamina densa.  Collectively 
these proteins constitute the hemidesmosome-anchoring filament adhesion complex. The 
integrins and BP180 also connect to laminin 332, previously known as laminin 5, and along 
with laminin-311 contribute to forming anchoring filaments (Uitto and Pulkkinen, 1996). 
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Laminin-332 is a heterotrimer of 3 polypeptide subunits, α3, β3 and γ2, each encoded by the 
LAMA3, LAMB3 and LAMC2 genes, respectively. Being a major component of anchoring 
filaments, laminin-332 is located primarily in the lower lamina lucida and lamina densa 
(Masunaga et al., 1996). The connection between these proteins and other ubiquitous proteins 
in the BMZ such as nidogen, type IV collagen and laminin-511 form the underlying lamina 
densa (Yurchenco et al., 2002). From the lamina densa, large band like structure loop down 
into the interstial dermal matrix and back up to the lamina densa. These structures are called 
anchoring fibrils and their main constituent is type VII collagen (C7) (Shimizu et al., 1997, 
Burgeson et al., 1990). 
 







Figure 1-3 Transmission Electron Microscopy of the basement membrane zone in 
normal skin 
HD = hemidesmosome, LD = lamina densa, LL = lamina lucida, AF = anchoring fibril, BMZ= basement 
membrane zone, KIF = keratin intermediate filament. Scale bar = 0.5 µm 
1.3 Type VII Collagen 
Type VII collagen (C7) is a genetically distinct collagen found predominantly in the basement 
membrane zone of the stratified squamous epithelia of the skin, mucous membranes and cornea 
(Wetzels et al., 1991). C7 is mainly synthesised and secreted by epidermal keratinocytes and 
also to a lesser degree by dermal fibroblasts (Bruckner-Tuderman et al., 1987). 
C7 is known to be the main component of anchoring fibrils, structures anchoring the basement 
membrane zone to the underlying papillary dermis (Sakai et al., 1982). C7 is composed of three 
identical α chains known as pro-collagen.  Each chain is composed of a central triple helical 













In contrast to other interstitial collagens I-III, C7 has a number of deletions and insertions as 
well as a 39-amino acid non-collagenous insertion in the middle of the collagenous domain 
postulated to confer flexibility to the molecule allowing anchoring the lamina densa to 
underlying dermis (Christiano et al., 1994a, Järvikallio et al., 1997). Once secreted these 
monomers aggregate to form homotrimeric triple helical molecules and are then assembled in 
anti-parallel dimers with overlapping carboxy-terminal ends (Chen et al., 2001). During this 
process, the NC2 domain is proteolytically cleaved off. Subsequently the dimers are stabilised 
by interchain disulphide bonds and then assemble laterally to form anchoring fibrils, providing 
a stable attachment between the lamina densa and papillary dermis.  
C7 is composed of a larger (~145kDa) amino terminal non-collagenous domain (NC-1), a 
central triple helical domain and the smaller (~30kDa) carboxyl terminal non-collagenous 
domain (NC-2). The NC1 domain contains multiple sub-units with homology to known 
adhesive molecules including fibronectin type III-like repeats and the A domain of von 
Willebrand factor (Chen et al., 1997). This larger NC1 domain is known to react with other 
extracellular matrix components including fibronectin, laminin-332, type I collagen (Villone 
et al., 2008), and type IV collagen (Burgeson et al., 1990).  
 




The COL7A1 gene is located on chromosome 3p21. The genomic structure was first fully 
described in 1994 and was demonstrated to have 118 exons, more than any other previously 
described gene (Christiano et al., 1994b). The resultant messenger RNA (mRNA) transcript  is 
~8.9 kb in size and is translated to give a precursor polypeptide, procollagen type VII (α1), 
~300kDa composed of 2944 amino acids (Christiano et al., 1994a). The full length cDNA for 
type VII collagen contains 8833 nucleotides encoding 2944 amino acids. Mutations in COL7A1 
underlie all types of dystrophic epidermolysis bullosa (Uitto et al., 1994). There is also an 
acquired form of this disease that can result from an autoimmune response to C7 (Woodley et 
al., 1984).  
1.4 Epidermolysis Bullosa and related skin fragility disorders 
1.4.1 The classification of Epidermolysis Bullosa 
Epidermolysis bullosa is a group of blistering disorders resulting from mutations in one of 18 
genes encoding extracellular proteins found in the cutaneous basement membrane zone (BMZ). 
Mutations in one of these genes leads to absent or reduced protein levels or the production of 
aberrant non-functioning proteins, and therefore disruption to the integrity of the DEJ. EB was 
first formally classified according to electron microscopic features in 1962 (Pearson, 1962) and 
since then has been further characterised according to clinical phenotyping, 
immunofluorescence mapping and molecular diagnostics. According to the 2008 International 
consensus meeting on epidermolysis bullosa (EB), epidermolysis bullosa can be classified into 
4 major subtypes: epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa 
(JEB), dystrophic epidermolysis bullosa (DEB) and Kindler syndrome (Fine et al., 2008). The 
subtypes can mostly be distinguished by the level of cleavage and blister formation. In EBS, 
the level of separation occurs at the suprabasal layer, in JEB at the lamina lucida and in DEB 
at the deepest level, the lamina densa within the upper papillary dermis. Kindler syndrome is 
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unique with blistering arising in multiple levels within the BMZ rather than within a discrete 
plane. This rare autosomal recessive blistering disorder with only 250 cases reported arises 
from premature termination of translation of kindlin-1 protein caused by mutations in the 
FERMT1 gene (Jobard et al., 2003). Expression of kindlin-1 is localised to basal epidermal 
keratinocytes where it functions as a focal adhesion adaptor protein. The latest classification 
published in 2014 progressively divides each subtype according to phenotype, mode of 
transmission, ultrastructural site of cleavage and associated findings, target proteins, 
mutational type and finally by specific mutation present (Fine et al., 2014); this has been 
referred to as the “onion skin” diagnostic algorithm. A simplified version useful in clinical 
practice is summarised in Table 1.1.   
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EB type EB Simplex Junctional EB Dystrophic EB Kindler syndrome 
Major subtype Suprabasal Basal Generalised Localised Dominant Recessive Generalised 
Level of 
cleavage 







Keratins 5 and 14; 
plectin; exophilin 5 
(Slac2-b); bullous 




α3  integrin 
subunit 
Laminin-332, Type 
XVII collagen, α6β4  
integrin 
Type VII collagen Fermitin family homologue 1 
(kindlin) 
Mutated genes TGM5, DSP, JUP, 
PKP1 














(some sparing of 
palms and soles) 
Palms and soles  Generalised Localised Generalised Generalised Generalised 
Clinical 
features 
Blisters, erosions, crusts, focal/diffuse 
keratoderma usually minimal extracutaneous 









Blisters, milia, dystrophic 
nails, dental caries,  
Blisters, milia, atrophic scarring, 
pseudosyndactyly, soft tissue oral 







Risk of SCC None 18-25% 
lifetime risk 
Rare Rare ++ Main cause of death Increased risk after aged 30 
years 
Death due to 
EB 
None; Uncommon in EBS Generalised Death within 
first 2 years 
(JEB-severe 
generalised) 
Rare Rare Usual life expectancy early 
30s RDEB severe generalised 
(metastatic SCC) 
Uncommon 
Table 1.1 Different subtypes and clinicopathological and molecular subdivision of EB  
Table showing the summary of clinical findings, associated morbidity and mortality, target gene, mutated protein and level of 
blister cleavage according to EB subtype (adapted from Fine et al 2014). Abbreviations: AD = autosomal dominant, AR = 
autosomal recessive, GU = Genitourinary, EBS = Epidermolysis bullosa simplex, JEB = Junctional epidermolysis bullosa, RDEB 
= Recessive dystrophic epidermolysis bullosa, SCC = squamous cell carcinoma 
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1.4.2 Incidence of inherited epidermolysis bullosa 
In the United States, the incidence of all subtypes of EB is estimated at 20 per million 
live births, with a prevalence of 8 per 1 million of the population. Specifically RDEB 
is thought to affect one in every 1 in every 100,000 newborns in the United States 
(Pfendner et al., 2001). A study in Scotland estimated point prevalence to be 
approximately 32 per million of EBS, 26 per million of DEB and 0.4 per million in 
JEB (Horn et al., 1997). In all, there are approximately 500,000 people globally who 
have EB. 
1.4.3 Epidermolysis bullosa simplex 
Epidermolysis bullosa simplex (EBS) is a clinically heterogeneous group of disorders 
characterized by intraepidermal blistering resulting from mutations in genes encoding 
for keratinocyte intermediate filaments; most commonly keratin 5 (K5) and keratin 14 
(K14) (Fine et al., 2014). The most common subtypes are localised, generalised 
intermediate and generalised severe. The phenotype is predominantly mild although 
Generalised Severe EBS (GS-EBS) is frequently associated with marked morbidity in 
infancy and childhood and, in rare cases, may result in death in early childhood 
(Sathishkumar et al., 2016). Recently further work has delineated rare subtypes of EBS 
and demonstrated the role of other important genes and target proteins, such as EXPH5 
encoding exophilin-5 (Liu et al., 2014, Pigors et al., 2014, McGrath et al., 2012) and 
DST encoding BP230 (Groves et al., 2010). Mutations in PLEC and TGM5 as well as 
the desmosomal genes PKP1, DSP and JUP may also underlie a spectrum of EBS 
phenotypes (Indelman et al., 2005, Bolling et al., 2010a, Bolling et al., 2010b, Pigors 
et al., 2011).  
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1.4.4 Junctional epidermolysis bullosa 
Junctional epidermolysis bullosa (JEB) results from mutations in genes encoding for 
proteins forming critical components of the hemidesmosome and anchoring filaments 
and leads to intra-lamina lucida blistering. JEB can be a devastating disorder in the 
generalised severe form and affected individuals rarely survive beyond the age of two 
years. Homozygous or compound heterozygous mutations occur in genes encoding for 
laminin 332 (LAMA3, LAMB3, LAMC2), integrin α6β4 (ITGA6, ITGB4) and type 
XVII collagen (COL17A1). The majority of the mutations occur in LAMB3 but specific 
phenotypes are associated with different gene pathology, such as JEB with pyloric 
atresia in which mutations are found in ITGB4 or, less frequently ITGA6.  
1.4.5 Kindler syndrome 
Kindler syndrome is a recently described additional EB subtype and is due to 
premature termination of translation of fermitin family homologue 1 (also known as 
kindlin-1 protein) caused by mutations in FERMT1 (also known as KIND1) (Ashton 
et al., 2004, Jobard et al., 2003).  This is an autosomal recessive disorder characterised 
by skin fragility, photosensitivity, poikiloderma, skin atrophy and scaling.  
1.4.6 The molecular basis of DEB 
Dystrophic epidermolysis bullosa (DEB) is characterised by a sub-lamina densa plane 
of blistering resulting from abnormal C7 synthesis and aberrant anchoring 
fibrils(Bruckner-Tuderman et al., 1989). Electron microscopy shows that AFs are 
absent, reduced or abnormal in structure or morphology (Hanna et al., 1983, Bruckner-
Tuderman et al., 1990). Disruption of anchoring fibrils due to mutations in C7 is a 
characteristic of dystrophic EB. 
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DEB is therefore due to mutations in the gene encoding for type VII collagen, 
COL7A1. The first mutations in COL7A1 were first reported in 1993 (Christiano 
1993). Currently the International Dystrophic Epidermolysis Bullosa patient registry 
contains detailed information on 669 DEB patients, of which 71 cases are unpublished, 
and their 425 COL7A1 mutations (van den Akker et al., 2011). Globally, however, the 
total number of COL7A1 mutations identified by research and diagnostic laboratories 
probably exceeds 2000.  The autosomal dominant form of the disease, dominant 
dystrophic epidermolysis bullosa (DDEB) is due to missense mutations in the Gl-X-
Y repeat sequence (Dang and Murrell, 2008, Uitto et al., 1994). The autosomal 
recessive form, recessive dystrophic epidermolysis bullosa (RDEB), is generally 
caused by bi-allelic mutations that result in a premature termination codon (PTC) (i.e., 
nonsense mutations, frame-shifting deletions, insertions/duplications, indels, and 
certain splice-site mutations). As a result of mRNA degradation through nonsense 
mediated decay, these patients would have scanty or absent levels of C7 resulting in a 
severe clinical phenotype. Compound heterozygosity including only one non-PTC 
mutation would usually result in the production of varying quantities of C7 which may 
be partially functioning. Typically, this combination of mutations results in a milder 
or intermediate clinical phenotype.  
1.4.7 Recessive dystrophic epidermolysis bullosa 
Patients with generalised forms of RDEB (sev) present with severe cutaneous 
involvement.  The condition is characterised by severe trauma-induced blistering and 
skin erosions from birth or early infancy. Wound healing is often slow, leading to 
chronic erosions, secondary infection and progressing to widespread, mutilating scars 
and contractures. Milia are often present. Trauma-prone areas such as hands, feet, 
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knees, elbows and bony prominences are most commonly affected. Recurrent wound 
infections are a common problem within extensive areas of eroded skin (Pillay, 2008). 
RDEB affects mucous membranes and as such, gastrointestinal complications can 
range from microstomia, oral mucosal fragility, oesophageal strictures to blistering 
anal margins. Constipation frequently occurs. Oesophageal erosions, web and 
strictures cause severe dysphagia which further exacerbates the malnutrition 
(Azizkhan et al., 2006) and patients often require multiple oesophageal dilatations 
under fluoroscopic guidance. Malnutrition is therefore common and compounded by 
the additional nutritional requirements as a result of the continuous disruption skin 
integrity. Malnutrition is further exacerbated by chronic anaemia, often with an iron 
deficiency profile. Although the precise aetiology has not been fully explained, it has 
been postulated that the main causes of this iron deficiency anaemia is continuous 
blood loss from open wounds, poor nutritional intake and anaemia of chronic disease 
(Mellerio et al., 2007). Ophthalmic involvement is common, in particular corneal 
blister formation occurs. Symblepharon formation has a higher incidence in RDEB 
compared to other subtypes of EB and approximately half of all people with RDEB 
have some degree of ectropion (McDonnell and Spalton, 1988).  Genitourinary tract 
involvement is less common and mostly reported in JEB. Urethral meatus stenosis is 
the commonest genito-urinary complication, occurring in 8% of RDEB patients 
(Rubin et al., 2007). Severe constipation in patients with RDEB may also result in 
urinary outflow obstruction with hydroureter and hydronephrosis. 
1.4.8 RDEB, severe generalised (RDEB sev-gen) 
This subtype was previously known as Hallopeau-Siemens recessive DEB (HS-
RDEB) (Fine et al., 2008) and is one of the most severe subtypes of EB associated 
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with high morbidity and premature mortality. Electron microscopy shows absent AFs 
at the DEJ. The cutaneous and extracutaneous features are discussed above. The 
chronic wounds and widespread mutilating scar formation cause considerable 
suffering and have a severe impact on the quality of life. Chronic scarring of the digits 
results in fusion and contraction referred to as mitten hand deformity (McGrath et al., 
1992). Mucous membranes are also affected. Oral involvement leads to ankylostomia 
and microstomia as a result of scarring and skin fragility. Oesophageal involvement 
leads to dysphagia and obstruction because of stricture formation. Malnutrition is 
secondary to these complications as well as the increased nutritional requirements as 
a result of skin barrier failure. Chronic constipation, painful defaecation and faecal 




Figure 1-5 Trunk and limb erosions and chronic wounds in an adult  patient with 
RDEB severe generalised showing extensive ulceration across the torso (courtesy 
of Professor J A McGrath) 
 
One of the main features of this subtype is the high incidence of early-onset squamous 
cell carcinoma (Mallipeddi, 2002). These tumours have a different pathophysiology 
to classical ultraviolet induced SCC and behave aggressively leading to early 
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mortality. One of the explanations for SCC development has been the persistent 
wounding and scarring suffered by those with RDEB, which can theoretically deplete 
basal stem cell progenitors and stimulate a pre-malignant microenvironment (Smoller 
et al., 1990). Additional factors affecting cell cycle regulation such as mutated p53, 
reduced expression of insulin growth factor-binding protein 3 and elevated matrix 
metalloproteinase (MMP-7) expression have been linked to SCC in RDEB patients 
(Martins et al., 2009). Data shows that the median survival from the diagnosis of the 
first SCC is only 5 years and nearly 80% will have died of metastatic SCC despite 
aggressive surgical resection  (Fine et al., 2009, Pfendner and Lucky, 1993, Ayman et 
al., 2002)  
1.4.9 RDEB, generalised other 
This subtype was previously known as RDEB non-Hallopeau-Siemens. The clinical 
phenotype is milder and more limited than RDEB-sev-gen. Electron microscopy 
shows reduced or rudimentary AFs as opposed to absent. Extra-cutaneous features 
including glomerulonephritis, renal amyloidosis, IgA nephropathy, cardiomyopathy, 
delayed puberty and osteoporosis are absent. Although the risk of developing skin 
cancer is also comparatively less, aggressive SCCs still represent a significant cause 
of morbidity and mortality (Fine et al., 2008).  
1.4.10 RDEB, inversa 
The inversa type of RDEB is rare and was first described by Gedde-Dahl Jnr in 1971 
and is characterised by generalised blistering from birth and during early infancy 
(Gedde-Dahl, 1971).  Later in childhood, the affected areas concentrate to the flexural 
sites as opposed to the exposed friction-prone sites. Common sites include the groins, 
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axillae, neck and lumbar area (Fine et al., 2008). Mucosal sites particularly the cornea 
and oesophagus are frequently severely affected.  
 
Figure 1-6 Ulceration and contractures of the fingers in patients with severe 
RDEB 
 (A) chronic scarring, dyspigmentation and mitten hand deformity in adult patient with severe RDEB 






1.5 Management of RDEB 
At present only palliative therapies are available for patients with RDEB. Appropriate 
wound care and daily dressing changes are the mainstay of management. A 
multidisciplinary approach to manage pain control, dental hygiene, chiropody, ocular 
complications, joint contractures as well as psychosocial support and care is absolutely 
essential. The Dystrophic Epidermolysis Bullosa Research Association (DebRA) has 
listed a number of  recommendations including the use of non-adhesive dressings only, 
cautious hand manipulation and exercise to prevent contractures. In addition to wide 
varieties of non-adhesive dressings available, tissue engineered skin substitutes are 
also commercially available. Recently human amniotic membrane grafts have also 
been trialled (Lo et al., 2010) utilising their biological properties to promote wound 
healing. In a retrospective, proof-of-concept study, amniotic membrane grafting was 
efficacious in promoting the healing of non-healing wounds in EB with a reduction in 
pain but complete re-epithelialisation was not achieved.  Before the genetic basis of 
dystrophic EB was discovered, ultrastructural studies indicated possible collagen 
degradation and phagocytosis of collagen fibrils in areas of blistering in RDEB skin. 
Early attempts at systemic treatment for RDEB focused on inhibiting collagenase. 
Anecdotal reports of systemic therapies have cited treatment with tumour necrosis 
factor- α (TNF-α) inhibitor etanercept (Gubinelli et al., 2010), vitamin E (Ayres 1986), 
phenytoin (Rogers et al., 1983, Wirth et al., 1983), mycophenolate mofetil (Eldarouti 
et al., 2013), oral trimethoprim (Lara-Corrales et al., 2012)  and recently systemic 
granulocyte colony-stimulating factor (G-CSF) (Fine et al., 2015); but none has shown 
significant clinical impact. Pre-clinical studies have been reported aiming for cell, 
drug, protein or gene therapies in order to increase levels of C7 at the DEJ and 
ameliorate the phenotype.  
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1.5.1 Cell therapies 
Cellular therapies to repair and restore a defective epithelium are an attractive option 
in the management of RDEB. Initial studies were based on the treatment of burns 
patients and the development of composite skin grafts, including a dermal component 
such as de-epidermized cadaveric dermis, biopolymers, or artificial scaffolds allowed 
for further refinement of cultured skin for clinical use (Auger et al., 2004, Ojeh et al., 
2001). Cultured epidermal keratinocyte grafts were trialled in EB in the early 1990’s 
but success was limited due to the high associated risks of graft infections (McGrath 
et al., 1993, Hill et al., 1992). In one study, cultured epidermal autograft (CEA) was 
manufactured by taking a full-thickness biopsy specimen of skin from an RDEB 
subject and culturing keratinocytes to confluence. The CEA was then grafted onto a 
selected area of ulceration with epithelialisation observed 2 weeks later (Shinkuma et 
al, 2014). Intradermal administration of cellular products is less invasive and 
fibroblasts able to secrete ECM are a possible option. Intradermal allogeneic 
fibroblasts have been used as a therapy for RDEB in both phase I and phase II clinical 
trials in human subjects (Wong et al., 2008, Petrof et al., 2013, Venugopal et al., 2013). 
The initial trial by Wong et al (2008) assessed the effect of single intradermal 
injections of neonatal-derived allogeneic fibroblasts (5 × 106 cells injected into the 
superficial dermis over ~ 1 cm2 )  to intact skin on the backs of 5 patients with RDEB. 
Clinically 3 subjects had RDEB-(sev-gen) with almost completely undetectable levels 
of C7, whereas 2 subjects had RDEB-(gen-intermediate) with reduced levels of C7 
protein still detectable. All 5 subjects demonstrated a 1.5-2 fold increase of C7 at the 
DEJ at 2 weeks and 3 months after injection. Concomitant cultured autologous 
fibroblasts and parental fibroblasts were administered as controls, but it was the 
allogeneic cells that induced greatest expression of C7. Subsequent studies showed 
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that this induction of C7 at the DEJ with subsequent improvement of dermal-epidermal 
blistering at the site of injection was achieved and remained stable for 3 months in 
most cases and up to 9 months in one subject with RDEB with no clinic-pathological 
inflammatory response observed (Nagy et al., 2011). Gene expression profiling 
showed that allogeneic fibroblasts injected directly into the dermis increased 
expression of, among other factors, heparin binding-EGF-like growth factor (HB-
EGF). HB-EGF has been shown to increase COL7A1 gene expression in normal or 
RDEB keratinocytes and fibroblasts, which in turn leads to an increase in expression 
of rudimentary AFs, which stabilise the DEJ and ameliorates the blistering tendency.  
Limitations of this approach are the clearance of allogeneic cells by host immune 
response, as fluorescent in situ hybridizsation (FISH) for the detection of donor Y-
positive cells in a female recipient demonstrated clearance of allogeneic fibroblasts 2 
weeks following administration. Furthermore, the therapy was only effective in 
patients with some level of expression at the DEJ.  It was proposed that either an initial 
burst of C7 from the introduced fibroblasts or a paracrine effect exerted on the 
patients’ keratinocytes stimulating production of mutant protein may have contributed 
to the partial improvement seen. Stimulation of endogenous C7 expression by patients’ 
own cells has been associated with a heparin EGF-like growth factor (HB-EGF) 
induced by fibroblast injections, which in turn leads to an increase in expression of the 
AF forming protein predominantly by the keratinocytes. These findings were further 
supported by a phase II double-blind randomised controlled trial of allogeneic 
fibroblasts administered to chronic wounds in RDEB (Petrof et al., 2013). Petrof et al 
(2013) demonstrated that a single administration of 5 x 106 allogeneic fibroblasts could 
increase the rate of erosion healing in RDEB up to 28 days but not thereafter. A further 
phase II study showed equal increase in wound healing and COL7A1 expression 
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following intradermal administration of allogeneic fibroblasts and a 2% albumin 
suspension solution (Venugopal et al., 2013). The benefits of administering fibroblasts 
as a cell therapy include the ease of access to commercially available fibroblast 
products, the robust nature of fibroblasts in cell culture and an excellent safety profile 
when used for other clinical indications.  
Cell therapies for RDEB have now expanded to the use of bone marrow derived cells, 
including mesenchymal stromal cells (MSCs) and haematopoietic stem cells (HSCs). 
It is now known that bone marrow (BM) cells contribute a proportion of cells in the 
skin that have roles in skin development, homeostasis, repair and regeneration. BM 
cells that are present in skin can be derived from either haematopoietic or 
mesenchymal stromal cell (MSC) populations. Some sub-populations of the BM cells 
can differentiate into skin epithelial cells (keratinocytes) (Fathke et al., 2004a, 
Badiavas et al., 2003, Borue et al., 2004) and also provide fibroblast-like cells to the 
dermis, although their precise nature is not fully understood. Human and murine 
studies involving transplantation of sex-mismatched or genetically-tagged BM cells 
have shown that keratin-positive BM-derived cells can be found in skin epidermis, 
hair follicles and sebaceous glands, sites that contain skin stem cell niches (Brittan et 
al., 2005, Krause et al., 2001). With respect to EB, Chino et al (2008) were first able 
to demonstrate the capacity of bone marrow cells to contribute dermal fibroblasts and 
prolong survival following the transfer of marrow cells from 8-week-old green 
fluorescent protein-positive (GFP+) mice into the circulation of 13-day-old col7a1-/- 
embryos (E-BMT)(Chino et al., 2008). Subsequently subsets of BM-derived cells 
were transplanted into neonatal col7a1-/-mice, with the result that bone marrow-
derived cells migrated to the skin, mediated C7 deposition leading to prolonged 
survival of col7a1 mice (Tolar et al., 2009). These observations of increased C7 in 
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skin BMZ following bone marrow transplant (BMT) thereby provided a rationale for 
BMT to be considered as a potential therapy for humans with RDEB. 
The first bone marrow transplant in human subjects with RDEB were reported in 2010 
(Wagner et al., 2010). Seven patients with RDEB were selected and 6 proceeded with 
allogeneic stem cell transplants following immunomyeloablative chemotherapy 
conditioning using busulphan, cyclophosphamide and fludarabine. 
Immunoprophylaxis against graft versus host disease using ciclosporin and 
mycofenalate mofetil was initiated and continued up to 100 days. In the majority of 
subjects (5 of 6 evaluable individuals), light microscopy demonstrated an increase in 
C7 at the DEJ. Clinically, there was a significant improvement with reduction in the 
amount of blisters and erosions on the skin and mucous membranes, and the physical 
benefits continued for at least 500 days after the BMT. Indeed, follow up for >6 years 
has shown sustained clinical benefits (Tolar et al, 2015). The associated high risk of 
mortality means that other safer alternatives should be explored, such as intravenous 
mesenchymal stromal cell infusions or reduced intensity conditioning (RIC) regimens 
of BMT. Combination conditioning has been reduced from using busulfan, 
fludarabine, and cyclophosphamide to combination therapy with fludarabine and low 
doses of cyclophosphamide and radiation.  The most recent update has reported a 
further 20 patients with RDEB-sev-gen between 0.4 and 20 years who underwent 
allogeneic HCT (Tolar et al, 2015). The hematopoietic graft was HLA-matched related 
BM (n=10), unrelated BM (n=7) or umbilical cord blood (UCB)(n=3). In addition, a 
single infusion of third-party HLA-mismatched MSC was administered. For the entire 
cohort of engrafted, surviving subjects with RDEB thus far (N=18 of 26), 14 
individuals demonstrated partial to marked biochemical and clinical improvement in 
mucocutaneous disease as evidenced by >50% reduction in affected body surface area, 
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and/or C7 expression. Although the reduced intensity conditioning regimen (RIC) had 
a significantly lower risk of morbidity and mortality compared with myeloablative 
conditioning (MAC) (2 year survival 90% with RIC compared with 69% with MAC), 
risks of therapy still remain significant necessitating other separate or adjunctive 
therapies. The incidence of graft versus host disease in this cohort although not 
specified was reported to be unexpectedly low, which may be due to the adjuvant MSC 
infusion or a specific feature of EB patients.  
1.5.2 Protein therapy 
The rationale for protein replacement consists of delivering recombinant human C7 
protein locally or systemically. In 2004, Woodley et al demonstrated unexpected 
efficacy when intradermally injected human C7 was reported to incorporate stably into 
the BMZ of wild-type mice, as well as into regenerated human RDEB equivalent skin 
transplanted onto immune-compromised mice (Woodley et al., 2004a). Remington et 
al (2009) were also able to show incorporation of intradermally injected C7 into the 
BMZ of RDEB mice with restoration of AF structure rescuing the clinical phenotype 
(Remington et al., 2009). Although these mice developed antibodies to the newly 
administered protein, this did not preclude the development of functional anchoring 
fibrils. Although these antibodies were found in the circulation they did not bind to 
the DEJ, therefore unlikely to lead to clinically deleterious consequences (Woodley et 
al., 2004a). Unlike other collagens, C7 is a soluble protein and would therefore be 
possible to administer intravenously. This would be a far preferable option in RDEB 
which has widespread systemic involvement. More recently Woodley et al have 
confirmed that intravenously administered C7 can home to wounds in a murine model 
where it formed AFs and led to improved wound healing (Woodley et al., 2013). 
Before considering phase I studies of intravenous therapy pre-clinical safety and 
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toxicology studies in larger animals may be necessary in order to determine 
appropriate dosing in humans and to investigate the overall risks of the procedure with 
respect to thrombus formation, production of anti-C7 antibodies and C7 deposition in 
vital organs. Momentum had been building for a phase I trial of recombinant C7 
protein (rC7) therapy for RDEB following the commercial backing of Shire’s recent 
acquisition of Lotus Tissue repair specialising in the production of rC7. These plans 
have been put on hold due to severe adverse effects and toxicity encountered during 
testing in larger animal models (no further information available at the moment, Sept 
2016). Furthermore, there have been recent data published regarding the half-life of 
C7 that would impact the schedule for protein therapies. Kühl et al. (2016) attempted 
to determine the half-life of C7 in the skin, tongue, and oesophagus of genetically 
altered mice that express C7 constitutively, but with its expression abrogated by 
genetic manipulation. Their results revealed a half-life much shorter than previously 
anticipated, some 30 days (Kuhl et al., 2016), although it is unknown whether this 
observation will be similar in human skin, and also in patients with continuous wound 
healing and epidermal renewal. Clinical trials in human subjects are needed to answer 
these questions.  
1.5.3 Drug therapies 
Drug therapies such as antibiotics with anti-inflammatory activity have been trialled 
with respect to the promotion of wound healing and reduction of blister formation in 
patients with EBS (Fine and Eady, 1999, Retief et al., 1999, Weiner et al., 2004, Veien 
and Buus, 2000). A proof-of-concept study in RDEB showed improved wound healing 
following oral trimethoprim compared to placebo (Lara-Corrales et al., 2012) but 
further studies are required to prove potential benefit. Newer therapeutic approaches 
are aiming to explore and exploit the observation of elevated TGF-β in acutely injured 
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RDEB skin. Indeed, TGF-β pathways may modulate disease variability. Observations 
of a monozygotic twin pair with RDEB presenting markedly different phenotypic 
manifestations, while expressing similar amounts of collagen VII, highlights the role 
of TGF-β in modifying disease severity (Odorisio et al., 2014).  Genome-wide 
expression analysis in twins' fibroblasts showed differential expression of genes 
associated with TGF-β pathway inhibition. In particular decorin, a skin matrix 
component with anti-fibrotic properties, was found to be more expressed in the less 
affected twin. Longterm use of losartan (diminishing levels of TGFβ and IL6) in 
RDEB mouse models has been shown to reduce scarring and fibrosis (Nystrom et al., 
2015) and is currently being assessed in RDEB in human clinical trials. Although there 
have been some limited studies using standard strategies aiming to target 
inflammatory cytokines, further exciting developments have utilised gene silencing 
mechanisms. Short-interfering RNAs (siRNAs) are double-stranded RNA molecules 
able to target and down-regulate specific genes and can be used to knockdown target 
gene expression, applicable for dominant disorders such as EB simplex and DDEB 
(Atkinson et al., 2011). Drug therapies that induce read-through PTC mutations have 
been developed as potential generic treatments for inherited disorders with nonsense 
molecular pathology, thus some cases of RDEB may also potentially be suitable for 
this approach. Cogan et al (2014) have showed that aminoglycosides (G418, 
gentamicin, and paramomycin) are able to induce PTC read-through and restore a 
functional full-length C7 by increasing the stability of C7 mRNA in RDEB 
keratinocyte cell lines (Cogan et al., 2014). Aminoglycosides such as geneticin, 
gentamicin and paromomycin when transiently delivered in an expression vector can 
mediate “readthrough” of nonsense mutations and restore C7 expression. This group 
has further described the generation of RDEB nonsense mutations by site-directed 
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mutagenesis, the constructs then being transfected into human 293 epithelial cells. 
Without aminoglycosides, these cells produced no C7. By contrast, treatment of the 
cells with aminoglycosides induced C7 expression between 10 and 80% of the level 
of C7 expressed in cells transfected with an expression vector for normal C7. These 
data suggest that aminoglycosides may provide benefit for the 10-15% of RDEB 
patients with nonsense mutations that create premature stop codons synthesising 
minimal or absent C7 (Cogan et al., 2014). Antisense oligonucleotides have been 
developed for RDEB to restore the open reading frame of COL7A1 through selective 
removal of the mutated exon, or by restoring correct splicing (Turczynski et al., 2012).   
In summary promising pre-clinical studies for strategies using protein replacement  
(Woodley et al., 2004a), cell therapy (Woodley et al., 2007, Wong et al., 2008) and 
drug therapies (Shiozuka et al., 2010) are underway. The most considerable progress 
in human subjects has been made in the area of cell therapies for RDEB, using dermal 
fibroblasts (Wong et al., 2008) and most recently bone marrow-derived cells. 
Allogeneic cell therapy is limited by host immune response and cell rejection. Gene 
correction offers great hope for the delivery of autologous cells that would have a 
sustained engraftment and therefore longer lasting clinical benefit. 
1.6 Gene replacement strategies 
In 1989, Rosenberg et al. performed the first human gene therapy trial using a 
retrovirus to introduce the gene coding for resistance to neomycin into human tumour-
infiltrating lymphocytes before infusing them into five patients with advanced 
melanoma (Rosenberg et al., 1990).  Thereafter the first therapeutic gene therapy 
clinical trial was for SCID (Severe Combined Immunodeficiency) caused by 
adenosine deaminase (ADA) deficiency (Blaese et al., 1995) and X-linked Severe 
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Combined Immunodeficiency (SCID-X1). Since these early trials there have been 
continuous improvements in the effectiveness and safety of these viral vector 
technologies to become a significant platform for both basic and clinical research. 
Therapeutic efficacy has now been reported for anti-cancer therapies as well as 
inherited diseases. Inherited diseases treated successfully in clinical trials have 
included chronic granulomatous disease (Kang et al., 2011), Leber’s congenital 
amaurosis (Bainbridge et al., 2008, Maguire et al., 2008), adrenoleukodystrophy 
(Cartier et al., 2012), β-thalassaemia (Cavazzana-Calvo et al., 2010), metachromic 
leucodystrophy (Biffi et al., 2013), Wischott-Aldrich syndrome (Aiuti et al., 2013), 
cystic fibrosis (Alton et al., 2013) and haemophilia B (Nathwani et al., 2011). The 
spectrum of acquired disorders currently being targeted with gene therapies is vast  
including neurodegenerative disorders, Alzheimers disease (Tuszynski et al., 2015), 
cancers (Buscail et al., 2015)  and HIV (Mitsuyasu et al., 2009). Overview of progress 
made in gene therapy clinical trials is available on a searchable database at: 
http://www.wiley.co.uk/genmed/clinical. As of June 2012, 1843 trials had been 
undertaken worldwide in 31 countries (Ginn et al., 2013). Currently there are 1172 
clinical trials actively recruiting patients for gene therapy phase I/II studies 
(www.clinicaltrials.gov 12th September 2016). Despite the large number of clinical 
trials to date, only one gene therapy product (Glybera®) has been approved for clinical 
applications (Yla-Herttuala, 2012). Alipogene tiparvovec (Glybera) is a gene therapy 
product approved in Europe under the "exceptional circumstances" pathway as a 
treatment for lipoprotein lipase deficiency (LPLD), a rare autosomal recessive 
disorder resulting in chylomicronemia and an associated increased risk of acute and 
recurrent pancreatitis, with potentially lethal outcome. The product is an intramuscular 
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injection of a recombinant adeno-associated viral vector (AAV) containing the 
Ser(447)X variant of the human lipoprotein lipase (LPL) gene (LPLSer(447)X).  
1.6.1 Viral vector mediated gene therapy 
Viruses are efficient biological vehicles that have sophisticated machinery to enable 
access to cells to exploit their own cellular mechanisms for replication. The use of 
viruses in gene therapy is achieved by harnessing their ability to integrate into the 
genome but avoid the viral genes leading to replication and cell death. The two 
components of viral vector gene delivery systems are a) the vector construct and b) 
the packaging elements which form the structural proteins, envelope and enzymes 
necessary to generate infectious particles. 
The number of viruses under development as gene therapy vectors is expanding but 
the main classes are oncoretroviruses, lentiviruses, adenoviruses, adeno-associated 
viruses and herpes simplex-1 viruses. Only oncoretroviruses and lentiviruses can 
integrate into host cellular chromatin and would therefore be suitable for tissue with 
high cellular turnover to achieve reproducible and stable gene expression. 
Furthermore, retroviral and lentiviral vectors have not been shown to induce a 
significant host immune response in comparison to adenoviral vectors (Worgall et al., 
1997). Vectors derived from the retroviridae family are nowadays among the most 
widely used. The retroviridae family comprise a group of positive-sense single-
stranded (ss) RNA diploid viruses, roughly spherical in shape which stably integrate 
a cDNA copy of their RNA genome into the host cell chromosomes by use of reverse 
transcription and integration. Up to 70% of gene therapy clinical trials thus far have 
utilised viral vectors. Almost 20% of these vectors are gamma retroviral vectors. 
Retrovirus’ have a unique life cycle (RNA genome-DNA genome - RNA - Protein) 
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and are divided into 7 genres: simple (alpha, beta, gamma or epsilon) and complex 
(delta, lenti and spira). The most commonly used are gamma retroviral vectors as well 
as lentiviral vectors. 
1.6.1.1 γ-retroviral vectors 
Moloney murine leukemia virus (MLV) based γ-retroviral vectors have been 
commonly used to transfer genes into dividing cells and was the vector used in the 
first successful gene therapy clinical trial in X-linked SCID (Cavazzana-Calvo et al., 
2000). Limitations of oncoretroviral systems include poor translocation across intact 
nuclear membranes and a tendency for transgene ‘silencing’ over time (Fenjves et al., 
1996). In addition, conventional murine retroviral vectors have been shown capable 
of mediating insertional mutagenesis in clinical gene therapy studies (Hacein-Bey-
Abina et al., 2003). Retroviral vectors favour integration within 5kB of transcriptional 
start sites (Wu et al., 2003). Integration close to cellular proto-oncogenes can lead to 
the trans-activation of those genes through the action of strong enhancer/promoter 
elements contained within the viral long terminal repeat (LTR)(Lazo et al., 1990). 
Genotoxicity is thought to derive from the long distance, cis-acting activity of the long 
terminal repeat (LTR) U3 enhancer combined to a target site selection mechanism that 
preferentially integrates close to transcriptional start sites and transcriptional 
regulatory elements (Wu et al., 2003, Bushman et al., 2005). A strategy to prevent this 
LTR activity is to delete the enhancer/promoter sequences from the U3 region, termed 
self-inactivating (SIN) vector design (Yu et al., 1986). Another issue in the use of both 
gamma retroviral and lentiviral vectors is the risk of transgene silencing via repressive 
DNA epigenetic effects including histone modification and DNA methylation (Bestor, 
2000).  A recent clinical trial for X-linked chronic granulomatous disease (X-CGD) is 
an illustration of this mechanism having a negative impact on clinical trial outcome. 
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In this study, two young adults treated for X-CGD using an infusion of autologous 
CD34+ cells gene corrected ex vivo using a γ-retroviral vector (Ott et al., 2006). This 
viral vector contained a spleen focus forming virus (SFFV) promoter enhancer 
element within the LTR to drive the therapeutic transgene (gp91phox cDNA). After 
the initial resolution of bacterial and fungal infections, both subjects showed silencing 
of transgene expression due to methylation of the viral promoter, and myelodysplasia 
with monosomy 7 as a result of insertional activation of ecotropic viral integration site 
1 (EVI1). One subject died from overwhelming sepsis 27 months after gene therapy, 
whereas a second subject underwent an allogeneic HSC transplantation (Stein et al., 
2010). These outcomes of trials using MLV based classical γ-retroviral vectors were 
a major stumbling block in the road towards the development of human gene therapy 
clinical trials. Over the last 5 years SIN lentiviral vectors have been developed and 
shown to be safer with reduced genotoxic potential.  
1.6.1.2 Lentiviral vectors 
The lentiviral vectors used for gene transfer are derived from the Human 
Immunodeficiency Virus (HIV). These are single stranded RNA viruses, capable of 
entry into mammalian cells and propagate via chromosomal integration (Barre-
Sinoussi et al., 1983). The integrated form of HIV-1, also known as the provirus, is 
approximately 9.8 kilobases in length (Muesing et al., 1985). The HIV genome 
encodes at least 9 different proteins: (1) the major structural proteins gag, pol and rev; 
(2) the regulatory proteins tat and rev; and (3) the accessory proteins vif, vpu, vpr, and 
nef. A viral core is formed encapsulated by two distinct protein shells, and enveloped 
by host cell lipid membrane. There are seven stages within the life cycle of the virus: 
attachment, entry, reverse transcription, nuclear import, proviral integration, 




Figure 1-7 Illustration of the HIV-1 life cycle (adapted from Rambault 2004) 
 
The viral proteins required for delivery into the nucleus and integration are carried into 
the cell by the virion, and appear to remain associated with the intracellular replication 
intermediates through the steps leading to integration. 
Lentiviral vectors have been shown to be able to transduce quiescent or minimally 
stimulated cells (Zufferey et al., 1998a) in contrast to their γ-retroviral counterparts. 
This property relies on the use of a nuclear import pathway enabling the viral DNA to 
cross the nuclear membrane of the host cell, facilitated by the pre-integration complex 
(PIC) (Miller et al., 1997).  This is important considering that for a longer term 
correction of phenotype, it is necessary to target the slow cycling stem cell 
populations. The main vectors used are derived from the HIV-1 virus and use a third 
generation HIV lentiviral vector system. In the second generation lentiviral vector 
system, five of the nine HIV-1 genes are eliminated, retaining genes for virion 
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structural proteins and enzymes (gag/pol) and genes relating to transcriptional and 
post-transcriptional functions (tat and rev). These vectors are produced with a 3 
plasmid packaging system. The latest third generation vectors have further HIV-1 
genes deleted leaving only gag, pol and rev and are produced using a four-plasmid set. 
This vector generation has been designed using a chimeric LTR (long terminal repeat) 
ensuring transcription in the absence of tat (Dull et al., 1998a). As a result, this vector 
system possesses a higher safety profile and is more suitable for clinical applications 
(Montini et al., 2006). The trial using an HIV based, lentiviral vector system reported 
the successful treatment of two children with X-linked adrenoleukodystrophy (X-
ALD) using a vector encoding the deficient peroxisomal adenosine triphosphate–
binding cassette transporter protein ABCD1 (Cartier et al., 2012). Despite the use of a 
lentiviral vector that contained an internal viral LTR to drive transgene expression, no 
clustering of vector insertions in oncogenes or growth-related genes was observed. 
This study paved the way for further trials for a wide variety of disorders including 
Wiskott-Aldrich syndrome (Aiuti et al., 2013), metachromic leukodystrophy (Biffi et 








Figure 1-8 The HIV virion and genome organisation 
(A) The structure of the HIV virion showing the viral envelope containing the matrix proteins and 
nucleocapsid. (B) The HIV genome organization is shown in this scheme from 5' to 3' end as found in 
the integrated provirus. The 5' long-terminal repeat (LTR) is subdivided in three functional regions; the 
U3 (HIV promoter), the R and U5 regions.The 5' LTR is followed by the packaging signal (ψ), which 
directs the specific packaging of the HIV genome into the lentivirus particles, and the Gag-Pro-Pol and 
Env genes. The distribution of the HIV-1 regulatory/virulence accessory genes vif, vpr, vpu, nef, rev, 





The development of biosafety safeguards have led to the development of third 
generation and now fourth generation lentiviral vectors. The packaging unit of the first 
generation of HIV based vectors comprised all proteins except the envelope (Naldini 
et al., 1996a). The next generation of safety measures ensured deletion of four 
additional genes, encoding pathogenic virulence factors: Vpr, Vif, Vpu and Nef. 
(Zufferey et al., 1997). Third generation vectors conserve only three of the nine genes 
present in parental virus genome: gag, pol and rev (Dull et al., 1998b).  
 
Wild type vector showing major structural proteins gag, pol and rev; the regulatory proteins tat and rev; 
and the accessory proteins vif, vpu, vpr, and nef.  The packaging signal (Ψ) and central polypurine tract 
(cppt) are indicated together with the U3, R, and U5 regions of the 3’- and 5’- long terminal repeats (LTR). 
The lentiviral vector shows the modified U3 region (∆U3) in the 3’-LTR. Figure courtesy from Dr M. 
Antoniou. 
Integration mapping has shown that HIV based lentiviral vectors integrate at gene rich 
sites but do not cluster around transcription start sites in the same manner as gamma 
retroviral vectors in haematopoietic progenitor cells (Cattoglio et al., 2010). To 
improve the biosafety profile, self-inactivating vectors (SIN) have been developed. 
These vectors contain deletions of the regulatory elements in the downstream 3’ long 




terminal-repeat sequence (LTR), eliminating the transcription of the packaging signal 
required for vector replication (Zufferey et al., 1998b). 
1.7.2 Promoter elements 
Strong viral promoters are required for efficient viral induction and propagation. Viral 
promoters include cytomegalovirus immediate early (CMV-IE) promoter, the simian 
virus 40 (SV40), rous sarcoma virus long terminal repeat (RSV-LTR), moloney 
murine leukaemia virus (MLV) LTR and other retroviral LTR promoters. Their use in 
vitro has been widespread however there is considerable evidence that viral promoters 
are prone to inactivation and silencing in vitro and in vivo, either via specific down-
regulation by interferons (Acsadi et al., 1998, Ghazizadeh et al., 1997) or other 
additional complex silencing mechanisms (Prasad Alur et al., 2002). The use of 
eukaryotic promoters, such as the non-tissue specific phosphoglycerate kinase 
promoter (PGK) or the human elongation factor 1α short promoter (EF1α) may confer 
a greater advantage in achieving long-term trans-gene expression in vivo and have 
been shown to be reduce the genotoxic risks due to insertional mutagenesis and 
activation of proto-oncogenes (Zychlinski et al., 2008).  
1.7.3 Enhancer Element 
Enhancers are among the set of eucaryotic promoter elements that appear to increase 
transcriptional efficiency in a manner relatively independent of their position and 
orientation with respect to a nearby gene. The prototype enhancer, the 72 bp tandem 
repeat of SV40 DNA is located more than 100 nucleotides upstream from the cap site of 
the early viral genes and was found to be required in cis for efficient gene transcription 
(Swimmer and Shenk, 1984). In current gene therapy clinical trials the CMV enhancer 
element is most frequently used as it has been shown to increase transgene expression 
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level under the control of a variety of different tissue specific promoters in different cell 
types (Powell et al., 2015). 
1.7.4 Cassette 
Woodchuck hepatitis virus post-translationally regulated element (WPRE) is an RNA 
element shown to enhance protein expression (Donello et al., 1998). Insertion of the 
WPRE in the 3' untranslated region of coding sequences carried by either 
oncoretroviral or lentiviral vectors substantially increased their levels of expression in 
a transgene-, promoter- and vector-independent manner (Zufferey et al., 1999). Use of 
the WPRE in SIN-LV enhances titre levels and ensures stably transmitted vectors with 
high-level erythroid-specific expression for gene therapy of red cell diseases (Moreau-
Gaudry et al., 2001). 
1.7 Gene therapy strategies for RDEB 
The use of gene therapy for RDEB mitigates the risks associated with HLA-
mismatched allogeneic cell transfer. In order to transfer genetic material, gene delivery 
vehicles such as viral vectors or non-viral transposon systems or phage mediated 
transfer have been used. 
1.7.1 Non-viral vectors  
The use of bacteriophage delivery systems have been shown to be a relatively safe 
method of gene delivery (Larocca and Baird, 2001). The φC31 based integrase vectors  
have been effectively used and showed correction of RDEB phenotype in vitro (Ortiz-
Urda et al., 2002a). Primary RDEB epidermal keratinocytes were transfected with a 
stably integrating transfer vector encoding COL7A1 cDNA driven by a CMV promoter 
and a φC31-integrase expression plasmid. Cells were then enriched using blasticidin, 
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a selective antibiotic, following transfection in order to enrich the transfected cell 
population. Skin regenerated using these cells displayed stable correction of hallmark 
RDEB disease features, including C7 protein expression and AF formation. This 
approach was also then applied to RDEB fibroblasts with impressive results showing 
that corrected intradermal fibroblasts were able to restore dermal-epidermal adhesion 
in a scid/scid xenograft mouse model (Ortiz-Urda et al., 2003a). In addition, there was 
a small encroachment of correction beyond the initial site of intradermal 
administration, perhaps due to overexpression of C7 in engineered fibroblasts. 
Importantly this study also demonstrated the superiority of autologous gene corrected 
fibroblasts in terms of C7 delivery compared with normal allogeneic cell (Ortiz-Urda 
et al., 2003a). More recently polymer mediated technology has been used to transfect 
RDEB cells with a full length COL7A1 transcript (Cutlar et al., 2015). Highly 
branched poly (β-amino ester) HPAE can mediate a 22.3 and 3-4 fold increase in 
transfection efficiency in keratinocytes with lower cytotoxicity than previous 
commercial plasmid measures. Further approaches have also included Spliceosome-
mediated RNA trans-splicing (SMaRT) which is an RNA-based technology to 
reprogramme genes for diagnostic and therapeutic purposes. SMaRT protocols have 
recently been used for in vitro phenotypic correction of a variety of genetic disorders 
and have been recently been applied to epidermolysis bullosa. Peking et al (2016) have 
used this system to restore C7 expression in murine keratinocytes. Using SMaRT  
model systems they were able to design a 5’RNA trans-splicing molecule capable of 
replacing COL7A1 exons 1-15. These were transferred to murine skin using 
minicircle-coated gold particles. The novel non-invasive and pain-free administration 




1.7.2 γ-retroviral vectors for RDEB 
γ-retroviral vectors are the most widely used vehicles in human gene trials (Khavari 
et al., 2002, Gache et al., 2004a) and have been used to transduce keratinocytes with 
COL17A1 (Seitz et al., 1999), LAMB3 (Vailly et al., 1998), ITGB4 (Dellambra et al., 
2001) as well as COL7A1. Most retroviral vectors only have the capacity for 7-8kb 
and therefore use of these vectors in RDEB had been limited by the large size (9.2kb) 
of the COL7A1 cDNA. In order to overcome this challenge Chen et al (2006) 
developed a truncated recombinant type VII mini-collagen containing the intact non-
collagenous domains, NC1 and NC2, and part of the central collagenous domain minus 
a 683-amino acid in-frame deletion (deletion from amino acids 1920 to 2603). (Chen 
et al., 2000a). Retroviral-mediated transduction of the minigene construct into RDEB 
keratinocytes (C7 null) resulted in persistent synthesis and secretion of a 230-kDa 
recombinant mini-collagen VII. However, the consequences and efficiency of 
truncated proteins has yet to be demonstrated. An alternative method of gene 
correction could be through the use of trans-splicing technology. Trans-splicing is a 
gene repair mechanism, using the cell’s spliceosome to recombine an endogenous 
target pre-mRNA and an exogenously delivered RNA molecule called pre trans-
splicing molecule (PTM) (Murauer et al., 2011). Gene correction of RDEB patient 
keratinocytes was achieved by 3 trans-splicing in which intron 64 was specifically 
targeted, allowing the reduction of 9.2-kb COL7A1 cDNA to a 3.3-kb transgene. Thus 
this mechanism could feasibly correct the phenotype of RDEB keratinocytes with 
mutations downstream of exon 65.  
Studies using a canine RDEB model were able to demonstrate efficient transfer the 
full length 9-kb COL7A1 cDNA into keratinocytes and achieve correction of  RDEB 
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phenotype in vitro (Baldeschi et al., 2003). Full length COL7A1 cDNA was packaged 
using two vector backbones LZRS-Col7 and MSCV-Col7 (murine stem cell vector). 
Transduction with the MSCV-Col7 vector yielded a range of 83–93% positive cells 
compared with 40-60% using the LZRS-Col7 vector; the highest efficiencies obtained 
with the retrovirus pseudo-typed with the MLV amphotropic envelope. Gache et al 
(2004) expanded on this further and showed that transplantable fibrin-based skin 
equivalents made with the transduced RDEB keratinocytes and grafted onto SCID 
mice generated cohesive and normal stratified epithelia including rapid formation of 
AFs (Gache et al., 2004a). The same group then was able to transplant the skin 
equivalents onto two dogs to demonstrate the longevity of the genetic correction. In 
the first animal, the grafted epidermis firmly adhered to the dermis throughout the 24-
month follow-up, which correlated with efficient transduction (100%) of highly 
clonogenic epithelial cells and sustained transgene expression. In a second dog less 
efficient (65%) transduction of primary keratinocytes resulted in a loss of the 
transplanted epidermis and graft blistering 5 months after transplantation (Gache et 
al., 2011). These disparate findings highlight an important issue of target cell selection 
and the importance of stem cell selection for autologous skin equivalent grafts 
incorporating epidermal keratinocytes ie possible inefficient targeting of highly 
clonogenic keratinocyte stem cells, key in providing the auto-renewal capacity of the 
grafted tissue. 
The use of classical γ-retroviral vectors is limited in clinical trials due to the known 
risks of insertional mutagenesis. Titeux et al. (2010) have been able to demonstrate 
the use of safer SIN retroviral vectors encoding the full-length COL7A1 cDNA driven 
by two alternative human endogenous promoters COL7A1 or EF1α (Titeux et al., 
2010).  Using these vectors efficient titres of viral supernatant were generated without 
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necessitating antibiotic selection. Primary RDEB keratinocytes and fibroblasts were 
transduced with high efficiencies (30-80% of keratinocytes and 38-70% of fibroblasts) 
and were able to show long-term restoration of phenotype using human skin 
equivalents grafted onto nude mice. The titre of their retroviral vector was far superior 
to the lentiviral equivalent, however the main concern had been the risk of gene and 
protein rearrangements. This work has then formed the basis of the development of a 
phase I clinical trial discussed within this thesis.  
1.7.3 Lentiviral vectors for RDEB 
Concerns regarding the pro-oncogenic potential of γ-retroviral vectors following the 
SCID-X cases (Hacein-Bey-Abina et al., 2003) then led to further developments and 
trials of safer lentiviral vectors. As well as the drive for safer constructs, lentiviral 
vectors have been shown to have greater efficiency for transduction of wild type 
clonogenic primary keratinocytes (Gagnoux-Palacios et al., 2005), their main 
advantage being due to the ability of lentiviral vectors to transduce both dividing and 
non-dividing cells (Naldini et al., 1996b).  
RDEB keratinocytes and fibroblasts have been successfully transduced in vivo with a 
SIN lentiviral vector containing full-length COL7A1 transgene (Chen et al., 2002b). 
This vector contained a murine LTR based internal promoter designated MND 
(modified from the murine leukaemia virus) which contained altered methylation 
target sites and negative control elements within the promoter that have been shown 
to be resistant to silencing in mouse stem cells in culture and in vivo. Gene transfer 
done at multiplicities of infection (MOI) of 25 achieved >95% efficiency in unselected 
RDEB cells with no immunostaining detected in the parent RDEB cells. Correction 
was sustained for up to 5 months in vitro. The gene corrected cells were also used to 
regenerate a human skin equivalent which was then grafted onto mice. C7 expression 
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at grafted sites was shown to be comparable to normal controls. Woodley et al (2003) 
have also transduced fibroblasts using a SIN-lentiviral vector expressing COL7A1 
cDNA under the control of retroviral-MND promoter demonstrating that the 
intradermally injected fibroblasts synthesised and secreted C7 for up to 4 months 
leading to anchoring fibril formation at the DEJ. Furthermore, intradermal 
administration of  5 x 106 of gene corrected fibroblasts alone could lead to sustained 
C7 expression, without the need for reconstituted keratinocytes (Woodley et al., 2003). 
The same group then developed an alternative in vivo strategy administering the 
lentiviral vector directly into skin (Woodley et al., 2004b).  VSV-G-pseudotyped LVs 
expressing human C7 intradermally were injected into the skin of athymic hair-less 
mice and also into an RDEB skin equivalent grafted onto a nude mouse. Skin biopsies 
taken up to 12 weeks after only one administration of LV vector showed sustained C7 
expression. Interestingly there was only minimal transduction of epidermal 
keratinocytes following the direct transdermal approach, presumably due to the large 
vector particles being blocked by the DEJ proteins. Although this approach is more 
straightforward than the ex vivo strategy, the concerns regarding bio-safety would add 
regulatory limitations on clinical trials utilising this method.  
 
1.7.4 Autologous cultured skin grafts 
In 1975,Rhinewald and Green first published their discovery that epidermal 
keratinocytes could be cultured in vitro (Rheinwald and Green, 1975). Subsequently, 
the development of tissue culture techniques led to revolutionary therapies for the 
management of burns victims (Gallico 1984). Cultured epidermal grafts also have 
been shown to promote re-epithelialization in some genetic skin diseases associated 
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with chronic wounds, including epidermolysis bullosa (McGrath et al., 1993, Hill et 
al., 1992, Roseeuw et al., 1994). The premise of using an autologous cultured skin 
graft following ex vivo gene transfer is fascinating. Thus far, the only successful 
clinical trial of ex vivo cutaneous gene therapy was in a 36 year old male man with 
generalised intermediate JEB (Mavilio et al., 2006). This form of JEB displays 
generalized blistering, nail loss and alopecia. Pathogenic mutations occur in LAMA3, 
LAMB3, LAMC2, and COL17A1, encoding for proteins critical for hemidesmosome 
assembly at the dermal-epidermal junction. The particular individual studied was a 
compound heterozygote for two mutations in LAMB3, encoding the β3 polypeptide of 
laminin-332.  Keratinocytes cultured from an acral skin biopsy were transduced with 
a Molony leukaemia virus (MLV) retroviral vector carrying full length LAMB3 cDNA. 
Finding sufficient holoclones necessary for epidermal graft generation was difficult: 
ideal cells were only cultivated from the palm, all other biopsy sites showing marked 
stem cell depletion. Nine epidermal grafts using these genetically corrected cells were 
surgically grafted onto prepared areas on the upper thigh. Wound beds were prepared 
using Timedsurgery (electrosurgery) (Guerra et al., 2000). The regenerated epidermis 
healed well and remained blister free with no evidence of graft infection or adverse 
immune response. Furthermore, quantitative PCR analysis and immunofluorescence 
studies up to 12 months following surgery showed full-length laminin-332 protein 
expression as well as continued transgene expression. Follow-up 7 years post-grafting 
confirmed that the regenerated skin still expressed normal amounts of laminin-332 
with phenotypically resilient, non-blistered grafted skin (De Rosa et al., 2014) . At this 
stage further patient recruitment was halted in order for the cell therapy facility in 
Modena to conform to the 2007 EU directive 1394 imposing Good Manufacturing 
Practices for advanced Medicinal Products.  There were also concerns regarding the 
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genotoxic potential of classical MLV- retroviral vectors. Insertional activation of a 
T cell proto-oncogene has been correlated with the occurrence of lymphoproliferative 
disorders in gene therapy trials of X-linked severe combined immunodeficiency (X-
SCID) (Hacein-Bey-Abina et al., 2003 and Hacein-Bey-Abina et al., 2008) and 
Wiscott-Aldrich syndrome (WAS) (Aiuti et al., 2012 and Boztug et al., 2010). The 
trial was suspended pending further development of safer SIN vectors in order to 
minimize the possible risks of insertional mutagenesis.  One further patient with JEB 
has been treated in Austria using the same vector for cell transduction as well as the 
same grafting methodology (Murauer et al., 2015). Five skin sheets each measuring 5 
x 7 cm were grafted onto the patients’ thighs. Data concerning the 1-year post 
transplantation follow-up are yet to be published.  
More recently, Siprashivili et al (2014) have now provided the first reports of the first 
subject enrolled for Phase I trial of genetically corrected autologous epidermal 
keratinocyte sheet for adults with RDEB trial in Stanford, USA (NCT01263379). 
Their study uses epidermis regenerated from retrovirally transduced autologous 
keratinocytes, LZRSE-COL7A1 Engineered Autologous Epidermal Sheets (LEAES). 
The first subject was a 23 year old man with severe RDEB with truncated C7 
expression and sparse rudimentary AFs visible on electron microscopy. Six ~35cm2 
autologous epidermal sheet grafts were grafted onto prepared wound beds. Thirty days 
following grafting the skin was clinically normal and on biopsy robust C7 expression 
was detectable (Siprashvili et al., 2014). This study is currently still recruiting and 
aiming to treat up to 5 patients. 
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1.7.5 Genome editing 
Genetic manipulation to rescue disease phenotype has now progressed to include gene 
editing, using innovative technologies such as zinc finger nucleases (ZFN), 
transcription activator like effector nuclease (TALEN), the clustered regularly 
interspaced short palindromic repeats (CRISPR)-Cas9 nuclease systems and 
meganucleases. The general mechanism aims to correct a mutation by providing a 
template for repair via homologous recombination (HR). Engineered nucleases are 
used as “molecular scissors” to generate a double stranded DNA break (DSB) at a 
specific location within the genome, subsequently promoting correction by HR with 
an exogenous DNA repair matrix (Urnov et al., 2005). Over the past 5 years, the 
potential of such gene editing strategies to correct inherited disorders at a pre-clinical 
level, both in animal models and human cells, has been demonstrated (Genovese et 
al., 2014, Lombardo et al., 2007).  Hockemeyer et al were able to demonstrate the use 
of TALEN nucleases in genome editing of human iPSC cells (Hockemeyer et al., 
2011). These technologies have been optimized to correct mutations in the genes for 
keratin 14 (Wally et al., 2010), collagen XVII, plectin (Wally et al., 2008) and collagen 
VII (Osborn et al., 2013b) in vitro. 
Izmiryan et al (2016) have recently demonstrated the feasibility of correcting COL7A1 
mutations using meganucleases (MNs) to mediate HR (Izmiryan et al., 2016). They 
used integration-deficient lentiviral vectors for delivery of meganucleases, the 
expression of which was controlled by EF1 promoter. COL7A1 correction in primary 
RDEB-K and RDEB-F carrying a homozygous null mutation (c.189delG; 
p.Lys64Trpfs*40) in exon 2 was achieved and no off-target activity was detected, 
although gene correction efficiency was low (<10% transcript correction). In addition 
to the plethora of nuclease technologies that have developed over the last 5 years, 
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AAV viral vectors previously used within gene therapy trials have been used as part 
of gene editing strategies. The transgene capacity is sufficient to contain ZFN 
monomers as well as donor constructs, and this approach has been used successfully, 
one of the main advantages being the minimisation of delivered viral particles to the 
cell which have been shown to cause significant toxicity (Ellis et al., 2013). Sebastiano 
et al (2014) have also used recombigenic species of adeno-associated virus to 
genetically edit COL7A1 mutations (Sebastiano et al., 2014). Two patient derived 
RDEB cell lines with mutations in exons 2 and 3 of the COL7A1 locus were targeted 
by an AAV mediated system that spanned 6 exons and contained 1.4 kb targeting arms 
on either side of a central puromycin selection cassette. Southern blotting and Sanger 
sequencing confirmed an absence of random integration events within the COL7A1 
locus. The corrected cell types in these experiments were iPSCs derived from RDEB 
keratinocytes and fibroblasts, which were then transformed into corrected 
keratinocytes. These were used to create autologous epithelial grafts with normal C7 
composition. This approach has also been demonstrated in cells derived from a patient 
with generalised severe JEB. Melo et al (2014) used recombinant adenoassociated 
virus mediated HR to correct mutations at the LAMA3 locus in primary keratinocytes 
(Melo et al., 2014). Critical to the development of the use of AAV platforms would be 
to maximise rates of homology-directed repair by using nucleases to generate DNA 
breaks (Miller et al., 2003). Thus far there have been no proposed phase 1 clinical 
trials for these editing platforms, and further work needs to be done to improve the 
correction efficiency, compare the technologies within the same disease and ensure 
sufficient safety data necessary from a regulatory aspect.   
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1.7.6 Revertant mosaicism – “natural gene therapy” 
Revertant mosaicism (RM) refers to the coexistence of cells in one individual carrying 
germline mutations together with cells in which the inherited, disease-causing 
mutation is corrected by a spontaneous genetic event resulting in partial or complete 
restoration of phenotype. These corrected cells are termed “revertant”. Several 
mechanisms can account for RM, including a reverse point mutation, crossing-over, 
gene conversion, and a second-site mutation (Jonkman et al., 1997). The first 
description of RM in human skin was reported by Jonkman et al (1997) in a 28 year 
old woman with autosomal recessive JEB and a compound heterozygous mutation in 
COL17A1 (Jonkman et al., 1997).  The mechanism behind this gene conversion was 
reciprocal transfer of part of the parental allele leading to loss of heterozygosity in the 
patches of normal appearing skin. The most common mechanism for reversion has 
recently been suggested to be mitotic recombination. Kiritsi et al (2014) described one 
of the largest cohorts of DEB patients with revertant mosaicism and determined that 
back mutation/mitotic recombination to be the underlying mechanism in up to 70% of 
cases and second site mutations affecting splicing in up to 30% (Kiritsi et al., 2014). 
RM has been reported to occur most commonly in JEB COL17A1 (Pasmooij et al., 
2007), but has also been found in the skin of patients with mutations in KRT14 
(Schuilenga-Hut et al., 2002), LAMB3 (Pasmooji 2005), FERMT1 (Lai-Cheong et al., 
2012, Kiritsi et al., 2012) as well as COL7A1 (Almaani et al., 2010, Pasmooij et al., 
2010, van den Akker et al., 2015). Although C7 is synthesized and secreted by both 
keratinocytes and fibroblasts, evidence for reversion has only been found in 
keratinocytes. This mechanism offers a unique opportunity for the use of revertant 
cells in autologous cell based therapies for RDEB, and yet attempts for culture of 
revertant keratinocytes and subsequent grafting have been unsuccessful (Gostynski et 
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al., 2009). Gostynski et al attempted this technique in a patient with JEB, however a 
biopsy taken from a patch of skin with ~30% reversion yielded a graft with < 3% 
corrected keratinocytes, raising possible issues of maintaining revertant cells in culture 
as well as the risks of mutant stem cell colonisation within the graft. In contrast the 
use of punch grafting revertant cells has shown stable and long-lasting reversion of 
phenotype and genotype in a patient with JEB, in this case treating a patient’s chronic 
ulcers (Gostynski et al., 2014).  
1.7.7 Induced pluripotent stem cells 
In 2006, Takahashi and Yamanaka first demonstrated that stem cells with properties 
similar to those of embryonic stem cells could be generated from mouse fibroblasts by 
simultaneously introducing four transcription factors (c-MYC, SOX2, OCT4 and 
KLF4) (Takahashi and Yamanaka, 2006), work that was subsequently extended to 
human fibroblasts (Takahashi et al., 2007). These stem cells were designated induced 
pluripotent stem cells (iPS cells or iPSCs). This exciting discovery demonstrated that 
almost all differentiated somatic cells had the capability to differentiate to a pluripotent 
state, albeit at different efficiencies. Bilusova et al (2011) were able to demonstrate 
directed differentiation of mouse iPS cells in culture into a multipotent keratinocyte 
lineage capable of forming a fully differentiated epidermis, hair follicles, and 
sebaceous glands in a reconstitutive in vivo environment (Bilousova et al., 2011). 
Simultaneously Tolar et al (Tolar et al., 2011) were able to demonstrate differentiation 
of gene corrected RDEB cells into corresponding iPS cells was similar to that observed 
for wild-type iPS cells. Interestingly, these investigators also observed differentiation 
of these cells into hematopoietic lineages, which suggests that such cells could be used 
to generate autologous hematopoietic cells for grafting. Recently iPS cells have been 
generated from revertant keratinocytes of a junctional EB patient with compound 
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heterozygous mutation in COL17A1 (Umegaki-Arao et al., 2014). Revertant iPSC 
keratinocytes were then used to create in vitro three-dimensional skin equivalents and 
used to reconstitute human skin in vivo in mice, expressing full length C17. Proof of 
principle studies have also demonstrated the safety and efficacy of iPSCs for RDEB 
in murine models (Wenzel et al., 2014) as well as in vitro (Tolar et al., 2014). 
Sebastiano et al have used adenovirus-associated viral genome editing to generate C7 
corrected iPSC banks to derive keratinocytes using GMP facilities and procedures. 
Cells were produced with minimal heterogeneity, and these cells secreted wild-type 
type C7 resulting in stratified epidermis in vitro in organotypic cultures and in vivo in 
mice (Sebastiano et al., 2014).  
The use of iPSCs taken from revertant skin could be an ideal therapeutic strategy, as 
this would obviate some of the technical difficulties and risks associated with gene 
therapy or gene editing. Tolar et al were able to demonstrate that revertant RDEB 
keratinocytes expressing functional C7 can be reprogrammed into iPSCs and that self-
corrected RDEB iPSCs can be induced to differentiate into either epidermal or 
hematopoietic cell populations (Tolar et al., 2014).  However spontaneous reversion 
remains rare, with only a few patients with RDEB confirmed to have patches of RM 





Table 1.2 Summary of gene correction strategies in inherited skin disorders 
Method Target gene Condition Target cell Comments Reference 
Self-inactivating 
lentiviral vector 
COL7A1  RDEB In vivo In vivo inoculation of skin equivalents grafted onto mice, 
C7 expression up to 3 months 




COL7A1 RDEB Fibroblast Gene corrected fibroblasts injected into murine skin able to 
produce C7 at basement membrane zone 




COL7A1  RDEB Keratinocyte Construction of skin equivalents using classical retroviral 
gene transfer; transduction efficiency 40% 





COL7A1 RDEB Keratinocyte + 
Fibroblast 
Generation of human skin equivalents showing in vivo 
functional correction of phenotype; C7 expression of 
recombinant C7 ranging between 30-80% keratinocytes and 
40-70% fibroblasts  
(Titeux et al., 
2010) 
Retroviral-vector COL7A1 RDEB Keratinocyte Genetic correction of both dog RDEB and human primary 
RDEB cells 
(Baldeschi et al., 
2003) 
φC31 integrase 
based plasmid  
COL7A1  RDEB Keratinocyte Non-viral approach into primary RDEB cells; regenerated 
skin (40% efficiency); stable correction required short-term 
drug selection and enrichment 




COL7A1 RDEB Keratinocyte Trans-splicing used to reduce size of COL7A1 transcript and 
therefore risk of genetic rearrangement 




LAMB3  JEB Keratinocyte Non-viral approach showing corrected hemidesmosome 
formation in JEB primary cells 




LAMB3  JEB Keratinocyte Sleeping beauty transposable element used to integrate 
LAMB3 cDNA into epidermal cells in 6 JEB patient 
primary cells; transfected cells enriched using drug 
selection.  





COL7A1  RDEB Keratinocyte Gene transfer using micro-injection of entire human locus 







COL7A1 RDEB Fibroblasts Transcription activator-like endonucleases (TALEN) gene 
editing of RDEB fibroblasts subsequently reprogrammed 
into iPS cells (induced pluripotent stem cells) 




COL17A1  JEB Keratinocyte Restoration of full-length BP180 protein expression in 
primary keratinocytes then used to regenerate human skin 
on immunodeficient mice 
(Seitz et al., 1999) 
Gamma retroviral 
vector 
LAMB3  JEB Keratinocyte Only case of successful gene transfer in an inherited skin 
disorder in an adult patient with non-herlitz junctional EB; 
restored phenotype and laminin 332 expression 7 years post 
graft 




LAMB3  JEB Keratinocyte Pre-clinical study using potentially safer lentiviral (LV) 
vector 








Functional in vitro correction of XPC keratinocytes (Arnaudeau-
Begard et al., 
2003) 
Adenoviral vector XPA Xeroderma 
pigmentosum 
In vivo In vivo inoculation of recombinant AV vector in UV 
irradiated murine skin 






Fibroblast Efficient SIN LV vector able to correct cellular phenotype 
in XP 






Keratinocyte MLV derived vector able to transduce primary cells and 
maintain XPC expression in up to 130 population doublings 














Keratinocyte Pre-clinical work demonstrating full length LEKTI 
expression in organotypic cultures grafted onto mice. 
Currently recruiting for phase I clinical trial 
(Di et al., 2011) 
Retroviral vector STS  X-linked 
ichthyosis 
Keratinocyte Restoration of enzymatic activity in cultured primary 
keratinocytes deficient in steroid sulfatase 
(Freiberg et al., 
1997) 
siRNA KRT5 EB Simplex Keratinocyte Pre-clinical study, specific knockdown of mutant keratin 5 
protein 




siRNA K6a mRNA Pachyonychia 
Congenita 
Keratinocyte Phase 1b trial injecting TD101 siRNA locally for plantar 
keratoderma in PC 
(Leachman et al., 
2010) 
Direct injection of 
plasmid 
TGM1  LI Keratinocyte Non-uniform restoration of gene expression on regenerated 
LI skin 
(Choate et al., 
1996) 
 
AV= adenoviral vector, JEB = Junctional epidermolysis bullosa, LI = Lamellar ichthyosis, LV = lentiviral vector, MLV = Murine leukaemia virus, RDEB 







1.8 Target cells for correction 
In order for sustained genetic correction in the skin it is critical to target the slow 
dividing stem cell population.  The definition relies on the property of unlimited or 
prolonged self-renewal and multipotency of stem cell capacity to produce at least one 
type of differentiated descendant. These stem cells are normally slow-cycling in vivo 
but possess high proliferative potential which can be triggered in response to tissue 
injury or to certain growth stimuli.  
1.8.1 Epidermal stem cells 
The epidermis is continually renewing and replaced every 18 days in adults (Epstein 
and Maibach, 1965). In order to accomplish this, the epidermis relies on epithelial 
stem cells. These cells are extremely slow-cycling and may undergo symmetrical 
division to form a few transit amplifying cells capable of limited further divisions. One 
hypothesis is of an epidermal proliferating unit (EPU) consisting of a single epidermal 
stem cell surrounded by transit amplifying cell progeny at the base of terminally 
differentiated keratinocytes (Potten and Morris, 1988). Slow cycling epidermal cells 
have been studied in vitro via so called label-retaining cells (LRCs), owing to their 
ability to retain radioactive thymidine incorporated into their DNA for prolonged 
periods of time after labelling (Mackenzie and Bickenbach, 1985). Using these 
techniques, epidermal stem cells have been shown to reside in 3 main areas: the first 
was localized to the inter-follicular basal layer of epidermis; the second was shown to 
reside in the bulge area of hair follicles and a third population was localized to the 
upper isthmus, a region between the bulge and the sebaceous gland. Keratinocytes 
grown in culture have been divided into three subtypes according to proliferative 
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capability: holoclones, meroclones and paraclones (Barrandon and Green, 1987). 
Holoclones have the greatest reproductive potential as under standard conditions, 
fewer than 5% of the colonies formed by the cells of a holoclone abort and terminally 
differentiate (Barrandon and Green, 1987). Indeed, a single holoclone has been shown 
to have the capability to generate the entire human epidermis (Rochat et al., 1994). 
(Jones Ph, 1993, Pellegrini et al., 1999). Subsequent studies have shown that 
epidermal stem cells firmly adhere to basement membrane and represent a minor 
subpopulation (~2–7% of basal keratinocytes) of relatively quiescent cells 
(Bickenbach, 1981, Li et al., 1998). The first progeny of stem cell division, transient 
amplifying (TA) cells, have a limited proliferative potential, yet share many molecular 
markers with their parent cell population (Jones Ph, 1993).  Epidermal stem cells are 
also capable of asymmetrical cell division and forming daughter cells committed to 
terminal differentiation without the need for TA cells at least in murine epidermis 




Figure 1-10 Schematic demonstrating symmetric and asymmetric stem cell 
division (adapted from Fuchs and Chen 2013) 
The asymmetrical cell division model to explain the ability of stem cells to self- renew in the long-term. At 
the end of anaphase, one daughter has received an excess of stem cell factors and remains undifferentiated, 
whereas the second daughter receives lineage commitment factors and embarks on a differentiated 
pathway.  
The challenge lies in ready identification of cell types as an agreed panel of epidermal 
stem cell surface markers has not yet been characterised. There are multiple 
approaches available in order to identify and isolate a pure EpSC population, including 
combined use of cell kinetic analysis and cell sorting (FACS) in vivo (Tani et al., 2000, 
Li et al., 1998). Keratinocytes with stem-like properties have been enriched using 
markers such as β1 integrin (Jones and Watt, 1993), α6 integrin (Kaur and Li, 2000), 
the nuclear transcription factor p63 (Pellegrini et al., 2001), LRIG-1 (Jensen and Watt, 
2006) amongst many others. In addition, classical developmental signalling pathways 
such as Notch, WNT, BMPs, Noggin, and SHH have all been reported to play 
important roles in maintaining adult stem cell niches (Fuchs, 2008).  However, the 
majority of advances in stem cell biology and the development of these panels of 
77 
 
markers have been accomplished in mouse models. How far this can be applied to 
human cell biology is unclear.  
1.8.2 Dermal stem cells 
The adult dermis contains several types of progenitor cells, including skin-derived 
precursors (SKPs), neural crest-derived stem cells (NCSCs), melanoblasts, 
perivascular cells (PCs), endothelial progenitors (EPs), and adipose-derived stem cells 
(ADSCs) (Feisst et al., 2014, Gimble et al., 2007, Fernandes et al., 2004, Murga et al., 
2004, Chang et al., 2014). The main cellular component of dermal tissue are dermal 
fibroblasts and the heterogeneity of fibroblasts is only recently being explored. Chen 
et al have shown that nestin-negative, vimentin-positive fibroblasts may represent a 
novel type of multipotent adult stem cells in human dermis (Chen et al., 2007). Kuroda 
et al further delineated a stem cell population named multilineage-differentiating 
stress-enduring (MUSE) cells in human dermal fibroblasts that are characterized by 
stress tolerance, expression of pluripotency markers, self-renewal, and the ability to 
differentiate into endodermal-, mesodermal-, and ectodermal-lineage cells from a 
single cell (Kuroda et al., 2010). These cells are also a primary cell source for induced 
pluripotent stem cell generation (iPS cell) in human fibroblasts.  
Recently lineage tracing has shown that dermal fibroblasts arise from a multipotent 
MSC cell population expressing PDGFRα, delta like homolog-1 (Dlk1) and LRG1 
(Driskell et al., 2013).  Upon differentiation, the fibroblasts begin to express different 
markers distinguishing common progenitor fibroblasts from specific fibroblasts within 
the papillary dermis (BLIMP1, LRG1) and those within the reticular dermis (Dlk1) 
(Driskell et al., 2013, Sorrell and Caplan, 2004). The heterogeneous cell lineages may 
also have differing functional capacity. Lineage studies have shown that the initial 
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phase of dermal repair occurring during wound healing is mediated by lower lineage 
fibroblasts, expressing myofibroblast markers such as SMA (Driskell et al., 2013). 
These cells secrete large amounts of ECM proteins including collagens. Therefore, 
transplantation of fibroblast lineages from the upper papillary dermis may have be 
more beneficial for promoting scar free wound healing as they secrete less fibrillar 
collagen than lower dermal fibroblasts.   In contrast transplantation of fibroblasts 
derived from lower reticular dermis that can differentiate into hypodermal adipocytes 
may be of benefit for surgical reconstructions requiring fibrofatty scar tissue (e.g. 
breast reconstruction).  
 
Figure 1-11 Lineage relationships of fibroblasts determined on murine skin 
(Driskell and Watt 2015). 
Fibroblasts arise from a common progenitor and progressively differentiate into upper 
fibroblast lineages and lower fibroblast lineages. A cluster of fibroblasts originating from the 
dermal papillae form the smooth muscle known as the arrector pili muscle (APM) in response 
to signals from the adjacent epidermal stem cells within the hair bulge. Subsets of reticular 
dermal fibroblasts can be differentiated into adipocytes.  
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1.8.3 Bone marrow derived stem cells 
Bone marrow stem cells (BMSCs) demonstrate plasticity in being able to contribute 
to mesodermal (e.g. muscle), endodermal (e.g. liver) and ectodermal (e.g. neural 
tissue, skin) structures (Grove et al., 2004). Indeed, BM cells contribute a substantial 
proportion of cells in the skin, both inflammatory and non-inflammatory, that have 
roles in skin development, homeostasis, repair and regeneration.  Some sub-
populations of the BM cells can differentiate into skin epithelial cells (keratinocytes) 
(Badiavas et al., 2003, Borue et al., 2004, Fathke et al., 2004b) and also provide 
fibroblast-like cells to the skin dermis, although their precise nature is not fully 
understood. Bone marrow derived stem cells can be derived from either 
haematopoietic or mesenchymal lineages. Bone marrow derived mesenchymal 
stromal cells (BM-MSC) are a heterogeneous population, and within that group is a 
cell type that has been shown to home to wounded skin in murine RDEB models. 
Tamai et al. (2011) showed that the BM-derived MSCs contained a sub-population of 
epithelial progenitors contributing to the restoration and maintenance of the epidermis 
(Tamai et al., 2011a). These cells were non-haematopoietic MSCs, with cell sorting 
determining that they were c-kit negative, lineage (Lin)- negative and platelet derived 
growth factor receptor alpha (PDGFRα) – positive. The level of this population of 
MSCs in RDEB bone marrow is unknown.  
1.9 Hypothesis and aims of thesis 
The development of gene therapy clinical trials for RDEB represents an important 
milestone in the pursuit of a cure for this devastating disease. There are numerous 
challenges in the journey to delivering gene therapies into human subjects. This 
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project aims to develop an ex vivo gene therapy approach to deliver a permanent 
treatment locally in RDEB skin.  Specifically:  
I.  To design and implement a preselection study to ensure appropriate patients 
are treated with a genetically corrected skin equivalent graft. 
II. To provide further rationale for the use of locally delivered gene corrected 
fibroblasts into RDEB skin. 
III. To design a phase I clinical trial of intradermal gene corrected fibroblasts in 
RDEB. 
IV. To identify potential obstacles and challenges in the design, development and 





Materials and Methods 
2.1 Research Ethics 
Study specific regulatory approvals are mentioned in the relevant chapters. The 
preliminary studies were performed using research ethics approval by Guy’s Research 
Ethics Committee, Guy’s and St Thomas’ NHS Trust was used (Characterisation of 
molecular and structural skin abnormalities in inherited skin disorders, Ref: 
07/H0802/104). 
2.2 Laboratory techniques 
2.2.1 Cell Culture 
2.2.1.1 Transport and isolation of primary keratinocytes from skin biopsy 
Skin punch biopsy specimens were kept in cell culture medium. The cell culture 
medium used for transport of skin biopsies constituted a solution of 90% Dulbecco’s 
Modified Eagle Medium, DMEM, (Gibco®, Life Technologies Ltd, Paisley, UK) and 
10% standard Foetal Bovine Serum, FBS, (Gibco®, UK) with the addition of 
antibiotic-antimycotic 100x (Gibco®, UK) and stored at 4ºC for a maximum of 24 
hours. Each specimen was trimmed to remove adipose tissue using a sterile scalpel 
and then incubated in Dispase I protease (Sigma Aldrich Company Ltd, Dorset, 
England) for at least 12 hours at 4 degrees. This ensured cleavage of the epidermis 
from the dermis. The epidermis was then minced into 1mm pieces using a sterile 
scalpel on a plastic tray and then immersed in 10ml 0.05% trypsin/EDTA (Sigma 
Aldrich, UK). This was incubated at 37ºC for 30 minutes and agitated every 5-10 
minutes. Trypsin activity was neutralised with an equivalent volume of media 
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containing serum and the contents were then filtered through a 100um cell strainer 
into a sterile falcon tube. The solution was then centrifuged at 1000 rpm for 5 minutes 
and the pellet resuspended in Epilife® medium (Life Technologies, UK) and plated 
onto a p60 petri dish which had been previously coated with the Epilife® coating 
matrix. In cases when samples were to be plated onto 3T3 irradiated feeders, the media 
used was RM+.  
2.2.1.2 Maintenance and passage of keratinocytes 
Primary cell cultures were maintained by changing the growth media three times a 
week. When culture dishes reached 80% confluence, the cells were passaged. A single 
cell suspension was obtained following incubation for twenty minutes in TrypLE 
Express (Life Technologies Ltd, UK). An equivalent volume of culture medium 
containing 10% FBS was added to neutralise trypsin activity and the mixture was 
centrifuged at 1600 RPM for 7 minutes. The filtrate was discarded by gentle aspiration 
and the cell pellet re-suspended in fresh media before re-plating into a new petri dish 
or flask using a ratio 1:4. 
2.2.1.3 Isolation of primary fibroblasts from skin biopsy using explant method 
After separation of the dermis and epidermis in dispase as shown above, the dermis 
was placed in sterile cell culture grade Phosphate Buffered Saline (Life Technologies 
Ltd, UK). Using sterile forceps and scalpel, the dermis was minced into 1mm2 pieces. 
Each piece was dried for 10 minutes and placed directly to a 100mm petri dish. Up to 
15 pieces were placed into each dish. Then 12-15 mls of DMEM with 10% FBS was 
added as well as 1/100 of this volume of 10,000 units penicillin, 10,000 g streptomycin 
and 25g amphotericin B / ml and stored in a 37ºC 5% CO2 incubator. The cell medium 
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was replaced with fresh medium every 5 days until growth was seen at 14 days. Once 
colonies formed, the fibroblasts would be trypsinised and transferred to a new dish.  
2.2.1.4  Isolation of primary fibroblasts from skin biopsy using digestion 
method 
After separation of the dermis and epidermis in dispase as shown above, the dermis 
was placed in sterile PBS. Using sterile forceps and scalpel, the dermis was minced 
into 1mm2 pieces. The minced pieces were then placed in a 15 mls falcon with  2mls 
of collagenase IV (Life Technologies, UK) and incubated at 37 degrees for at least 4 
hours agitating every 20 minutes. Following digestion, the solution was centrifuged at 
200G for 10 minutes and the supernatant removed carefully and re-suspended in 3 mls 
cell culture media and plated in a p60 dish.  
2.2.1.5 Cryopreservation and recovery of cells 
A cell suspension was obtained and re-suspended in 90%FBS and 10% 
Dimethylsulphoxide (Fisher Scientific, Leicestershire, UK) in 1.2ml sterile cryovials. 
The cells were cooled slowly, initially at 80◦ C overnight and then transferred to a 
liquid nitrogen dewar for long term storage. Cells were recovered by thawing in a 37ºC 
water bath and then re-suspended in warmed media. The mixture was centrifuged at 
1000 RPM for 5 minutes and re-suspended in fresh culture media and re-plated in a 
dish or flask.  
2.2.1.6  Preparation of 3T3's 
Frozen vials of 3T3-J2 cells (donated from the Dr Qasim’s laboratory, Institute of 
Child Health, London, UK) were used to generate fresh stocks.  These cells were 
grown in DMEM medium with 10% FBS into T150 flasks. These cells were routinely 
split two to three times a week in 1:5 dilutions.  Cells were trypsinised using 0.05% 
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trypsin in EDTA, neutralised by 10% FBC/DMEM and then spun the cells down for 
5 minutes at 1,000 RPM. Cells were re-suspended in RM+ and irradiated with 6,000 
rads for 20 minutes using a -irradiator. Irradiated cells were counted and plated on a 
fresh flask or dish at the appropriate density. The keratinocytes were then inoculated 
after at least 2 hours.  
2.2.1.7 Sterile culture technique 
To prevent contamination of cultured cells by infection, the cells were maintained in 
a good laboratory practice (GLP) facility and cultured in dedicated class 2 hoods. All 
surfaces were carefully disinfected with Virkon (Antec International, Suffolk, UK); 
disposable sterile equipment was used and solutions containing antibiotics prior to use 
2.2.1.8 Transduction with viral vector 
All procedures involving the use of viral vector were performed in a designated 
retroviral laboratory tissue culture suite at the Institute of Child Health. Following 
titration of viral titre, transduction was planned aiming for 1-3 copies per cell, 
correlating with MOI 3-10%. MOI was calculated using the formula MOI = (Viral 
titre/1000)  x volume viral supernatant (ul)/ Cell number. Cells were then seeded at 
required density 24 hours before incubation with required viral supernatant. Cell 
media was then aliquoted to be added to each flask or well. At this point, the vector 
aliquots were thawed quickly, pooled and then added to the media. Once added, the 
media was then placed in the well or flask and incubated for a minimum of six hours. 
The following day, the media was changed. For double transduction, the above process 




2.2.2.1 Immunofluorescent staining of skin tissue specimens for C7 
Skin samples were cryo-embedded with optimum cutting temperature (OCT) 
compound (VWR International, Lutterworth, Leicestershire, UK) and cut into 5µm 
thick sections using Cryostat Bright OTF 5000 (Jencons Scientific, East Grinstead, 
West Sussex, UK) at -28 C. Normal human skin was used as the positive control and 
the negative control was normal skin without primary antibody incubation. Frozen 
sections were air-dried at room temperature for 15 minutes and outlined with a liquid 
blocking PAP pen (Vector laboratories, California, USA) and then fixed with 4% PFA 
for 20 minutes. All slides were then washed in PBS for 5 minutes and then 
permeabilised with Triton X 0.1% for 15 minutes. Following a further 5 minute PBS 
wash, the sections were blocked with blocking buffer containing 10% goat serum 
(Sigma-Aldrich, UK) with 0.1% bovine serum albumin (Sigma-Aldrich, UK) diluted 
in PBS and 0.1% Tween®20 (Sigma-Aldrich, UK). Primary and secondary antibodies 
were diluted in blocking buffer and incubated for 20 minutes on ice. At all times the 
secondary antibody was stored in the dark. Following blocking, the sections were 
incubated with the primary antibody at 4 degrees overnight. The slides were then 
washed in PBS three times for 5 minutes each. The appropriate secondary antibody 
diluted in blocking buffer was then added and incubated for 30 minutes at room 
temperature in the dark. Sections were washed in PBS for 5 minutes and then lastly 
rinsed in distilled water for 5 minutes. Once air-dry, they were then mounted with 
DAPI (Prolong Gold Anti-fade) (Life Technologies) and a cover glass applied. The 
sections were then left overnight to set at room temperature in the dark. For short term 
storage the sections were kept at 4 degrees and for long term at -80 degrees.   
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Dilution and selection of primary antibodies to C7 were optimised and all 
immunohistochemistry illustrated is using the LH 7.2 mouse monoclonal antibody to 
C7. Polyclonal antibodies obtained from commercial suppliers as well as those 
prepared by another research groups (courtesy of Prof M. Chen) are illustrated below. 
 
Figure 2-1 Immunohistochemistry using three different antibodies to C7, All 
1:200 dilution (see Table 2.1) 
Optimisation of the primary anti C7 antibody showed suitable staining with all three anitbodies; 
LH7.2 mouse monoclonal, Calbiochem rabbit polyclonal and a rabbit polyclonal antibody purified 





2.2.2.2 Immunofluorescent staining of cultured keratinocytes and fibroblasts for 
C7. 
Coverslips measuring 60μm were sterilised and soaked in culture media for 5 minutes. 
They were then dried and placed in a 24 well tissue culture plate. Cultured cells were 
trypsinised, counted and plated in each well at a density of 1 x 105 per cover slip. Cells 
were cultured for 24-48 hours and then the media was removed and the slips washed 
with PBS three times for 5 minutes and then fixed with 4% Paraformaldehyde solution 
for 20 minutes. All coverslips were then washed in PBS for 5 minutes and then 
permeabilised with Triton X-100 0.1% (Sigma-Aldrich) for 15 minutes. Following a 
further 5 minute PBS wash, the cover slips were blocked with blocking buffer 
containing 3% Foetal Bovine Serum diluted in PBS for one hour. Primary and 
secondary antibodies were diluted in blocking buffer and incubated for 20 minutes on 
ice. At all times the secondary antibody was stored in the dark. Following blocking, 
the slips were incubated with the primary antibody at 4ºC overnight. The slides were 
then washed in PBS three times for 5 minutes each. The appropriate secondary 
antibody diluted in blocking buffer was then added and incubated for 30 minutes at 
room temperature in the dark. Sections were washed in PBS for 5 minutes and then 
lastly rinsed in distilled water for 5 minutes. One drop of Prolong® Gold antifade 
reagent (Invitrogen) containing 4’6-diamidino-2-phenylindole (DAPI) was added to 
simultaneously mount and counterstain the nuclei. Prolong Gold preserves the 
fluorescent signal and DAPI binds to the region of double-stranded DNA rich in A 
and T bases.  
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Table 2.1 Antibodies used for immunohistochemistry and 
immunocytochemistry 
Primary Antibody Secondary Antibody 
Mouse monoclonal antibody type VII 
collagen LH7.2 (Chemicon Europe 
Hampshire, UK) 
Goat anti mouse conjugated to AlexaFluor 
488 (Invitrogen); 1:200 
Rabbit polyclonal antibody type VII 
collagen “Chen” (kindly donated from 
Professor M. Chen, Stanford) 
Goat anti-rabbit conjugated to AlexaFluor 
488 (Invitrogen); 1:200 
Rabbit polyclonal antibody type VII 
collagen 234192 (Calbiochem, San Diego, 
USA) 
Goat anti-rabbit conjugated to AlexaFluor 
488 (Invitrogen); 1:200 
2.2.2.3 Quantification of immunofluorescence signals 
Quantification of immunofluorescence data was carried out by counting cells showing 
a positive immunofluorescence signal for C7 in three independent fields containing 
100 cells. Data are presented as percentage of cell numbers in relation to the total 
number of DAPI positive cells. Values are presented as mean +/- standard deviation. 
Unpaired two-tailed Students’ t-test was used to analyse data for statistical 
significance. Graphs and analysis were generated with GraphPad Prism (Version 6) 
Software.  
2.2.3 Protein analysis 
2.2.3.1 Cell protein extraction 
Protein was extracted from cultured cells. At least one T25 flask of keratinocytes and 
one T75 flask of fibroblasts was necessary for appropriate protein extraction. When 
cells were at 70-80% confluence the culture media was removed and cells washed with 
fresh PBS three times. Following trypsinisation with 0.05% Trypsin/EDTA for 5 
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minutes, trypsin was neutralised with equal volume of cell media and the solution 
centrifuged at 16000 RPM for 7 minutes. The supernatant was aspirated and the pellet 
resuspended in 100ul of RIPA buffer containing 1x protease-inhibitor-cocktail 
(Complete, Roche, UK) and 1x phosphatase inhibitor (Complete, Roche, UK). The 
pellet was kept on ice for 10 minutes during cell lysis and then centrifuged at 4 degrees 
for 20 minutes at 4000RPM. The supernatant was collected, aliquoted and stored at -
80 degºC until analysis.  
2.2.3.2 Cell protein quantification 
The amount of total protein was quantified using the BCA assay. A standard protein 
curve was obtained following measurement of optical density produced using different 
concentrations of Bovine Serum Albumin, which were then plotted against each 
concentration. The optical density was measured at 595nm. The formula for the line 
of best fit was used to calculate unknown concentrations. A new standard curve was 
calculated for each assay.  
2.2.3.3 SDS Gel Electrophoresis 
Cell pellets or cultured media supernatant from cells grown for 48 hr in the absence of 
serum and supplemented with 50 µg/ml ascorbic acid were used for western blot 
assays. Loading buffer (6x) containing β-mercaptomethanol was added to each lysate 
sample and heated at 90 degrees for 5 minutes prior to SDS-gel electrophoresis. A 4-
15% Mini-Protean® TGX™ gradient gel (Bio-rad laboratories Ltd, Hemel 
Hempstead, Hertfordshire) was used. Fibroblast extracts from cultured cell samples 
were each loaded with a total protein of 50-70 ug of protein and 10ul of Amersham ™ 
Rainbow™ Full Range molecular weight marker (GE Healthcare UK Limited, 
Amersham Place, Buckinghampshire,UK) were used. The gel was run at 250V for 90 
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minutes in 1x Tris/Glycine/SDS Buffer (Bio-rad laboratories) and protein was 
electrotransferred to a nitrocellulose membrane using a Biorad® TransBlot Turbo at 
25 V and 2.5 A for 12 minutes. The membrane was stained with Ponceau Red solution 
(Sigma-Aldrich) for 5 minutes to check transfer of protein and then washed and 
incubated in 5% skimmed milk in TTBS at room temperature for one hour followed 
by overnight incubation with the primary antibody at 4 degrees. The loading control 
marker used was either βactin or vinculin (See Appendix). The membrane was washed 
three times for 5 minutes in 1 x Tween20/Tris buffered saline (TTBS) before 
incubation with a secondary antibody conjugated with horseradish peroxidise (HRP), 
for one hour at room temperature.  
Table 2.2 Antibodies used for protein immunoblotting 
Primary Antibody Secondary Antibody 
Rabbit polyclonal collagen type VII 
(antibody targets NC1 domain); kindly 
sent from Prof Chen, CA; 1:5000 
HRP Conjugated swine anti- rabbit (Dako); 
1:2000 
Mouse monoclonal vinculin (Sigma-
Aldrich); 1:250 000 




The membrane was washed in 1 x TTBS before the addition of enhanced 
chemiluminescence (ECL) and Western blotting detection reagent (GE Healthcare, 
UK). The latter is a substrate of horseradish peroxidase and a positive reaction leads 
to the production of a luminescent substance which is then visualised by exposure of 
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the membrane to high performance chemiluminescence film (GE Healthcare) in a dark 
room. Films were exposed for 1 minute and 10 minutes.  
2.2.3.5 Quantification of Western blot data 
Image J Software was used to quantify the proteins in each band by performing a 
densitometry analysis of the TIFF or JPEG image (Schneider et al., 2012). Once the 
density of each peak was calculated, this was expressed as a percentage of the 
reference standard, in most cases the standard being a normal control cell type. This 
was therefore expressed as a percentage value. 
2.2.4 Fluorescence Activated Cell Sorting (FACS) analysis of fibroblasts  
Cultured fibroblasts were trypsinized using Trypsin 0.05%/EDTA and centrifuged at 
500g for 5 minutes at room temperature. The cell pellet was resuspended in media to 
ensure a concentration of 0.5 x 10 6 cells per 1ml and then centrifuged again. The 
pellet was then washed with 2ml of FACS buffer (2% FBS in PBS) at 350g for 5 
minutes. The supernatant was carefully aspirated and cells resuspended in residual 
fluid. 100ul of ice cold 4% PFA was added to the cell pellet suspension and incubated 
for 15 minutes at room temperature in the dark. The cells were then washed with 2.5 
ml of FACS buffer and centrifuged for 5 minutes at 350g. The supernatant was 
aspirated carefully. The cells were then incubated in an antibody dilution buffer (1% 
BSA, 0.3% Triton X 100 in PBS) containing the primary antibody or IgG3 isotype. 
Cells were incubated for 30-40 minutes in the dark at room temperature.  A sample of 
unstained cells was prepared for each cell type analysis and incubated with antibody 
dilution buffer only. Following incubation, the cells were washed with 2mls of FACS 
buffer, centrifuged and re-suspended in appropriate secondary antibody diluted in 
antibody dilution buffer and incubated for 30-40 minutes in the dark. Unstained cell 
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samples were again incubated in dilution buffer alone.  Following 2 further washes 
with FACS buffer, the cells were re-suspended in 350-500µl of FACS buffer and 
analysed. Acquisition and analysis were performed using an CyAn™ ADP cell 
analyser (Beckman Coulter Ltd, Oakley Court, High Wycombe, UK) and data 
analysed with Summit software (Beckman Coulter).  
Table 2.3 Antibodies for FACS analysis 
Primary Antibody Secondary Antibody 
Mouse monoclonal Antibody type VII 
collagen LH7.2 (Santa Cruz, UK); 1:25 
Goat anti mouse conjugated to AlexaFluor 
488 (Invitrogen); 1:200 
2.2.5 Viral vector production 
Viral vector production took place at the Institute of Child Health (by the GMP trained 
team). Virions were prepared by transient transfection of validated 293T cells in five-
layer cell factories. The culture medium in which particles are harvested was 
compatible for fibroblast transduction (DMEM and approved source 10% FCS). The 
crude vector batch was concentrated, pooled and filtrated through 0.22um filters 
before aseptic filling into cryovials. The vector batch was stored at < -80ºC. 
2.2.6  Real-time PCR for assessment of copy number  
Total DNA was harvested from cells grown to 70% confluence (Qia-Amp DNA Mini 
kit, Qiagen, Venlo, Limburg, Netherlands).  Integrated vector copy number was 
assessed in transduced cells after multiple passages by quantitative PCR using primers 
and probe designed to target the Psi post-regulatory element region of the vector in 
comparison to signal generated for the housekeeping gene albumin. Integrated copy 
number was calculated with the aid of standard curves generated using plasmids 
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encoding the vector and complementary DNA for human albumin. The set of standards 
comprised plasmid vector containing both the HIV Psi and human albumin sequences  
(Stock tube 1 is 2.784 x 1011 copies/l, Genethon, France) and this was serially 
diluted from 107 copies/l (108 copy standard) down to 101 copies/l.  
Incorporating a second PCR using primer and probe sequences based on an internal 
control human albumin, together with appropriate plasmid DNA standards allows the 
amount of genomic DNA (and thus the number of cells) to be quantified. 
Following DNA extraction from cultured cells, the DNA was eluted in DNA/Nuclease 
free water and the DNA concentration calculated by adding a drop of DNA to the 
Nanodrop spectrophotometer. For the qPCR reaction, each DNA sample was then 
adjusted to a concentration of 10 ng/l for the HIV lentivirus psi qPCR using 
DNAase/RNAase free water. The PCR reaction comprised the components: 0.25 µl 
HIV Psi reverse primer (5’ TCC CCC GCT TAA TAC TGA CG  3’), 0.25 ul HIV Psi 
forward primer (5’ CAG GAC TCG GCT TGC TGA AG  3’), 0.25 ul Albumin reverse 
primer, 0.25 ul Albumin forward primer, 0.25ul HIV Psi probe (5’ FAM-CGC ACG 
GCA AGA GGC GAG G TAMRA-3’, Reporter is FAM, the Quencher is TAMRA), 
0.25ul Albumin probe (5’ VIC-CCT GTC ATG CCC ACA CAA ATC TCT CC-
TAMRA 3’, Reporter is VIC, the Quencher is TAMRA), 12.5ul Platinum Quantitative 
PCR Supermix-UDG W/ROX (Invitrogen, UK), 1 µl RNAase free H2O (Qiagen, 
Crawley, UK) and 10 μl genomic DNA. All PCR reactions were carried out in 
triplicate, in 96-well plates (ABgene) covered by optical adhesive lids and samples 
were amplified by the ABI PRISM 7000 sequence detection system and computer ABI 
Prism software (Applied Biosystems). The reaction was run for 1 cycle at 50°C for 2 
min, 1 cycle at 95°C for 10 min, 40 cycles at 95°C for 15 seconds and 60°C for 1 min 
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on a ABI Prism 7000 sequence detection system (Applied Biosystems). Integrated 
copy number was calculated with the aid of standard curves generated using serially 








The development of a phase 1 study of ex vivo gene therapy using 
autologous gene corrected keratinocytes and fibroblasts to generate 
a skin equivalent graft in RDEB patients (GENEGRAFT) 
3.1 Introduction 
3.1.1 Ex vivo gene therapy for RDEB 
Gene therapy for inherited skin diseases can be attempted via in vivo or ex vivo 
techniques. In vivo approaches directly administer the target gene/DNA plasmid or 
gene containing vector into the skin. Advantages of this approach are the avoidance 
of surgery and the lack of cell manipulation and prolonged in vitro cell culture. 
Although this method permits the treatment of large areas of skin, the main limitations 
have been concerns over the bio-safety and bio-distribution of directly administered 
viral vectors directly into skin and any potential non-target tissue effects (including 
reproductive organs), as well as possible immunogenicity. 
Ex vivo gene therapy circumvents many of these issues. The first step requires an initial 
skin sampling via biopsy followed by isolation of target cells (keratinocytes and/or 
fibroblasts) using well-established tissue culture techniques (Rheinwald and Green, 
1975). The next stage involves transduction using an appropriate vector containing the 
target transgene. Genetically cultured autologous cells are then further expanded in 
culture and transplanted or grafted back onto the patient. Pre-clinical studies using 
these techniques in models of RDEB are discussed and summarised in Chapter 1. At 
the time of starting this thesis, there had been no successful cases of ex vivo genetically 
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corrected cells or grafts attempted for patients with RDEB. The broader aims of this 
work are to develop an autologous skin equivalent graft corrected with a validated 
retroviral vector carrying the COL7A1 transgene (SIN RV COL7a1 vector EF1 α). The 






3.1.2 Project aims 
The aim of this study was to design and implement a phase I/II ex vivo gene therapy 
clinical trial for RDEB using skin equivalent grafts genetically corrected with a 
COL7A1-encoding SIN retroviral vector (GENEGRAFT).  The application for 
funding was made in 2009 and was awarded an FP7 grant, based on the collaboration 
of multiple academic sites within the European Union. The objectives of the 
GENEGRAFT project are to develop an ex vivo gene therapy approach to deliver a 
permanent treatment locally in RDEB skin. Titeux et al (2010) first developed the pre-
clinical model and used an SIN retroviral vector with COL7A1 cDNA under the 
control of a human EF1α promoter to transduce both primary RDEB keratinocyte and 
fibroblast cell populations  (Titeux et al., 2010). This pre-clinical model was able to 
demonstrate long term stable in vivo engraftment with restored levels of C7 and 
functioning AFs at the DEJ.  
The aims of the GENEGRAFT project (phase 1 trial) were to translate this pre-clinical 
model into a phase I clinical trial, and treat up to 3 patients selected from centres in 
both France (IMAGINE institute Paris, Necker Hospital for Children) and the United 
Kingdom (Guys and St Thomas’ NHS Foundation Trust). This would be termed a 
CTIMP (Clinical trial of an Investigational Medicinal Product) incorporating the 
whole process including grafting. In this case, the Investigational Medicinal Product 
(IMP) is a fibrin based skin equivalent graft composed of genetically modified 
autologous keratinocytes and fibroblasts. The fibroblasts are embedded in a fibrin gel 
made from cryoprecipitate of human plasma derived from the recipient, which allows 
further cultivation of keratinocytes to produce a stratified epithelium. Using methods 
successfully utilised to treat burn patients (Llames et al., 2004, Navsaria et al., 1995) 
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the aim is to develop an IMP for patients with RDEB. Genetically modified 
keratinocytes cultured to form epidermal sheets have been developed for patients with 
JEB (Mavilio et al., 2006) but the addition of a dermal component has a number of 
advantages both reproducing the natural microenvironment and introducing two cell 
types both capable of secreting C7.  
Following consultation with the UK National Research and Ethics Service (NRES) 
directors, the project was divided into two parts. The first part of the study is an 
observational study with no investigational study intervention, aiming to characterise 
a cohort of patients with RDEB most suited for future ex vivo gene therapy 
interventions. This would be an observational study rather than a CTIMP and therefore 
would only require regulatory approval from the NRES committee rather than the 
MHRA. This was done to ensure that the selected patients would be suitable for entry 
immediately once the CTIMP gained regulatory approval within the European Union. 
3.1.3 Workpackages 
Being a European wide project, this phase I study was subdivided into work-packages 
with designated deliverables and responsibilities for each beneficiary. The main roles 
detailed in this thesis are related to patient selection and recruitment, protocol design, 
protocol implementation and regulatory applications.  
3.2 Methods 
3.2.1 Study design 
This multicentre prospective study aimed to characterise up to 30 patients with RDEB 
across all clinical sites in terms of immune response to type VII collagen, epidermal 
cell proliferative capacity and clinical and biochemical criteria most suited for a study 
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for ex vivo gene correction. The study in France initially assessed those aged 7-65 
years whereas the UK study only assessed adults over the age of 18 at study 
recruitment. In order to initiate the pre-selection process for the GENEGRAFT study, 
the project was divided into two parts, the primary observational study only examining 
the clinical and molecular features necessary for patient selection. The secondary 
study would then involve the delivery of the genetically corrected skin equivalent graft 
to the selected patients. The UK National Research and Ethics Service (NRES) agreed 
that a primary “pre-selection” study would be necessary, critically ensuring that all 
patients consented for pre-selection would not be obliged to take part in the second 
part. This pre-selection study was entitled EBGen, “Study of immune tolerance and 
wound healing in patients with recessive dystrophic epidermolysis bullosa”. This 
study involved assessment of clinical features including disease severity and extent of 
chronic wounds. This was documented using an objective severity score (Birmingham 
Epidermolysis Bullosa Severity Score, BEBSS) as well as medical photographs. The 
BEBSS is a validated scoring system takes into account the percentage of cutaneous 
disease involvement, mucosal and nail involvement, hand scarring and deformity, 
number of squamous cell carcinomas, EB related alopecia and nutritional compromise 
(Moss et al., 2009). All patients had an assessment of immune response to C7, utilising 
ELISA, ELISPOT, HLA Genotyping and Indirect IF. Only a select few would then 
have a further skin biopsy in order to assess keratinocyte proliferative capacity. The 
limitation of only up to 2 patients for this assessment was due to cost and time required 
for each sample process. The design of validated documents for the ethics submission 
included a clinical protocol for the study, Patient Information leaflet (PIL), Consent 





Figure 3-1 Diagram showing EBGen study flowchart and study method 
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3.2.2 Human subjects 
The study EBGen (Study of Immune Tolerance and Capacity for Wound Healing for 
RDEB, Ref: LO/12/1472) was approved by London Brent Ethics Committee in 
October 2012. Subsequently the application to Guy’s and St Thomas’ Research and 
Development (R+D) department was submitted via the National Institute for Health 
Research Coordinated System for gaining NHS Permission (NIHR CSP) which is a 
streamlined system for gaining R+D permission in the NHS in England for studies that 
fall under the NIHR Clinical Research Network Portfolio. R +D approval was 
confirmed on 18th July 2013. For the diagnostic assessment and characterisation of 
patients suitable for entry into this study, previous research ethics approval by Guy’s 
Research Ethics Committee, Guy’s and St Thomas’ NHS Trust was used 
(Characterisation of molecular and structural skin abnormalities in inherited skin 
disorders, Ref: 07/H0802/104).  
3.2.3 Substantial Amendments 









Table 3.1 Details of EBGen study substantial amendments  
Amendment no Date Justification 
1.0 
  
Jan 2013 The EBGen study was reviewed by the French Ethics Committee (CPP) in Paris on the 13th November 2012. 
The ethics committee were keen to avoid any mention of future potential gene therapy in relation to this study. 
This was in order to ensure patient expectations are related solely to the EBGen study. This required 
modifications to protocol, patient information leaflet and study title.  
2.0 June 2013 1) Change of Chief Investigator (CI) to Prof John McGrath. This was due to advice from the CSP group that the 
CI must be UK based. As such, Prof Hovnanian will be the main EU coordinating investigator rather than the 
UK CI. 2) Change in laboratory processing the skin biopsy samples for proliferative capacity assessment. This 
will now be performed in an approved GMP grade laboratory in Modena, Italy, led by Prof Michele De Luca.  
3.0 July 2014 Change of inclusion and exclusion criteria to allow inclusion of patients with severe phenotype expressing 




3.2.4 Development of pre-selection study protocol (EBGen) 
The pre-selection study was designed to screen RDEB patients and select the “ideal 
candidates” for a phase I study of ex vivo gene therapy in RDEB. The definition of the 
“ideal candidate” has evolved over time and the challenges to determine the most 
suitable candidate for this approach are discussed in detail. The initial aim was to graft 
unblistered sites on a patient with moderately severe RDEB (RDEB, generalised-
intermediate). Disease severity, co-morbidities, social and family supports are all 
important factors in determining the likelihood of tolerating a graft procedure. One of 
the main theoretical risks of the therapy is the development of a systemic immune 
response to the transgene or new C7 produced. Therefore, individuals were assessed 
using ELISA and ELISPOT to C7. The main criteria for initial assessment are shown 
below. Patients deemed suitable according to these set criteria would then undergo a 
further two skin biopsies for assessment of keratinocyte proliferative capacity  
I. History and examination in order to ascertain disease severity, inclusion and 
exclusion criteria and assess for possible graft sites 
II. BEBSS score (Birmingham Epidermolysis Bullosa Severity Score) (See 
Appendix) 
III. Immune tolerance to C7 wild type protein using ELISA and ELISPOT assays 
IV. HLA Genotyping to determine the likelihood of immune response to C7 wild 
type protein 
3.2.5 Skin biopsy technique 
Using an aseptic technique, local anaesthetic (Xylocaine 2% with adrenaline 
1:200,000) was infiltrated into each of the biopsy sites. Full thickness 5mm skin punch 
biopsies were taken and the wounds closed with prolene sutures or in the cases of 
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severe RDEB left to heal via secondary intention. Routine wound care advice was 
given and sutures were removed after 7 days. 
3.2.6 Western blot analysis of cultured cells 
Protein extraction was performed from cultured fibroblasts and keratinocytes using 
the methods described previously. SDS Page Gel electrophoresis was then performed 
using at least 50µg of protein lysate according to previously described methods. 
Immunodetection was performed using rabbit polyclonal antibodies targeting the NC1 
domain of C7 and then membranes were incubated with a secondary antibody 
conjugated with HRP.   
3.3 Results 
3.3.1 Patient pre-selection 
Patients were screened using the database located at the Robin Eady National 
Diagnostic Laboratory at St Thomas’ hospital. A total of 153 patients were identified 
and screened from the electronic database with mutation analysis showing 
heterozygous, compound heterozygous or homozygous mutations in COL7A1. From 
this list of patients, further data was retrieved from medical records and reviewed with 
the clinical team including the Debra EB specialist nurses. A proforma was devised to 
filter only patients suitable according to study inclusion and exclusion criteria. This 
document was used across the EU recruitment sites to collate data. The initial selection 
criteria targeted a list of patients with moderate disease, classified as RDEB-
generalised intermediate. This was based on the assumption (no proven supportive 
data) that patients with RDEB generalised-severe (RDEB-Gen-Sev) would have a 
complete absence of C7 and therefore be at much higher risk of developing an adverse 
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immune response to wild type C7. According to these criteria there were 10 suitable 





Table 3.2. Patients with RDEB (Gen Inv) selected showing C7 immunostaining and Western blot results 
MS = missense, GS = Glycine substitution, PTC = Premature termination codon, FS = Frameshift, M = male, F = female, N/A = not assessed, IVDU = 




           
Figure 3-2 The clinical phenotype of a patient with RDEB (Inversa) and correlated 
with immunofluorescent labelling of skin with anti-type VII collagen antibody, LH 
7.2.             
The patient  labelled EB1 showing a longstanding non-healing erosion on the left axilla.  The 
immunofluorescent labelling with anti-type VII collagen antibody in EB1 skin sections compared 
with controls, showing linear labelling with subtle slight  discontinuous staining in some focal 
places. Due to the mild phenotype and almost normal levels of C7 present on DIF this patient was 








             
Figure 3-3 The clinical phenotype of a patient with RDEB Generalised Intermediate 
and correlated with immunofluorescent labelling of skin with anti-type VII collagen 
antibody, LH 7.2. 
The patient labelled EB013 showing a large erythematous plaque on the anterior leg with overlying 
excoriations and erosions.  The immunofluorescent labelling with anti-type VII collagen antibody in EB013 
skin sections compared with controls, showing linear labelling with subtle slight  discontinuous staining in 
some focal places. The patient had severe disease affecting only the lower legs. Due to the perceived 
difficulty grafting these areas and the almost normal levels of C7 present on DIF, this patient was not 
selected for the EBGen study. Scale bar  =100µm. 
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3.3.2 Subject details and molecular diagnoses 
Following further consideration and review of this patient cohort, a change to the protocol was 
made in order to include patients with RDEB (Gen Sev).  On reflection, patients with only 
moderate disease would be far less likely to be willing to undergo a grafting procedure of their 
“normal skin”. Furthermore, the desired increase in levels of C7 following gene correction 
strategies would be less apparent via DIF and Western Blot in patients with near normal levels 
of C7. In total nine patients with RDEB (Gen,Intermed) or RDEB (Gen Sev) were suitable 
according to amended inclusion and exclusion criteria (see Section 3.3.3). All patients 
presented with generalised blistering at birth or shortly afterwards. The most frequently 
affected areas were the back, neck, upper legs, hands and feet. Only 2 had developed mitten 
deformities and 6/9 had required previous hand surgery. Swallowing difficulty or dysphagia 
was reported in 5/9. For 6/9 patients oesophageal strictures were evident and 4/9 required 
repeated oesophageal dilatations. One patient had renal failure requiring regular renal team 
input (glomerulonephritis). At study entry none of the patients had a squamous cell carcinoma. 
All recruited patients had anaemic periods requiring intravenous iron therapy, and Patient BH-
01 required intermittent blood transfusions. Of note, 5/9 of the cohort had received previous 
intradermal allogeneic fibroblast therapy as part of the phase II study of intradermal allogeneic 
fibroblast therapy for chronic wounds in adults with RDEB (ISRCTN6775729)(Petrof et al., 
2013).  The study had completed in 2013 and most had shown a beneficial impact on wound 
healing although only transiently (up to 28 days only), and therefore would assume no impact 






3.3.3 Study inclusion and exclusion criteria 
Inclusion criteria 
1. Confirmed molecular diagnosis of recessive dystrophic epidermolysis bullosa, 
established for both alleles; 
2. Moderate to severe RDEB; 
3. Presence of the NC1 domain type VII collagen on skin biopsy and/or western-blot 
analysis detected with a set of specific antibodies; 
4. Presence of blistered or erosive areas, including chronic wounds; 
5. No recent hospitalization related to EB complications; 
6. Subjects and their parents when applicable should be able and willing to return for 
follow up; 
7. Patients should be able and willing to give signed informed consent.  
8. Ability to undergo local anaesthesia. 
Exclusion criteria 
1. Severe disease indicated by  
a. Absence of detectable type VII collagen expression on skin biopsy and Western 
blot analysis from cultured cells; 




a. Active infectious diseases, including  systemic  infections  and  known positive 
HIV serology (Kaposi’s sarcoma), hepatitis B and C; 
b. History of current psychological or psychiatric disease; 
c. Absence of an adequate familial and social support; 
d. History of current or previous organ diabetes mellitus; 
e. Non corrected severe anaemia (Haemoglobin level: < 8 g/ml); 
f. Non corrected iron deficiency; 
g. History of significant allergy to anaesthetic procedure 
h. Patient currently receiving anticoagulant or anti-platelet treatment; 








Figure 3-4 Clinical features and immunofluorescence results for BH-01 
Patient BH-01 had chronic wounds affecting the axillae, neck and lower legs.   The 
immunofluorescent labelling with anti-type VII collagen antibody in BH-01 skin sections 
compared with controls, showing occasional areas of punctate staining and fragmentation 








              
Figure 3-5 Clinical features and immunofluorescence results for AF-02. 
Patient AF-02 has generalised fragile skin and some superficial erosions but no chronic 
wounds.  Immunofluorescent labelling with anti C7 antibody shows reduced staining 
intensity and focal interruptions. Some DAPI nuclear staining is also shown to highlight 
the epidermis. The extent of C7 reduction is not mirrored by the relatively mild clinical 










Figure 3-6 Clinical features and immunofluorescence results for SC-03 
Patient SC-03 has RDEB (sev-gen) with extensive chronic wounds affecting her back and 
posteriod neck. . Immunofluorescent labelling with anti C7 antibody shows reduced 











Figure 3-7 Clinical features and immunofluorescence results for AK-04  
Patient AK-04 has RDEB (sev-gen) with skin fragility and erosions evident particulary over 
the shoulders and lower legs. Immunofluorescent labelling with anti C7 antibody shows 









Figure 3-8 Clinical features and immunofluorescence results for MJ-05 
Patient MJ-05 with RDEB (Sev-Gen) showing extensive chronic wounds affecting his entire 
back and both shoulders. Immunofluorescent labelling with anti C7 antibody shows some 
linear labelling below a separated epidermis. Although the intensity is reduced, the 







      Figure 3-9 Clinical features and immunofluorescence results for HS-06 
Patient HS-06 has RDEB (sev-gen) with extensive chronic wounds affecting her back. 
Immunofluorescent labelling with anti C7 antibody shows reduced staining intensity and 
occasional interruptions to the linear staining pattern. Some DAPI nuclear staining is 






Table 3.3 Clinical characteristics of 9 UK patients recruited for EBGen study 
Abbreviations: Gen Intermed = Generalised Intermediate, Gen Sev = Generalised Severe, M= male, F= female, OD = oesophageal dilatation, RDEB = recessive 



















 Significant comorbidities 
BH-01 52 F RDEB (Gen, 
Intermed) 
Y ( x 5 OD)  Contractures and 
proximal webbing 
 Back,Left shoulder 
and axilla, right knee 
30 Y N 33 Recurrent severe iron 
deficiency anaemia 
AF-02 28 M RDEB (Gen, 
Intermed) 
N Mitten deformity  
Finger release 2003 
 Elbows, hands, knees, 
dorsum feet 
10 N N 24  Nil 




 Right hand surgery  Posterior neck and 
lower back 
10 Y Y 23 Anxiety and depression  
AK-04 23 F RDEB (Gen, 
Intermed) 
N  Hand surgery  Knees, elbows and 
right shoulder                     
35 Y N 27  Nil 
MJ-05 48 M RDEB (Gen 
Intermed) 
N  Hand surgery  Back, legs and 
forearms 
60 Y Y 42 Hypothyroidism, contractures 
both knees 
HS-06 23 F RDEB (Gen 
Sev) 
Y ( x 4 OD)  Obvious 
contractures and 
proximal webbing 
 Back and posterior 
neck 




29 M RDEB (Gen 
Sev) 
Y ( x 5 OD)  Finger release x 3  Back, forearms and 
posterior thigh 
30 Y Y 32 Acute Renal Failure  
Severe left ventricular 
Impairment,  
Previous thyroid dysfunction 
WB-08 37 M RDEB 
(Inversa) 
N N Arms and back 45 N N 25 Depression 
JD-09 22 M RDEB (Gen 
Sev) 
Y (>10 OD)  Hand surgery x 3 Hands, arms, legs and 
back 





Table 3.4 Mutation analysis for recruited RDEB patients (performed by Robin Eady National Diagnostic EB lab) 
Abbreviations: PTC = premature termination codon, NC1 = non-collagenous domain 1, NC2= non-collagenous domain 2
 























AF-02 c.8506insC  p.Val2836fsX12 115 PTC NC2   c.8506insC p.Val2836fsX12 115 PTC NC2 
SC-03 IVS 13-1G> C   Splice site NC1   IVS 13-1G>C   Splice site NC1 
AK-04 c.5660_5661delGGinsATA p.Gly1887fsX27 67 PTC Triple 
helix 
c.5660_5661delGGinsATA p.Gly1887fsX27 67 PTC Triple 
helix 
MJ-05 c.1732C>T  p.Arg578X 13 PTC NC1  IVS20+2T>C   Splice site  
HS-06 c.7139G>A  p.Gly2380Glu 93 Missense Triple 
helix 
 IVS115-1G>A   Splice site NC2 
CK-07 
 
c.425A>G  p.Lys142Arg 3 Splice site NC1  c.425 A>G p.Lys142Arg 3 Splice site NC1 
WM-
08 
c.3480delC p.Gly1280ValfsX44 31 PTC Triple 
helix 
c.8780G>A p.Arg2927His 117 Missense NC2 
JD-09 c.425A>G p.Lys142Arg 3 Splice site NC1 c.565C>T p.Gln189X 5 PTC NC1 
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3.3.4 Chronic wound microbiological assessment 
RDEB patients have chronic wounds that are commonly colonised. Graft infection is a 
significant anticipated risk in this patient cohort. Of all the study patients, n= 6/9 have current 
or previously documented history of bacterial colonisation of chronic wounds with a range of 
organisms most commonly Staphylococcus aureus sp, and Streptococcus sp. One patient (BH-
01) had a previously treated MRSA positive skin infection and unusually one of the patient 
group developed a cutaneous infection of Diphtheria isolated from a chronic wound over the 
back. This was discussed with the microbiology team who advised this may have been an 
unusual skin contaminant or commensal but was treated with two weeks of oral macrolide 
antibiotics and full screening was subsequently undertaken for the EB patient cohort. Wound 
colonisation would have a definite impact on healing and increases the risk of graft failure. The 
results of wound swabs taken from chronic wounds within this patient cohort are summarised 





Microbes isolated Site Perceived risk for 
grafting 
BH-01 MRSA (treated 2008) Nose High 
Staphylococcus aureus (mild)  Back/Chest -- 
Streptococcus dysgalactiae (Group C/G) Knee High 
AF-02 Staphylococcus aureus Ear -- 
SC-03 Staphylococcus aureus Neck -- 
Pseudomonas aeruginosa Neck,  back -- 
AK-04 Staphylococcus aureus  Back -- 
MJ-05 Heavy growth of Acinetobacter Right thigh -- 
HS-06 Staphyloccocus aureus  Back -- 
Streptococcus Group C  Back  High 
Diphtheria Back High 
CK-07 Pseudomonas aeruginosa Thigh -- 
JD-08 Streptococcus dysgalactiae, Pseudomonas 
aeruginosa, Staphylococcus aureus 
Arms High 
WM-09 Nil -- --- 
 
 
Table 3.5 Microbiology assessments of wound swabs taken from recruited patients and 
predicted risk of wound infection following grafting 
Wound swab results were reviewed with a consultant microbiologist at GSTT  and given a subjective opinion of 
those organisms most likely to lead to graft failure (labelled “High”)
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3.3.5 Results of type VII collagen expression analysis 
The presence of C7 was assessed using direct immunofluorescence on skin biopsy 
using a monoclonal antibody to the NC1 domain of C7 (Mouse monoclonal Antibody 
type VII collagen LH7.2 (Chemicon Europe Hampshire, UK); 1:100). Each sample 
was compared with a wild type control during each run, and a negative control used 
to assess for non-specific binding of the secondary antibody. 3/9 patients had almost 
completely absent levels of C7 on DIF. Patient subjects’ skin biopsies showed varying 
levels of staining ranging from minor interruptions in staining at the DEJ to complete 







































Table 3.6  Immunolabelling for type VII collagen in patient subjects 
Subjective measures of intensity are shown in the table when verified with the reporting team at the 
National Diagnostic EB laboratory (+++) = normal  (++) = slightly reduced pattern of staining,  (+)= 
faint staining, (-)= complete absence. Using identical image settings three measurements the relative 
mean fluorescence intensity of C7 fluorescence signals was calculated using Image J software 




























3.3.6 Western blot detection of C7 protein from cultured cells 
The amount of residual levels of C7 protein can be extracted from cultured cells and 
analysed using Western blot. Western blot analysis would be able to demonstrate any 
traces of residual non-functioning or aberrant levels of C7. This would be particularly 
useful in patients that exhibit almost completely absent levels of C7 on DIF. There 
were challenges in culturing keratinocytes from patients with RDEB, but fibroblast 
lysates were isolated from each patient. As keratinocytes express far higher levels of 
C7 protein than fibroblasts, further stimulation of cell cultures were shown to be 
necessary in order to elicit the C7 band. Ascorbic acid has been shown to increase 
secretion of C7 from dermal fibroblasts and TGF-β has also been shown to stimulate 
fibroblasts in culture (Amano et al., 2007). Ascorbic acid was added to cell cultures at 
least 48 hours before protein extraction in order to increase levels of C7 detectable in 
fibroblast samples by Western blot. All patients included in this study had varying 
levels of C7 using Western blot. Due to the difficulties encountered with blots from 
fibroblast cultures, it was not possible to run all samples in one simultaneous run with 






Figure 3-10 Western blot showing bands at the level corresponding to 290 kD 
from cultured cell lysates 
(A)Samples were collected from cultured fibroblasts and keratinocytes. Fibroblast and 
keratinocyte extracts from cultured cell samples were each loaded with a total protein of 50-70 
ug of protein. Immunodetection was performed using rabbit polyclonal antibody directed against 
the NC1 domain of C7, 1/3000. Samples show comparison of patient keratinocyte and fibroblast 
lysates (in this case patient 05) with a negative control (EB sample containing absent C7) and wild 
type positive controls  (B) The relative quantities of C7 protein detected using western blot from 
study patients 1-7  were calculated using Image J software and expressed as a relative proportion.  
 
3.3.7 Immune response to type VII collagen 
These results are described in Chapter 4 
3.3.8 Selection of patients for assessment of keratinocyte proliferative capacity 
The first patient selected for assessment of keratinocyte proliferative capacity was MJ-
05. This assessment determines the time taken for generation of an epidermal sheet 
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and therefore indirectly a measure of the number and function of epidermal stem cells 
capable of sustained proliferation. This is an essential criterion in terms of patient 
selection for this study which utilises keratinocytes isolated from skin biopsy in order 
to generate a long terms skin equivalent graft. In RDEB there is a significant risk of 
keratinocyte stem cell “exhaustion” due to continuous and recurrent blistering. Those 
patients considered most suitable for grafting should have initial assessments of 
keratinocyte proliferative capacity. In this cohort, keratinocyte proliferative capacity 
may be determined by i) subject’s age ii) biopsy sample location iii) sampling 
conditions iv) transport and culture conditions as well as the effects of the underlying 
C7 deficiency. Clinical observations have suggested that epidermal stem cell numbers 
or function may be depleted with increasing age (Barrandon and Green, 1987, Youn 
et al., 2004), however this has not been borne out in murine models. Charruyer et al 
(2009) have shown that slower wound healing in ageing mice may be due is not due 
to a decline in stem cell potential but rather the decreasing proliferative output of 
progenitor cells (Charruyer et al., 2009). Slower wound healing in ageing skin may 
therefore not represent an absolute reduction of EpSCs (Racila and Bickenbach, 2009, 
Gago et al., 2009) but rather impaired stem cell mobilisation and ability to respond to 
recruitment signals. Scientific observations from the centre of regenerative medicine 
in Modena have suggested that the number of holoclones isolated from skin biopsy 
samples as assessed via colony forming assays is related to subjects’ age (personal 
communication, Michele De Luca, November 2015).  Clonal analysis of keratinocytes 
in culture also varies according to location in the human cornea (Builles et al., 2008) 
and the likely determinant of stem cell numbers in human skin would be the amount 
of hair follicles as well as the thickness of the epidermis. Based on the location of 
human epidermal stem cells within both the hair follicle bulge and upper isthmus, hair-
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bearing sites would be preferred for sampling. However, Mavilio et al (2006) observed 
that only the hairless palmar aspects in their subject yielded sufficient holoclones for 
generation of an epidermal graft. Therefore, one would assume that sites with thicker 
epidermis may have higher numbers of epidermal stem cells within the interfollicular 
region or that the relatively unblistered sites may have preserved numbers of epidermal 
stem cells.  However, this study also demonstrated that donor biopsy site skin cells 
still retain the characteristics of that anatomical location through serial doublings. 
Keratin 9 expressed exclusively in keratinocytes isolated from palms and soles was 
still detected in the transgenic epidermis 6.5 years after grafting (De Rosa et al., 2014). 
This clearly demonstrates the presence of a few epidermal stem cells able to maintain 
the characteristics of the donor site despite multiple epidermal turnovers.    
The skin biopsy taken from MJ-05 was therefore taken from an unblistered hair-
bearing site. This was an incisional biopsy measuring 2cm2 taken from the right 
abdomen. The transport media and containers for transport were received from 
Modena 24 hours before the biopsy and all measures taken to ensure that the 
designated containers were maintained between 2-8ºC alongside the temperature 
loggers. To ensure transport according to GMP standards, all timings of delivery of 
the containers, removal of skin biopsy and delivery of the sample had to be 




Figure 3-11. Photograph of transport materials and packaging required for 
transport of skin biopsy according to GMP protocol 
The biopsy site was shaved to minimise the risk of contamination and then cleaned 
with Betadine solution followed by 70% ethanol. Excess disinfectant was removed 
with sterile saline solution and then the local anaesthetic was injected intradermally. 
Mepivicaine hydrochloride was used as lignocaine hydrochloride has been shown to 
exert toxic effects on keratinocyte cell cultures (Mountford et al., 1991).  
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Samples were then analysed in Modena in order to assess stem cell proliferative 
capacity according to methods described by Mavilio et al (2006). The results are 
discussed in the next section.  
3.3.9 Selection of patients most suited for phase I clinical trial 
Following the final review of data described in this chapter there were three patients 
felt to be most suitable for consideration of entry for a phase I clinical trial of ex vivo 
gene therapy for RDEB. The main criteria for assessment were as follows 
1. A strong desire and motivation to take part. 
2. Mutations on both alleles of COL7A1 predicting a severe disease phenotype. 
3. Minimal amounts of C7 demonstrated on either WB or IF reducing the 
likelihood of an immune response to gene therapy product increasing C7 
levels. 
4. Blistering or wounding in areas best suited for surgical grafting and ease of 
dressing changes. 
5. Absence of anti-C7 antibodies binding to DEJ as evidenced by IIF. 
The first patient to be considered was CK-07. This patient has a strong desire for 
participation and has blistering affecting areas such as the forearms, a relatively 
straightforward area for grafting. In terms of immune response to C7 this patient had 
a negative ELISPOT and IIF result, with only a borderline positive ELISA using one 
of the assays. This patient has a homozygous mutation c.425A>G in exon 3. Gardella 
et al. have previously demonstrated this variant is a pathogenic splice site mutation (-
2 position of the splice donor of intron 3) through the creation of three out of frame 
transcripts each resulting in a PTC (Gardella et al., 1996). Therefore one would expect 
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complete absence of C7 protein. This was confirmed on immunofluoresence but 
unusually a small amount of C7 was demonstrated on Western blot from cultured 
keratinocytes only (not fibroblasts).  
The second patient to be considered was HS-06. The key determinant for inclusion has 
been her strong desire to graft troublesome wounds on her back that have been present 
for over 10 years. Despite a relatively severe clinical phenotype she has evidence of 
C7 both on IF and Western blot analysis using antibodies against the NC1 domain. 
This patient has two heterozygous mutations in COL7A1; a glycine substitution 
c.7139G>A in exon 93 leading to p.Gly2380Glu and an acceptor splice site mutation 
IVS115-IG>A likely to result in exon skipping or aberrant splicing, which may 
account for the higher than expected levels of C7 demonstrated. Immune response was 
favourable as she only had a borderline positive ELISPOT but ELISA and IIF were 
negative. One of the clinical concerns would be the risk of wound infection at graft 
site as she had previously been found to have positive Diphtheria swab showing a toxic 
strain. This has been appropriately treated and wound swabs from multiple sites would 
need to be taken before undertaking a surgical procedure. 
The third patient for consideration was MJ-05.  This individual is highly motivated 
and keen to be involved in a clinical trial. This patient has mutations resulting in a 
PTC on exon 13 (p.Arg578X) within the NC1 domain and a splice site mutation 
IVS20+2T>C. The location of chronic wounds again includes the back area, which 
could be difficult in terms of grafting unless he would be able to sleep on his front 
during the post-operative period. There was demonstrable C7 on both IF and Western 
blot from cultured cells and no evidence of an immune response to C7 based on 
ELISPOT and IIF analysis, although both ELISA assays were positive strongly 
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suggesting the presence of some anti-C7 antibodies that do not bind to the DEJ. These 
antibodies may be a consequence of previous therapy with intradermal allogeneic 
fibroblasts, although there is currently no direct evidence to support this theory.  
3.4 Discussion 
The aim of this study was to select a suitable cohort of patients for a phase I study of 
ex vivo gene therapy for RDEB. The definition of the “ideal patient” has evolved over 
time. Initially patients with only mild to moderate disease, classified as having RDEB 
(Gen Intermed) or RDEB (Inversa) were identified, rather than RDEB (Gen Sev). 
Patients with moderate severity disease would be likely to have varying amounts of 
aberrant or non-functioning C7 as opposed to those patients with RDEB (Sev-gen) 
who typically have minimal or absent levels of C7. Those with moderate disease 
hypothetically have a reduced risk of developing a significant immune response to an 
engineered graft containing exogenous C7 (Pendaries et al 2010). Patients with 
moderate disease severity would also be more likely to have large areas of unblistered 
skin suitable for grafting. Conversely the tolerability and ethical considerations of 
performing an invasive procedure such as skin grafting in a moderately affected 
patient need to be considered. The majority of patients with RDEB (Gen Intermed) or 
RDEB (Inversa) had a strong preference for therapies targeting their chronic wounds, 
which were very localised. Approaching these patients with a trial protocol designed 
to graft an area of normal appearing skin with the associated risks of scarring would 
be challenging. Demonstrating graft success using an increase of levels of C7 would 
also be difficult in those secreting higher levels of baseline mutant protein. Based on 
these points, only patients with multiple chronic wounds and moderately severe/severe 
disease were selected.  
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Further consideration critical to patient selection was subject age at time of grafting. 
From a purely biological perspective selection of a younger patient should ensure a 
higher likelihood of optimal keratinocyte proliferative capacity and ensure higher 
number of epidermal stem cells isolated and cultured from skin biopsy. This is based 
on unpublished experience of cell culture of RDEB patient samples and comparison 
of keratinocyte clonal capacity between adult and paediatric patients (discussion with 
Matthias Titeux, July 2014). From an ethical perspective, one should consider that 
clinical trials should be targeted at the paediatric population primarily in order to 
prevent the inevitable and devastating scarring leading ultimately to lethal squamous 
cell carcinomas in adulthood. Clinical trials in adults whom already have mutilating 
scars and contractures will have a different impact clinically compared with therapies 
administered to infants. Clinical trials in paediatric populations in the first instance 
have been performed for cell therapies such including BMT and intravenous MSC 
therapy. One consideration is that young children would be least likely to tolerate 
grafting procedures requiring strict wound care and with a high risk of graft failure 
due to infection. Steps necessary for optimal post-surgical wound care in young 
children would be challenging to implement, such as dressing care and avoidance of 
tampering with the dressing and wound site.  The main consideration for phase I 
studies utilising gene therapies is the unknown risks related to the insertional 
mutagenesis and possible tumorigenesis. The adverse events occurring in the early 
SCID trials leading to the deaths of two children due to leukaemias directly related to 
the gene therapy product still clouds the field. Regulatory bodies are understandably 
cautious and therefore the preference would be for phase I gene therapy studies to be 
trialled in adults first and offered to children only once shown to be safe.   
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Graft site is one the critical factors determining the clinical outcome. One of the most 
challenging considerations has been whether to place the graft onto unblistered 
patches of skin versus previously wounded or ulcerated areas. An unblistered site 
provides a clean and even wound bed suitable for grafting. The level of wound 
cleavage and wound size would then be standardised between patients. However, the 
risk of creating a new artificial wound in an area that had previously been unaffected 
may be extremely unappealing from a patient perspective. Counselling regarding the 
risk of graft failure and the possibility of creating an artificial wound is difficult. The 
alternative option of grafting chronically wounded areas is fraught with difficulties, 
predominantly related to microbial colonisation, but certainly more appealing from a 
patient perspective. The ideal clinical case would be to graft a freshly blistered wound. 
New blister sites have higher amounts of recruited epithelial progenitors released in 
response to the hypoxic stimulus. Necrotic keratinocytes are known to secrete the non-
histone nuclear protein, high mobility group box 1 (HMGB1) into the RDEB blister 
roof. Tamai et al. have shown HMGB1 to be released by keratinocytes within the first 
10 min after blister formation and to readily enter the bloodstream (Tamai et al., 
2011b). This group also identified a subpopulation of bone marrow cells containing 
epithelial progenitors contributing to the restoration and maintenance of the epidermis. 
These cells are non-haematopoietic MSCs with cell sorting showing that they were c-
kit negative, lineage (Lin) negative and PDGFRα- positive. These cells were shown to 
be directly mobilised by HMGB1 released from freshly wounded skin, the focal 
recruitment being guided by the higher local tissue concentration of HMGB1 in the 
damaged skin as compared with the circulation (Iinuma et al., 2015). Higher levels of 
these epithelial progenitors would likely lead to improved wound healing and likely 
successful graft take. Fresh wounds are impractical to graft from a practical 
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prospective, as the graft requires at least 6 weeks for development. The notion of 
“induced fresh wounds” (ie a blister mechanically induced by rubbing non-traumatised 
skin) is an option to produced standardised wounds in specific locations amenable to 
grafting. Siprashivili et al (2016) did select 5 chronic wounds and one induced wound 
for each patient.  One conflicting hypothesis against grafting freshly wounded areas is 
that there may also be a risk that endogenous recruited epithelial progenitors would 
preferentially compete with the genetically corrected material.  The ultimate decision 
has been to decide on the anatomical location of the graft on an individual basis.  All 
areas will be considered but those that allow ease of local anaesthetic administration 
and wound dressings will be preferred. Sites such as the forearms will be the optimal 
graft site and therefore this was considered during patient selection for this study. Four 
out of the nine selected patients have chronic wounds affecting the forearms and 
therefore would be preferable for the future consideration.  
Since the conclusion of this study, there have been a number of changes that would 
alter my optimum patient selection. Firstly, there has now been a change in the 
workgroup, and therefore assessments for proliferative capacity will now be sent to 
Madrid (CIEMAT). This will delay the date for the likely first patient to be grafted. 
Secondly,  patients CK-07 and HS-06 have developed cutaneous SCC. This therefore 
would exclude them from participation. This highlights the importance of ensuring a 
large number of potential patients in studies of rare diseases, in which the patient 
cohort may succumb to both infections and cutaneous malignancies. My next options 
for patient recruitment would be to widen the study to include patients from other 
centres such as Birmingham and Solihull, with their regional EB sites designated as 
patient identification centres (subject to regulatory approval).  The GENEGRAFT 
project is currently still yet to open (July 2017) and is pending approval from ANSM 
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the EU regulatory body. ANSM have advised that further murine studies are required 
in both male and female mice to ensure no downstream germline adverse effects 
related to the genetically corrected graft.  
3.5 Summary 
This chapter summarises the work performed in order to find the most suitable RDEB 
patient cohort for the application of a gene corrected skin equivalent graft. The main 
factors assessed were related to the severity of phenotype, possible predictors for the 
development of an immune response, likely tolerability of the graft procedure, risk of 
infection and possible graft site. A total of 9 patients were selected and the best three 
possible candidate patients were identified although since the completion of the study 





Predicting immune response to ex vivo delivered C7 
4.1 Introduction 
Induction of immune responses to the transgene product within donor recipients is a 
serious concern in the development of gene therapy clinical trials. The exact nature of 
response and association between transgene or target protein expression profiles and 
immune induction following gene transfer remains unclear. The potential for 
immunogenicity to the vector, transgene or newly expressed therapeutic protein can 
give rise to three principal concerns. First, an immediate type I hypersensitivity may 
occur as an immune response. Secondly, an immune response directed at the target 
protein may attenuate or minimise its efficacy. Thirdly, the immune response to the 
newly expressed protein (stimulated via gene expression of the transgene) may then 
induce autoimmunity to the patient’s own residual native C7 protein (Schellekens, 
2002).  
4.1.1 The role of anti-C7 antibodies in RDEB 
Antibodies targeting C7 are most commonly detected in Epidermolysis Bullosa 
Acquisita (EBA), an acquired auto-immune disorder characterised by mechanobullous 
skin fragility and similar clinical signs and symptoms as RDEB (Roenigk et al., 1971). 
Patients are born with normal skin and during adulthood develop IgG antibodies 
against C7 and anchoring fibrils in the DEJ.  Epitope mapping of the C7-specific 
immune response in EBA patients identified the NC1 domain of C7 as the major 
antigenic site (Tanaka et al., 1994). Binding to the collagenous or the NC2 domain is 
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rarely observed in EBA (Ishii et al., 2004) although pathological blister induction is 
independent of targeted epitopes. Pendaries et al (2010) state that in silico prediction 
in RDEB samples has shown that peptide binding on different Human Leucocyte 
Antigen (HLA) demonstrate antigenic binding on the full length of the protein 
including NC1 domain, NC2 domain and the triple helical component (Pendaries et 
al., 2010). Experimental studies have shown that these antibodies are pathogenic. The 
transfer of both rabbit and human anti C7 antibodies to nude mice have resulted in the 
development of sub-epidermal blisters (Woodley et al., 2006, Sitaru et al., 2005).   
Anti-C7 antibodies have been detected in other inflammatory conditions apart from 
EBA such as inflammatory bowel disease and systemic lupus erythematosus, without 
necessarily leading to the clinical phenotype of skin blistering (Hundorfean et al., 
2010, Licarete et al., 2012).  
The expression or administration of a new recombinant therapeutic protein is known 
to initiate a humoral response (Koren et al., 2002). Remington et al (2009) have shown 
that injection of recombinant C7 in a C7 knockout mouse model led to an immune 
response evidenced by circulating human anti-C7 antibodies. These antibodies neither 
bound to the BMZ nor prevented the incorporation of newly injected human C7 into 
the BMZ (Remington et al., 2009).   
There have now been a number of reports of a more than expected number of 
circulating antibodies to C7 detected in patients with RDEB prior to any treatment 
with gene, cell or recombinant protein therapies. Woodley et al (2014) have shown 
that 12 out of 22 RDEB patients had low levels of circulating anti-C7 autoantibodies 
that do not bind to the BMZ. Pendaries et al (2010) published the first reports of a 
newly validated ELISA to C7 using the full length C7 protein epitopes as well as an 
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ELSPOT assay to analyse the B cell and T cell responses to the full length C7 protein. 
Seven patients with RDEB were evaluated; only 1/7 had a positive ELISA and 3/7 had 
a positive ELISPOT (Pendaries et al., 2010).  Two of these patients had a COL7A1 
mutation indicative of RDEB (Gen Sev) and leading to the complete absence of C7 
protein evidenced on DIF and western blot. This suggests that these patients recognize 
C7 as a foreign antigen and points to potential rejection of  C7 collagen-based gene or 
protein therapy. Patient 8, who showed also an elevated ELISA as well as ELISPOT 
score, had a healthy dizygotic twin who died at birth, suggesting that she may have 
developed C7-reactive T-cell clones through her contact with this protein in utero. 
These results highlight the necessity for assessment of an individual’s immune 
response to C7 using in vitro methods, as an adjunct to the COL7A1 mutation analysis 
and C7 expression levels. Tampoia et al (2013) have shown that 13/15 patients 
exhibited anti C7 antibodies.  Although there have been no proven associations 
between levels of C7 expression and anti-C7 antibodies, both Woodley et al (2014) 
and Tampoia et al (2013) had commented on an association between antibody levels 
and disease severity scores.  
However, within these cohorts of patients with RDEB there have not been any 
antibodies detected binding to the BMZ. The clinical significance of these antibodies 
is difficult to interpret. To date there has only been one case of DDEB complicated by 
EBA induced by autoantibodies to the NC1 domain of C7 (Hayashi et al., 2016). The 
mutation identified in this individual was a glycine substitution within the central triple 
helical domain of COL7A1 and the mutant protein expressed was predicted to inhibit 
triple helix formation of wild type C7 in a dominant-negative manner. Although EBA 
is not known to occur in RDEB, this case highlights that COL7A1 mutations 
generating mutant C7 peptides may be a risk factor for EBA in some cases.  
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In summary, circulating anti C7 antibodies have been detected in vivo in RDEB 
patients as well as in animal models following exposure to therapeutic C7 protein, but 
rarely do these antibodies bind to the DEJ. Nevertheless, all therapies for RDEB 
including gene therapy, cell therapy and protein therapy will involve exposure of the 
patient to new epitopes or domains of C7 and therefore there will be a potential to 
generate anti-C7 antibodies. Clearly, the presence of these antibodies should be 
evaluated and taken into consideration in the selection of patients for clinical trials.  
4.1.2 Immune Response to genetically corrected cells 
Immune response to the viral capsid of AAV vectors has been a known hurdle using 
this vector subtype. In contrast, lentiviral and retroviral vectors have a reduced 
immunogenic potential, however, the risk of immune response to transgene as well as 
newly expressed protein is a persistent issue. Previous studies of cutaneous gene 
therapy have shown that the expression of a neo-antigen in a non-tolerant host to be 
associated with rejection of the genetically modified tissue (Ghazizadeh et al., 2004, 
Dellambra et al., 2000). In ex vivo gene therapy studies, immune response and 
activation of cytotoxic T lymphocytes (CTL) is thought to be elicited by cross 
presentation of keratinocyte derived antigens (Heath et al., 2004). Specific transgene 
immune responses have been shown to develop as early as 2 weeks post 
transplantation using immunodeficient mouse models (Lu and Ghazizadeh, 2007). In 
addition to the CTL mediated destruction of gene corrected tissue following ex vivo 
gene transfer, Lu and Ghazizedah (2010) have also shown a role for the Th2 pathway 
and eosinophilic response. In clinical studies, however, there have been no reported 
incidents of adverse immune response or rejection of genetically corrected tissue in 
RDEB thus far. In the case of the JEB phase I study the lack of immune response was 
likely due to appropriate patient selection (Mavilio et al., 2006). The adult patient had 
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compound LAMB3 mutations allowing residual (<5%) expression of laminin β3 
polypeptide, therefore the newly grafted antigen would be unlikely to be perceived as 
“foreign” by the host immune system. Antibodies to the vector derived LAMB3 in the 
patients’ serum were not detected using western blot analysis, immunoprecipitation 
and immunohistochemistry. There was no evidence of an allergic or inflammatory 
cutaneous reaction on serial monitoring skin biopsies from the graft and donor sites. 
There was no detected cytotoxic or IFN-γ immune response to an autologous, LAMB3 
transduced lymphoblastoid cell line in PBMC samples at follow-up time points. This 
suggests that the selected patient was “tolerant” to laminin β3 polypeptide. Despite 
this outcome in this pioneering study in inherited skin disease, the theoretical 
possibility of induction of immune response to the transgene product is a definite 
consideration in developing clinical trial protocols for cell, gene or protein therapies 
that aim to increase levels of C7 at the DEJ. 
When designing phase I studies, this safety aspect is of primary concern, however, the 
development of an immune response to transgene is also critical when aiming for 
increased efficacy of the proposed graft. Several other studies using ex vivo gene 
therapy have shown a correlation between antibodies against the therapeutic protein 
and treatment failure in animal models of liver disease (Aubert et al., 2002) and 
haemophilia (Van Damme et al., 2003). However, this has not been demonstrated in 
RDEB.  
The aim of the next phase of the study was to assess the immune response to C7 in 
vitro in selected patients and to use these data to stratify those with the highest risk of 




4.2.1 Detection of anti-C7 antibody using indirect immunofluorescence 
microscopy 
Sera were obtained from each of the RDEB subjects at time of recruitment and sent to  
the Immunodermatology Laboratory at St Thomas’ Hospital for analysis. Frozen 
sections of normal human skin (5 µm), split with 0.02M EDTA, were exposed to serial 
dilutions of the RDEB subjects’ sera (1:10 and 1:100 in Dulbecco’s PBS) for 45 
minutes at 37◦C and then washed and dried in Dulbecco’s  PBS. FITC-labelled anti-
human IgG and IgA antibodies (Dako) were diluted 1:100 in Dulbecco’s PBS and 
applied to the sections for a further 45 minutes at 37◦C. Sections were then washed, 
as before, prior to mounting in Citifluor AF2 solution (TAAB Laboratories) and 
microscopy. 
4.2.2 Detection of anti-C7 antibodies using ELISA commercial kit 
Sera were obtained from each of the RDEB subjects and either used as a fresh sample 
or stored at -80ºC  before assessment. Each sample was analysed using the MESACUP 
anti-C7 test kit (Medical and Biological laboratories, Japan), which is a semi-
quantitative enzyme linked immunoabsorbent assay (ELISA) for the detection of 
antibodies to C7 in human serum. This was performed by the Immunodermatology 
laboratory at Guys and St Thomas’ NHS Trust. 
4.2.3 Detection of B-cell and T-cell response to type VII collagen using 
ELISPOT  
The enzyme linked immunoabsorbent spot (ELISPOT) assay is a widely used assay 
for monitoring cell-mediated immunity, detecting antigen specific T and B cells within 
a popul ation of peripheral blood mononuclear cells (PBMCs). This can detect an early 
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antigen directed activation of lymphocyte sub-populations at the single cell level, as a 
complement to the detection of circulating antibodies using ELISA. Full length 
recombinant C7 protein was purified from the conditioned medium of an RDEB 
keratinocyte cell line transduced with a COL7A1 retroviral vector. T cells from healthy 
donors were stimulated with puriﬁed recombinant type VII collagen to measure the 
baseline reactivity to the protein. Concanavalin A (25 ng ml) was used in parallel as a 
positive control of T-cell reactivity. IFN-γ response was expressed as spots per well. 
To ensure standardisation of results compared with recruits from other centres, 
ELISPOT samples were sent to Paris for analysis by Professor Alain Hovnanian and 
his team.  
4.3 Results 
4.3.1 Predicted immune response to C7 based on ELISA, ELISPOT and 
Indirect IF 
Immune response to C7 was assessed using ELISA and ELISPOT assays to detect 
antibodies targeted against the C7 protein. Binding of these antibodies to the BMZ, 
and therefore the likelihood of pathogenicity in vivo, was determined using indirect 
immunofluorescence. These assays were used in this cohort to determine the risk of 
developing an adverse immune response to C7, and therefore select the best candidates 























BH-01   33 
 ++ -- -- -- -- 
AF-02 
24 + 90 (+) 18 (+) -- -- 
SC-03 
23 + 29.08 (+) 61 (+) -- -- 
AK-04 
27 -- -- 34 (+) -- -- 
MJ-05 
42 ++ 26.58 (+) 14 (+) + -- 
HS-06 
47.5 ++ -- -- Borderline -- 
CK-07 
32 -- 17.55  
(+/-) 
-- -- -- 
 
Table 4.1 Summary of patients’ C7 expression in the skin and anti-C7 
autoantibodies in serum. 
(+++)   = normal   
(++)   = slightly reduced pattern of staining,  
(+)  = faint staining 
(-)  = complete absence 
C7 expression at the DEJ was determined by immunofluorescence staining of cryostat sections with an 
anti-NC1 antibody. ELISA was performed with a commercially available Mesacup kit (Medical and 
Biological laboratories, Japan) that uses a mixture of immobilized NC1 and NC 2 domains as the target 
substrate (<6 U = normal). A further assay used full-length, recombinant human C7 as the target 
substrate (C7 ELISA full length, < 20 U = normal dependent on parallel control). ELISPOT assay 
analyses B- and T-cell responses to full length C7. Indirect immunofluorescence was used to assess the 
binding of circulating IgG antibodies to salt split skin. 4/7 (02, 03, 04, 05) patients showed positive 
anti-C7 antibodies in their sera using a commercially available ELISA kit which targets both the NC1 
and NC2 epitopes. 4/7 (02, 03, 05, 07) also showed positive anti-C7 antibodies in their sera using 
ELISA assay targeting full length recombinant C7 protein.  
Abbreviations : BEBS = Birmingham Epidermolysis Bullosa Score, IF = Immunofluorescence, NC-1 
= non-collagenous domain 1, NC2 = non-collagenous domain 2.  
144 
 
4.3.2 Correlation of immune response with markers of disease severity 
Woodley et al (2014) and Tampoeia et al (2013) have both shown a correlation between disease 
severity scores and predicted immune response to C7 (Woodley et al., 2014, Tampoia et al., 
2013), with those with a higher BEBS score having a greater predicted immune response. My 
data shows a similar association but not significantly. The limitation in most cases is the small 
numbers of cases analysed, as well as the objective measure of disease severity. I used the 
BEBS score which takes into account eleven items, including area of damaged skin, 
involvement of nails, mouth, eyes, larynx and oesophagus, scarring of hands, skin cancer, 
chronic wounds, alopecia and nutritional compromise. The method is simple, easy to use and 
applicable to all types of EB but the limitations are that only one item takes into account disease 
activity. Although BEBS is a validated objective measure of diseases severity, it can be difficult 
ascertain subtle or transient changes in disease activity versus chronic scarring and 
contractures. Other disease scores such as the Epidermolysis Bullosa Disease Activity and 
Scarring Index (EBDASI) score has the ability to distinguish activity scores that are responsive 
to therapy separately from damage (Loh et al., 2014). The iscorEB (Instrument for Scoring 
Clinical Outcome of Research for Epidermolysis Bullosa), in contrast to previous scoring 
models, includes not only the perceptions of disease severity of EB health care professionals, 
but also patient and parent perception of disease severity. Perhaps other scores such as EBDASI 
and iscorEB would be useful to run in parallel for the assessment of immune response to C7. 
At the time of study design the BEBS score was the only validated published severity score for 










Figure 4-1 Correlation between BEBS scores and ELISA assays. Correlation is 
determined by Spearman rank coefficient, r = 0.16 and r = 0.41. 





This study has shown that circulating anti-C7 antibodies have been detected using 
ELISA and to a lesser extent ELISPOT analysis in a significant number of study 
subjects (See Table 4.2 ). This observation has been validated by other groups 
(Woodley et al., 2014, Tampoia et al., 2013) also demonstrating that a higher than 
expected proportion of patients with RDEB have de novo circulating antibodies that 
are non-pathogenic through lack of binding to the BMZ. Woodley et al (2014) reported 
that 12/22 of RDEB patients exhibited anti-C7 antibodies, but none showed 
pathogenic binding to BMZ. The finding of anti-C7 antibodies did not correlate with 
expression of C7 in patients’ skin, however a correlation between antibodies and 
BEBS score was detected by both Woodley et al (2014) and Tampoia et al (2013). 
Perhaps an explanation for this observation could be an altered recognition of “self” 
due to altered protein synthesis secondary to epigenetic mechanisms affecting cDNA 
gene expression. Epigenetic mechanisms primarily consist of DNA methylation, 
histone modifications and small non-coding RNA transcripts, which may then lead to 
the development of autoimmunity.  The correlation between anti-C7 antibodies as well 
as auto-antibodies to other constituents of the BMZ such as BP180 and BP230 could 
suggest “epitope spreading” as an underlying phenomenon, with recruitment and 
activation of autoreactive T-lymphocytes specific for secondary epitopes (Tampoia et 
al., 2013). Previous exposure to neo-antigen following previous fibroblast cell therapy 
may be relevant in my own cohort. 4/7 study subjects (02,03,05,07) had received 
previous intradermal allogeneic fibroblasts at least six months before study inclusion 
and interestingly all of these patients had detectable anti-C7 antibodies using either 
ELISA assay and one of them had a positive ELISPOT. Of these patients, 2/7 patients 
had received allogeneic fibroblasts at more than one time point with no development 
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of detectable clinical adverse immune response to the therapy. In terms of efficacy, 
MJ-05 reported improved response to the cell therapy after second administration of 
cells, therefore suggesting that the development of anti-C7 antibodies did not play a 
role in a reduction of therapeutic efficacy.  The high proportion of positive C7 auto-
antibodies using ELISA in this and other cohorts does minimise its usefulness and 
validity as a screening tool for ex vivo gene therapy clinical trials. These findings have 
been substantiated by the recently published EBSTEM study, in which 9/10 children 
with RDEB had positive anti-C7 antibodies detected using a commercially available 
ELISA kit (Petrof et al., 2015). In this cohort there were no sera binding to the DEJ 
using IIF and also there were no changes in ELISA or IIF following treatment with 
intravenous allogeneic mesenchymal stromal cell therapy. Based on our findings as 
well as others, a positive ELISA should only be used as an inclusion or exclusion 
criteria if a corresponding IIF analysis shows binding of the antibodies to skin. The 
ELISPOT assay appears to be a more specific assay in this study cohort. Only one 
patient had a positive ELISPOT compared to 4/7 patients with positive ELISA. None 
of the patients showed pathogenic binding of these autoantibodies to the BMZ. There 
have no experimental animal models assessing whether these antibodies have a 
pathogenic role in RDEB. There have been several reported cases of adult patients 
with RDEB who developed patches of clinically normal skin that never blister due to 
spontaneous COL7A1 gene correction in a subpopulation of keratinocytes (not 
fibroblasts) (Almaani et al., 2010, Tolar et al., 2014).  In one case exposure to the 
newly recognised C7 protein led to the development of auto-antibodies, but with no 
pathological binding to the BMZ and no reported clinical sequelae. Based on clinical 
studies it would appear that these antibodies are not clinically relevant, however, the 
effect on graft outcome and risk of rejection has yet to be demonstrated. In terms of 
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grafting the first patient, it may be preferable to select a subject with negative 
ELISPOT and Indirect IMF in the first instance as a definitive criterion. The positive 
finding of anti-C7 antibodies as detected by ELISA appears to be a finding more 
common than previously anticipated in untreated RDEB patients and therefore should 
not represent an absolute exclusion criterion: this observation has important 
implications for defining inclusion/exclusion criteria in other clinical trials in the 
future.  
4.5 Summary 
This chapter summarises the findings related to a predicted immune response to 
exogenous C7 protein in 7 of the selected patients recruited in for the EBGEN study. 
4/7 patients had a positive ELISA to C7 and only one patient had a positive ELISPOT. 
None of the samples showed binding to the BMZ suggesting likely pathogenicity. This 
raises the question for the necessary investigations required to predict a likely immune 





Patient perspectives towards gene therapy clinical trials 
5.1 Patient and public involvement in clinical trials 
Patient and public involvement (PPI) in the design and development of clinical trials 
is critical both to ensure that the primary needs of the patient community are addressed 
but also to guarantee adequate levels of recruitment (Gamble et al., 2014, Boote et al., 
2011). The research community has been increasingly made aware that patients and 
the public are stakeholders in clinical trials and should be directly involved in trial 
design (Mullins et al., 2014). The UK Department of Health (2006) Best Research for 
Best Health guidelines state that PPI must be included in all stages of the research 
process including priority setting, defining research outcomes, selecting research 
methodology, patient recruitment, interpretation of findings and dissemination of 
results (Evans, 2006). This is particularly important in rare diseases such as RDEB. 
Studies examining the challenges of planning clinical trials for other rare genetic 
disorders such as phenylketunoria (PKU) have highlighted issues including the 
relatively small pool of known patients with specific phenotypes, the logistical issues 
including the long distances to travel to the nearest disease centre, and the significant 
burden of disease leading to dependence on carers and family leading to psychological 
burdens and lack of hope for curative treatments (DeWard et al., 2014). Davila-Seijo 
et al (2014) have also highlighted that most current randomised clinical trials for 
RDEB do not match the research needs as perceived by clinicians and patients (Davila-
Seijo et al., 2014), as researchers appeared to be dedicated to more high-risk high 
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technology approaches such as bone marrow transplant whereas patients research 
needs were mainly related to symptoms control and more “everyday problems”. Phase 
I proof of principle studies such as the GENEGRAFT study aimed at developing long-
term curative approaches for the disease may not be perceived to be a research priority 
by patients. Patient and public involvement at an early stage is therefore critical to 
ensure patient engagement in these early studies and tailor the protocol to patient needs 
as much as possible.  
PPI can be undertaken using patient questionnaires, focus groups or the involvement 
of patients or patient organisations in review of trial documents and protocols. The 
main areas for patient involvement related to the GENEGRAFT study would be in 
relation to the location of the grafted skin equivalent and also the outcome measures 
that should be assessed. Methodology and outcomes based on relevance to patients 
would lead to findings having a greater impact on patient care. The key questions areas 
that I wished to explore were related to  
1. Awareness of current gene therapy clinical trials for RDEB. 
2. Willingness to proceed with grafting procedure for the purposes of a clinical 
trial.  
3. Favoured locations of wounds requiring grafting.  
4. Favoured areas of grafting (ie. blistered versus unblistered sites). 
5. Willingness to travel outside of the UK for the purposes of a clinical trial. 
5.2 Electronic patient survey 
An electronic patient survey was designed and reviewed by the clinical lead for the 
EB service (see Appendix 2). The survey entitled “A survey of opinions regarding 
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gene therapy options for patients with RDEB” received approval from the Research 
and Development division at Guys and St Thomas’ NHS Trust in September 2014 
(RJ114/N254).  
5.3 Survey outcomes 
Following consultation with the clinical specialist nursing team 20 patients with 
RDEB were identified with access to email and a current email address. There were 
12 respondents to the survey sent out using the server “survey monkey”. All results 
were anonymised and data stored in accordance with the Guys and St Thomas’ 
Hospital NHS Foundation Trust Data Protection guidance. All respondents had a 
confirmed diagnosis of RDEB and were under the clinical care of GSTT. The majority 










Table 5.1.  Abridged results of electronic survey of patients' opinions regarding options for gene therapy clinical trials 
 YES NO NOT SURE 
HAVE YOU EVER TAKEN PART IN A CLINICAL TRIAL? 9 (75%) 3 (25%) - 
HAVE YOU HEARD OF A NEW THERAPY FOR RDEB CALLED “GENE THERAPY”? 7 (58.3%) 3 (25%) 2 (16.6%) 
WOULD YOU CONSIDER DISCUSSING TAKING PART IN A GENE THERAPY CLINICAL TRIAL? 8 (66.6%) 3 (25%) 1 (8.33%) 
WOULD YOU CONSIDER HAVING A SKIN GRAFT OF GENETICALLY CORRECTED CELLS? 6 (50%) 2 (16.6%) 4 (33.3%) 
WOULD YOU BE WILLING TO HAVE A SKIN GRAFT OF ON AN AREA OF YOUR BODY THAT WAS UNBLISTERED? 4(33.3%) 3(25%) 5(41.67%) 
WOULD YOU BE WILLING TO HAVE A SKIN GRAFT OF AN AREA OF YOUR BODY THAT WAS RECENTLY 
BLISTERED? 
4(33.3%) 3(25%) 5(41.67%) 
WOULD YOU BE WILLING TO HAVE A SKIN GRAFT ON AN AREA OF YOUR BODY THAT WAS CHRONICALLY 
WOUNDED (IE >6 MONTHS)? 
5(41.37%) 3(25%) 4(33.3%) 
WOULD YOU CONSIDER HAVING AN INJECTION OF GENETICALLY CORRECTED CELLS INTO A WOUND? 6(50%) 3(25%) 3(25%) 
WOULD YOU BE WILLING TO TRAVEL OUTSIDE OF THE UK TO RECEIVE A SKIN GRAFT OR INJECTION OF 
CORRECTED CELLS AS PART OF A CLINICAL TRIAL? 




The results presented in Table 5.1  highlight both positive and negative patient 
perspectives. The majority of respondents had already taken part in a clinical trial 
previously which had coloured their perspectives on entering another trial. Over half 
of those questioned would consider taking part in a gene therapy clinical trial in the 
future and similar numbers would consider intradermal injections as well as a 
genetically corrected graft. This was an unexpected finding, as the grafting procedure 
is a more invasive procedure and I would have expected the majority to prefer the 
intradermal approach. This may reflect the strong willingness of the patient population 
to further the research field in desperate hopes for a cure. Another factor may be that 
most of the patients who had been involved in a previous clinical trial would have 
received intradermal allogeneic fibroblasts and therefore would be aware of the 
associated pain.  One of the main aims of this survey was to help guide the decision 
regarding graft site however there did not appear to be significant differences in patient 
preferences between unblistered sites, recently blistered sites or chronically wounded 
sites, with only a slight majority favouring chronically blistered sites (33.3% vs 33.3% 
vs 41.7%). The significant majority of patients would be willing to travel outside of 
the UK in order to receive treatment as part of a clinical trial, and also outside of the 
EU if necessary. One limitation of the survey was that the duration of time outside of 
the UK was not specified. A protocol involving grafting multiple sites would 
necessitate a significant period of time outside of the UK with up to 21 days to ensure 
direct surgical wound reviews and dressing reviews in a sterile monitored 
environment.  
One of the most interesting aspects of this survey were the responses to the open-ended 
questions (Appendix 1). There are clear limitations in the interpretation of qualitative 
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data in such a small number of respondents. The reasons given for their decision to 
participate (or not) in a gene therapy clinical trial involving a skin graft clearly showed 
both points of view. Four of the seven responses were positive in relation to the study 
and showed a somewhat altruistic desire to further clinical trials in RDEB with 
comments such as “…I am keen and willing to support any initiatives that may be of 
benefit, be that for me 'today' or others in the future…” and “..I know it's not a cure 
yet but if one piece of skin is corrected maybe with more trials more of my affected 
skin can be corrected”. Three responses were perceived to be negative in regards to 
participation and are related to previous experiences with grafting and the expected 
reaction to an invasive procedure such as grafting, with comments such as “..having 
had my hand operated on and a skin graft done on my leg… I can see the negative 
effects the procedure can create on the donor site and also issues that can arise with 
the newly placed skin”.  
5.5 Summary 
In summary, this brief survey has highlighted the perceived value of gene therapy 
clinical trials within my own cohort of patients and emphasised both the optimism and 
valid trepidations of such ventures. The most important finding is that, despite 
concerns, the majority of patients would be willing to consider involvement in a trial 








Pre-clinical development of phase I clinical trial of transduced 
primary RDEB fibroblasts using a SIN lentiviral vector 
6.1 Introduction 
Pre-clinical studies have thus far aimed to increase levels of C7 at the DEJ via gene 
replacement strategies, cell therapies, protein therapies or drug therapies. The rationale 
for the use of gene modified fibroblasts in RDEB is based on the earlier clinical studies 
that used intradermal allogeneic and non-gene modified autologous fibroblasts to treat 
localized wounded areas (Petrof et al., 2013, Wong et al., 2008). Allogeneic fibroblasts 
have been shown to increase patients’ own levels of C7 and improve skin integrity for 
up to 9 months following a single injection (Wong et al., 2008, Nagy et al., 2011). 
These studies have shown promising results but are limited.  Wong et al used 
fluorescent in situ hybridization (FISH) for the detection of donor Y-positive cells in 
a female recipient and demonstrated the clearance of fibroblasts within 2 weeks 
following intradermal injection. The use of gene corrected autologous cells would 
therefore offer a complementary approach that could feasibly offer longer term 
correction and reversion of C7 at the DEJ, but also diminish the need for 
immunosuppressive medication. Ex vivo gene therapy pre-clinical studies have shown 
that viral vectors, either retroviral or lentiviral vectors carrying the COL7A1 cDNA, 
are able to efficiently transduce patients’ own fibroblasts. In vitro and murine models 
have shown that the gene corrected cells were able to secrete C7 at the DEJ and reduce 
blistering tendency. The rationale for using autologous gene-modified fibroblasts is 
that (a) these cells will persist for far longer than the allogeneic cells and (b) they will 
generate wild-type and not mutant C7. Goto et al (2006) have shown that gene 
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corrected murine fibroblasts alone is sufficient to correct the DEB phenotype (Goto et 
al., 2006). The major challenge is to translate this to a phase I study and provide proof 
of principle data necessary for larger studies.  
 
Figure 6.1. Schematic showing the rationale for the use of gene corrected 
intradermal fibroblasts 
6.1.1 SIN COL7A1 lentiviral vector for the transduction of RDEB fibroblasts 
In order to improve the safety of gene therapy using retroviral vector technology, 
newer self-inactivating (SIN) retroviral and lentiviral vectors have been developed. 
SIN vectors have a 400bp deletion in the U3 region within the 3’ LTR of the transfer 
vector (designated ∆U3) which abolishes full-length vector RNA in transduced cells 
following reverse transcription (Thornhill et al., 2008). Based on these studies a viral 
vector was developed under the guidance of the Institute of Child Health, based on a 
vector construct previously used for previous clinical trials for treatment Wiskott-
Aldrich Syndrome (Galy and Thrasher, 2011, Scaramuzza et al., 2012), ADA-SCID 
(Gaspar et al., 2004) and Chronic Granulomatous Disease (Grez et al., 2010). The 
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vector backbone is based on the 3rd generation SIN lentiviral vectors first published 
by Dull et al in 1998 (Dull et al., 1998b). Packaging constructs are deleted of all HIV 
accessory proteins (vpu, vpr, nef, vif) and Tat. The conditional packaging system 
segregates gag/pol and rev genes.  The transfer vector (pCCL SIN cPPTmtWPRE) 
encodes a modified cDNA COL7A1 under control of a human PGK promoter element. An 
internal human cellular phosphoglycerate kinase (PGK) promoter element (Ginn et al., 
2010, Huston et al., 2011) is incorporated in pCCL-PGK-COL7A1 vector. The PGK 
promoter has been previously shown to drive COL7A1 gene expression in RDEB 
fibroblasts as well as in keratinocytes using SIN retroviral vector systems (Pendaries 
et al., 2010). Incorporating human promoter elements has been shown to reduce the 
risk of unwanted activation of genes adjacent to the integration site (Modlich et al., 
2006) and predisposition to toward activation near to transcriptional start sites 
(Zufferey et al., 1998a, Montini et al., 2006).  The vector encodes the HIV-1 central 
polypurine tract element (cPPT) and mutated Woodchuck hepatitis post-regulatory 
element (WPRE) which has been shown to enhance transgene expression (Zufferey et 
al., 1999). The vector is pseudotyped with the Vesicular Stomatitis Virus (VSV) envelope, 
which exhibits strong multi-lineage tropism. The Rev responsive element (RRE) 





Figure 6.2 Diagram showing SIN pCCL-PGK-COL7 construct. 
The transfer plasmid is shown above with the modified COL7A1 cDNA under control of the human 
PGK promoter element. The packaging plamids in blue segregate gag/pol and rev and the envelope 
plamid on the bottom row is pseudotyped with VSV. 
6.1.2 Aims 
The aim of this part of the thesis was to prepare the pre-clinical data and rationale 
necessary for a phase I clinical trial of intradermal autologous pCCL-PGK-COL7A1 
gene corrected autologous fibroblasts in patients with RDEB. The specific aim was to 
assess the transduction efficiency and levels of gene replacement of a SIN pCCL-
PGK-COL7 vector in primary RDEB fibroblasts. 
6.2 Methods 
6.2.1 Viral vector production 
Viral vector production was performed by the team at the Institute of Child Health. 
The production of lentiviral vector involves four stages: (1) Seeding of master cell 
bank 293T cells at optimal density, subculture and expansion (2) Transient transfection 
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with the 4-plasmid lentiviral packaging system, (3) Harvesting of viral supernatant 
containing the lentivirus pCCL-PGK-COL7A1 and (4) Concentration and aliquoting 
the lentivirus.  
6.2.2 Fibroblast transduction with LV vector 
Primary RDEB fibroblasts were extracted from skin biopsies using the explant method 
(Normand and Karasek, 1995) cultured to generate sufficient numbers and transduced 
using the SIN LV vector at the earliest passage possible. The main aim was to achieve 
transduction efficiencies approaching 10-20%, aiming for less than mean 1 copy/cell. 
Multiplicity of Infection (MOI) is a standardised parameter for the prediction of gene 
transfer events (Andreadis et al., 2000). MOI was based on the following equation: 
MOI = (Viral titre/1000)  x volume viral supernatant (ul) 
 Cell number 
Cell number and volume of supernatant added was adjusted based on the viral titre of 
each supernatant batch. Cell toxicity is likely at volumes over 10% supernatant 
volume: media volume. Based on cell number used, either 6 well, 24 well or T25 flasks 
were used. Untransduced fibroblasts were cultured alongside the transduced cells and 
subjected to parallel culture conditions and passage number. Vector titre was assessed 
by seeding of 105 293T cells in 24 well plates followed the next day by exposure to 
serial dilutions of vector stock. After 72 hours, vector copy number was quantified by 
qPCR targeting HIV psi and subsequently calculating virus copies per cell based on a 
control albumin gene. The vector titre can be estimated across a range of virus volumes 
(0.0032ul to 10.0ul) but the estimate of stable transducing units is considered most 
accurate when 1-10% of cells are transduced (0.01-0.1 copies per cell). A control cell 
line known to encode 3 lentiviral copies per cell provided a reading of 2.6 copies per 
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cell in this assay and was used as an internal control. Copy number in untransduced 
fibroblasts was 0%.  
6.2.3 Migration assay  
The Oris™ Cell Migration Assay (AMS Biotechnologies UK Ltd, Abingdon, UK) is 
a reproducible, sensitive, and flexible assay that can be used to monitor cell migration. 
Formatted for a 96-well plate, the assay utilizes Oris™ Cell Seeding Stoppers made 
from a medical-grade silicone to restrict cell seeding to the outer annular regions of 
the wells. Removal of the stoppers reveals a 2mm diameter unseeded region in the 
centre of each well, i.e., the detection zone, into which the seeded cells may then 
migrate. The Oris™ Detection Mask is applied to the plate bottom and restricts 
visualization to the detection zones, allowing only cells that have migrated to be 
detected. Readout can be performed by microscopy or use of a microplate reader.  
The Oris plate was first placed in the tissue culture hood in order to normalise the 
temperature and then the seeding stoppers placed firmly into the 96 well plate. 
Fibroblasts were then trypsinised, counted and plated at a density of 5 x 104 per well 
in 100µl. The cells were then incubated at 37ºC for 24 hours in order to allow cell 
attachment. The cell stoppers were then carefully removed, the media removed and 
then the cells washed very gently with PBS. Those wells designated t=0 were then 
fixed and imaging analysis performed. The rest of the cells were then left for 30 hours 
in order to assess cellular migration into the detection zone. After 30 hours, the cells 
were washed and then immunocytochemistry performed using according to methods 




This chapter describes the results of experiments performed to assess the transduction 
efficiency of the pCCL-PGK-COL7 vector in primary RDEB fibroblasts.  
6.3.1 The pCCL-PGK-COL7 fibroblasts express moderate amounts of type VII 
collagen 
The expression levels of C7 were assessed in pCCL-PGK-COL7 fibroblasts using 
immunofluorescence microscopy and Western blot techniques. There was a 
discernible increase in levels of C7 in RDEB fibroblasts up to 2 months post 
transduction with the pCCL-PGK-COL7 LV vector, despite cells going through at 
least five passages. There was no evidence of gene silencing up to 2 months post 
transduction. There were higher levels of C7 staining using a protocol of transduction 




Figure 6-3 Immunocytochemistry showing C7 expression in RDEB fibroblasts 
transduced with LV vector 
Primary FBs were stained with COL7A1 antibody (LH7.2 7.2  Sigma) (green), cell actin-filaments were 
stained with phalloidin (red) and cell nuclei were stained with DAPI (blue). Transduced fibroblasts 








Figure 6-4 C7 Expression in cultured fibroblast showing the effect of 
transduction with pCCL-PGK-COL7 LV vector 
Increase C7 immunolabelling is seen in cultured primary RDEB fibroblasts 2 months following 
incubation with pCCL-PGK-COL7 LV vector. (A)Primary wild type Fibroblasts, (B) Primary RDEB 
fibroblasts, (C) RDEB fibroblasts 60 days following incubation with SIN LV COL7A1 vector, 
Multiplicity of Infection = 7, (D) RDEB fibroblasts 60 days following incubation with SIN LV 
COL7A1 vector, Multiplicity of Infection = 17.4. Scale bar = 25µm.  
 
Figure 6-5 Comparison of RDEB fibroblasts before and after gene correction 
and normal control by immunofluorescence staining 
Percentage of C7 positive cells as calculated per three independent fields of 100 DAPI positive cells. 
Values expressed as mean +/- standard Deviation. A significant difference in C7 expression levels was 
seen in cultured primary RDEB fibroblasts 2 months following transduction with pCCL-PGK-COL7 
LV vector. Unpaired two-tailed Students’ t-test,  ** p<0.01 
The increased level of C7 protein in transduced cells was also demonstrated using 
Western blot assay in both keratinocytes and fibroblasts. C7 protein expression was 
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determined once sufficient cell numbers had been cultured (at least 2 x 106). C7 
represents less than 0.001% of total protein extracted from skin, and therefore it was 
not possible to detect C7 using Western blot at early stages post-transduction as 
sufficient cell numbers were required. I could therefore not compare protein extraction 
at earlier time points.  As discussed previously, keratinocytes secrete far higher 
quantities of C7 than dermal fibroblasts and therefore higher protein lysate 
concentration was required to adequately show a band corresponding to 290kD. The 
levels of protein expression were quantified using Image J software (NIH image) and 
show that transduction using pCCL-PGK-COL7 LV vector led to protein levels a more 








Figure 6-6 Detection of C7 expression in RDEB fibroblasts 
Protein was extracted from cell lysates of fibroblasts and keratinocyte cultured cells 60 days after 
transduction with pCCL-PGK-COL7 LV vector (MOI 20). 50μg of protein were subjected to 4–15% 
SDS-PAGE followed by immunoblot analysis using an anti-NC1 antibody.(A) Lane 1: Day 24 (MOI 
10) post- transduced fibroblasts; Lane 2: untransduced RDEB fibroblasts; Lane 3: day-24 (MOI 20) 
post-transduced fibroblasts); Lane 4: wild type control fibroblasts; Lane 5: untransduced RDEB 
keratinocytes,  Lane 6 and 7: day-24 (MOI 10) transduced keratinocytes, Lane 8 day 24 (MOI 20) 
transduced keratinocytes, Lane 9 : wild type control keratinocytes. Protein ladder is shown on the left 
side of the blot.  The position of full-length 290 kDa C7 and loading control marker 116kD vinculin is 
indicated. (B) The relative quantities of C7 protein in fibroblast cell cultures only (Lanes 1-4) were 
calculated using Image J software and expressed as a relative proportion. 
6.3.2 MOI of pCCL-PGK-COL7 vector  
In order to develop the most efficient transduction protocol for this cell type, optimal 
MOIs were assessed by observing fibroblast proliferation rates and assessment of cell 
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death. Based on the results outlined, it is clear that MOI > 25 leads to increased levels 
of cell toxicity and increased cell death.  
 
 
Figure 6-7 Primary RDEB Fibroblasts at Day 0 (UT), and at Day 6 post 
transduction at MOI 20 and MOI 50. 
The morphology of gene corrected fibroblasts is increasingly altered with evidence of increasing cell 
death (cell shrinkage with evidence of cellular debris) with increasing MOI
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6.3.2 Transduction efficiency assessment following gene transfer  
The transduction efficiency of viral vectors is typically assessed using qPCR methods 
in order to assess viral copy number as a percentage of cells transduced, and has been 
a validated method following gene transfer in haematopoietic stem cells (Hanawa et 
al., 2004). However, in these experiments the qPCR transduction efficiency did not 
correlate directly with the results generated using FACS analysis. Copy number 
assessment on transduced fibroblasts harvested on D3 showed only 0.009 copies per 
cell (9% transduction). Results showed reconstitution of C7 in RDEB fibroblasts 
transduced with the pCCL-PGK-COL7A1 vector with the initial transduction 
efficiency assessed using FACS analysis at ~21% at day-3 reflecting transient gene 
expression, and by 24 days, stabilising at ~9% in keeping with copy number data. 
Inaccuracies of qPCR in transduction efficiency assessment has been observed in other 
studies (Klein et al., 2000) and therefore both assays should be used to assess efficient 
gene transfer in vitro. 
Source of Fibroblasts Days post transduction Copy number 
MOI = 10 MOI = 20 
EB-CK Day 24 0.09 0.09 
EB-8 Day 24 0.071 0.088 
 
Table 6.1. Copy number assessment of primary RDEB fibroblasts following 




To further determine the level of C7 expression in transduced fibroblasts using the 
current transduction protocol I used FACS analysis to accurately count the number of 
cells expressing C7 as evidenced by staining with LH 7.2 monoclonal antibody. Flow 
cytometry performed on primary fibroblasts was assessed using the monoclonal 
antibody (LH 7.2) to the NC1 domain of the type VII collagen protein. Culture 
conditions were standardised ensuring that all cell types were at a similar passage and 
had been grown in similar conditions. Using flow cytometry, the transduction efficacy 
ranged from 18-22% at day-3 and 9-10% at day 24, with a mean pro-viral copy 
number, using qPCR, of 0.063-0.09 at day 3. 
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Figure 6-8 Flow cytometry analysis of C7 expression in pCCL-PGK COL7A1 fibroblasts compared to untransduced REB fibroblasts and wild type normal 
control fibroblasts. Gating strategy to gate fibroblasts on their FSC and SCC profile and then sequentially applied to C7+ population stained with Alexa 
Fluor 488 flurochrome correlating to FITC.    Dot plot of positive C7 populations (red dots) in un transduced or transduced RDEB fibroblasts and wild 





Figure 6-9 C7 Expression demonstrated using FACS analysis in gene 
corrected fibroblasts (RDEB-FB C7) compared to untransduced 
RDEB-FB and normal wild type fibroblasts from a healthy control 
RDEB  fibroblasts transduced with LV-COL7 vector were stained for intracellular C7 
expression 2 weeks post viral exposure. Untransduced (UT) RDEB and wild-type 
(Normal) fibroblasts representing experimental controls were run in parallel. Flow 
cytometry shows positive C7 expression in LV-COL7 transduced RDEB and WT 
fibroblasts, but not in the UT cells. Isotype staining confirmed specificity of secondary 
antibody. Triplicate values of flow cytometry data were plotted against each other. 
Error bars represent SD amongst triplicates. 
6.3.4 Functional in vitro assessment of transduced fibroblasts 
The absence of C7 at the DEJ has been associated with altered keratinocyte 
migration and invasion in vitro. C7 corrected RDEB cells show functional 
restoration in migration assays as gene corrected RDEB cells efficiently 
closed the wound as compared to null C7 RDEB cells. There have been 
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contradictory reports concerning the effect on in vitro wound closure of 
keratinocytes in the absence of C7 expression. Originally described by Chen 
et al. (Chen et al., 2000b, Chen et al., 2002a), RDEB keratinocytes (KCs) 
appear to migrate in an inverse fashion to our findings with wild type (WT) 
KCs having a lower migration index value. This observation, however, might 
be explained by different protocols, with Chen et al. (2000) coating the cell 
culture surface with type I collagen prior to seeding and performing a 
colloidal gold migration assay. My assay, on the other hand, involves 
fibroblasts in untreated tissue culture dishes cultured to confluency before 
performing the migration assay, thereby allowing for the secretion and 
deposition of extracellular matrix proteins (collagens, laminin, fibronectin). 
Nystrom et al. (2013) demonstrated a significant reduction in migration speed 
of COL7A1-hypomorphic mouse keratinocytes, expressing 10% of normal C7 
levels, when compared to wild type KCs, and similarly myofibroblast 
migration and maturation in granulation tissue was delayed (Nystrom et al., 
2013). This finding was proposed to have been mediated by a direct 
interaction of C7 with the laminin-332/integrin α6β4 complex that is known 
to influence directed/directional migration of keratinocytes (Pullar et al., 
2006, Sehgal et al., 2006, Tsuruta et al., 2011). Hence the reduced migration 
speed in the monoallelic and biallelic COL7A1 keratinocyte knockouts 
observed, can be most likely explained by aberrant laminin-332 organisation 
altering α6β4 signalling caused by the knockout and lack of C7 protein 
deposition. A similar pattern was observed in C7-deficient fibroblast cells, 
showing that C7 expression has a keratinocyte independent effect on dermal 
fibroblast migration. Based on these functional studies RDEB fibroblasts 
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(MJ-05) having undergone transduction with pCCL-PGK-COL7A1 LV were 
assessed for their ability to occupy an artificially created migration zone using 
methods previously described.  Migration data from primary RDEB 
fibroblasts taken from a patient with partial C7 expression revealed increased 
wound closure speed of Col7a1(+) RDEB transduced fibroblasts compared 





Figure 6-10 Migration of primary RDEB fibroblasts is increased 
following transduction with pCCL-PGK-COL7 LV vector. 
Primary RDEB patient (EB8) fibroblasts either untransduced or following  
transduction were assessed for cell migration. The migration zone was imaged at t =0 
and t=30. Increased migration was noted in transduced fibroblasts compared with 




6.3.5 Isolation and expansion of sufficient number of gene corrected 
fibroblasts 
My aim was to ensure that > 1 x 106 fibroblasts would be generated according 
to GMP protocol. Skin biopsies taken from patients with RDEB were sampled 
to assess optimum biopsy size. 3mm, 4mm and 6mm punch biopsies were 
taken from RDEB patients in order to harvest fibroblasts. The optimum size 
punch biopsy was 6mm, as this sample was able to generate 5.7 x 106 cells 
following vector transduction and three passages (4-5 weeks) as well as 7 x 
106 untransduced cells. In order to reduce the amount of time needed to 
expand sufficient cell numbers, I also opted to use an alternative method to 
the standard explant technique. Based on normal control skin biopsies, 
sufficient fibroblasts would only be cultured within 6- weeks. The use of 
collagenase D was shown to reduce the time to first passage compared with 
the explant technique, therefore minimising the time required within the GMP 
Cellular Therapies laboratory. The method involves digestion of the skin 
biopsy for two hours after soaking off the transport media with sterile PBS 
and peeling off the epidermis. Dissociated fibroblasts and the remaining 
dermal material are then seeded in a T25 flask 
Table 6.2 Table showing the passage of primary RDEB fibroblasts from 







Passage I Passage II Passage III 

















D10 1.2 x 
10^5 
D21 1.7 x 
10^6 





This data indicates that ex-vivo gene transfer to a modest fraction of 
fibroblasts using this vector results in high levels of C7 expression. The vector 
supports supra-normal levels of protein expression in transduced cells, as 
indicated by the high intensities of C7 detected by western blot and flow 
cytometry.  Transduction efficiency at a cellular level is usually a reflection 
of the titre of the viral vector. In this study, the titre was limited by the large 
size of transgene insert, COL7A1. Reduction was attempted by using a codon 
optimised sequence (as described) however only a titre of 1 x 107 was 
achievable. The usual titre achieved in other gene therapy clinical trials using 
LV titres is generally between 1 x 108 and 1 x 109. Lentiviral vector titre is a 
critical factor influencing transduction efficiency. In CD34+ cells 
transduction frequency is related directly to vector concentration and not to 
multiplicity of infection (Haas et al., 2000). However, the necessity for higher 
levels of transduction efficiency in this clinical scenario are debateable. It is 
known that carriers of a single COL7A1 mutations only producing 50% of 
wild type C7 levels are phenotypically normal, and therefore the level of 
protein required to maintain an intact epidermis is between 0% and 50%. 
Fritsch et al (2008) have shown that only very small increases in C7, up to 
35% of normal levels, can significantly stabilise the skin against shearing 
forces and ameliorate the phenotype of a hypomorphic mouse model of 
RDEB (Fritsch et al., 2008). A level of gene correction up to 20% of baseline 
as demonstrated in this pre-clinical study would still feasibly still ameliorate 
the RDEB phenotype.   
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Further optimisation of levels of gene correction could be achieved by sorting 
the cultured fibroblasts post transduction, selecting only the C7(+) cells for 
propagation and use in a clinical trial. This could be theoretically facilitated 
by the use of a cell surface marker, such as CD34, vimentin, collagen I, 
fibroblast surface protein or α smooth muscle actin to enable sorting using a 
magnetic labelling system, however, in order to apply to a phase I study 
further validation and safety studies repeated using this surface marker are 
necessary. 
Titeux et al (2010) have shown that rearrangements occur at both a protein 
and genomic level following transduction of both keratinocyte and fibroblast 
populations using a SIN retroviral vector with an EF1α promoter (Titeux et 
al., 2010). The clinical significance of these genomic rearrangements is 
unknown. Retroviruses are known to have a relatively high mutation rate 
contributing to their evolutionary success. Significant levels of genomic 
rearrangements are known to occur within both gamma-retroviral and 
lentiviral viruses (Jetzt et al., 2000, De Angioletti et al., 2002). The frequency 
of the mutation rate in the coding region of eukaryotic cells by retroviral 
vectors has been examined in the human glucose-6-phosphate dehydrogenase 
gene transferred by Moloney murine leukemia virus based vectors into 
murine bone marrow cells. Abnormal hG6PD variants were estimated to 
occur at a relatively low rate of 1.4 x 10-5 per base pair per replication cycle 
(De Angioletti et al., 2002). Genomic rearrangements have been shown  to 
occur in 3 out of 50 keratinocyte clones transduced using the pCCL-PGK-
COL7 vector with deletions occurring within genomic DNA leading to 
truncated C7 protein bands (F Syed, co-worker at Institute of Child Health, 
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unpublished work). Following single cell cloning the majority of transduced 
clones expressed full length C7 but ~6% had truncated versions of the protein. 
Further sanger sequencing identified 3 deletions in these clones between 
5200bp and 7900bp likely to have arisen during reverse transcription due to 
repeat sequences within the C7 gene.  The clinical relevance of a small 
percentage of truncated protein is likely to be negligible. Dominant-negative 
interference in protein expression is known to occur following heterozygous 
glycine substitutions (Fritsch et al., 2009) or exon skipping (Toyonaga et al., 
2014) of COL7A1. Mutant truncated forms of C7 due to in-frame deletions in 
COL7A1 are present physiologically in patients with RDEB with milder 
phenotypes with no evidence of protein degradation or deleterious clinical 
consequences (Terracina et al., 1998, McGrath et al., 1999). It should 
therefore be anticipated that the small percentage of gene corrected fibroblasts 
synthesising truncated forms of C7 should not impact the formation of 
anchoring fibrils or lead to worsening disease, although the efficiency of 
therapy would be enhanced with a reduction in truncated forms.  
Further concerns from a regulator’s perspective may be related to the risks of 
over-expression of the target protein. Pre-clinical studies using retroviral 
driven expression of full length C7 in cultured keratinocytes greatly exceeds 
those seen in wild type control cells (Gache et al., 2004a).  Studies assessing 
the impact of C7 over-expression are mainly concerned with the risks of SCC 
development. In vitro studies have shown that manipulation of C7 yields 
varying results depending on the cellular context and approach used (Martins 
et al., 2009, Ortiz-Urda et al., 2005). Many RDEB tumours do not express C7 
and patients can develop SCCs regardless of baseline C7 expression levels 
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(Pourreyron et al., 2007). Over-expression of C7 in dermal fibroblasts has 
been shown to reduce tumour invasion and tumour formation in RDEB 
keratinocytes (Ng et al., 2012). Studies attempting to over-express C7 in 
cultured RDEB keratinocytes (up to 35 fold) using recombinant COL7A1 
cDNA in a retroviral vector show that supra-physiological levels of C7 are 
associated with increased invasion and migration of keratinocytes in RDEB 
SCC keratinocytes, associated with an activation of the phosphoniositide 3 
kinase pathway (Pourreyron et al., 2014). However, the results of this study 
have not shown significant levels of fibroblast over-expression in gene 
corrected cells using this pCCL-PGK-COL7 LV vector. Assessment of 
cellular migration in COL7A1(+) RDEB cells did not exceed those of RDEB 
COL7A1(-) cells.  
Production and release of a clinical batch of LV-COL7A1 vector has been 
performed and demonstrated engineering of human RDEB fibroblasts under 
GMP conditions. These data have been used to support the application for 
MHRA approval for a phase 1 study. 
6.5 Summary 
This chapter summarises the preclinical data generated related to the 
transduction efficiency of the LV-COL7A1 vector in primary RDEB 
fibroblasts. 
(1) Transduction efficiency assessed using both qPCR and FACS 
analysis showed up to ~20% transduction efficiency reducing down 
to 9% at 3-4 weeks post transduction 




(3) Functional assays confirmed increased migration in transduced cell 
types 
(4) Cell toxicity was demonstrated at higher MOI (>20) 
This data was included as part of the Investigators Brochure required for the 






Protocol design for a phase I study of gene corrected 
intradermal fibroblasts in RDEB 
7.1 Introduction 
One of the main ambitions at the start of my research period was to design 
and launch a phase 1 study of autologous intradermal gene corrected 
fibroblasts in RDEB. This was following discussion and collaboration with 
Dr Waseem Qasim and Professor Adrian Thrasher at the Institute of Child 
Health. In anticipation of the pre-clinical safety data, one of my roles was to 
develop the clinical trial protocol and the practical development of the trial, 
running in parallel to the pre-clinical work. This would ensure a speedy 
application to both the ethics committee as well as the MHRA in order to take 
this forward to a human clinical trial. Applications for gene therapy clinical 
trials can be extremely protracted and time consuming and therefore this work 
running concurrently would rapidly accelerate the launch of the clinical trial.  
If successful, further systemic therapies would be planned using the same 
vector platform and could lead to new therapeutic avenues for RDEB and 
other skin diseases. 
This chapter details my work and initial protocol development for the phase 
1 study. My experience working collaboratively on developing phase 1 trials 
of intravenous mesenchymal stromal cells for children with RDEB 
(EBSTEM) as well as facilitating with a phase I trial of a gene corrected 
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epidermal graft for adults and children with Netherton syndrome aided to my 
expertise in this area.  
7.2 Study design 
The main aim was to assess whether intradermally administered self-
inactivating (SIN) lentiviral vector (LV)-mediated COL7A1 gene-corrected 
autologous fibroblasts are safe and to evaluate their potential efficacy in 
adults with RDEB. This would be a Phase 1, non-randomised, open-label, 
single-centre, proof-of-concept study.  The ideal sample size would be 10 
adult patients with RDEB, with a minimum of 5 patients. Following advice 
from our statistician, even if no subjects report side effects (0%), a sample 
size of 10 would give a 95% confidence interval of 0% to 31% (exact CI from 
Stata®. A sample of 10 could still provide reassurance that no more that 3 in 
10 subjects should experience a given side effect. Recruitment in rare 
disorders can be extremely challenging, particularly with recruitment of adult 
patients with RDEB whom have complex medical needs and often more 
significant social limitations affecting the ability to recruit to phase I clinical 
trials as compared with the paediatric population.  
As the purpose of a phase I study is the demonstration of short to medium 
term safety at both a local and systemic basis, an active comparator such as 
allogeneic fibroblasts would not be necessary. However, ideally a control of 
a presumed non-active control comparator would be used and therefore the 
study would also assess non-gene corrected autologous fibroblasts. 
Comparing two cell populations at three time points would require six 
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biopsies per patient, excluding the larger biopsy required for harvesting 
fibroblasts.  
7.3 Trial protocol 
I designed the basis for the LENTICOL study which underwent at least 3 
version changes during the research period. The design of the trial protocol 
was based on previous work performed by our group using allogeneic 
fibroblasts. Wong et al (2007) performed the first study of allogeneic 
fibroblasts injected into RDEB intact skin. This study protocol utilised three 
cell types (patients’ own autologous fibroblasts, allogeneic fibroblasts 
derived from a parent and allogeneic fibroblasts from an unrelated donor). 
Biopsies were carried out at 2 weeks and 3 months. All five subjects 
demonstrated an increase in C7 immunolabelling at the DEJ at 2 weeks after 




Figure 7-1 Fibroblast injection site map and biopsy time points 
performed by Wong et al 2007. 
Grids measuring 1cm2 were drawn onto intact, non-blistered skin of each subject. The 
baseline skin biopsy used to generate patients own autologous cells and to determine 
baseline parameters is shown. Six injections were administered as shown and biopsies 
were then taken at either at 2 weeks or 3 months.  
The study design for LENTICOL-F  is illustrated in Figure 7.2 and will utilise 
two cell types only : autologous pCCL-PGK-COL7 gene corrected fibroblasts 
(IMP) and autologous untransduced fibroblasts (control). Each study 
participant will receive three intradermal injections of each cell type on Day 
0 only. Each injection (both IMP and control) containing 0.8–1.2x10 cells 
suspended in 0.25ml of 0.9% saline, will be administered intradermally into 
separate 1cm areas of intact skin as shown on the grid map of injection sites 




Figure 7-2 Flowchart showing the planned visits and procedures for the 
first 12 months of the clinical trial 
D0= Day 0, W2 = Week 2, M3 = Month 3, M6= Month 6, M12 = Month 12, Inflam markers = 
Bloods including full blood count, urea and electrolytes, liver function tests, bone profile, lactate 
dehydrogenase, erythrocyte sedimentation rate and C-reactive protein, DIF = Direct 
Immunofluorescence, EM = Electron Microscopy, qPCR = transduction efficiency assessment of 





Figure 7-3 Planned injection site map on intact skin 
The shaded blocks show areas that will not be injected or subsequently biopsied. In order to 
ensure the grid is replicated on each visit a “tattoo” will be placed using an indelible marker 
pen in order to orientate the transparency with the gridlines. Each biopsy site will need to 
have 2 x 4mm punch biopsies taken to ensure sufficient material for IMF, EM and qPCR. 
All patients will have previous baseline values performed as part of screening.  
Subsequent biopsies would be sampled at week 2, month 3 and month 12 post 
administration and compared with baseline biopsy data. From the injection 
site skin biopsies: (1) presence of C7 protein by direct immunofluorescence 
(DIF); (2) presence of anchoring fibrils at the dermal-epidermal junction by 
transmission electron microscopy (TEM) (3) transduction efficiency using 
vector copy number assessed via qPCR. From the blood/serum: full blood 
count (FBC), urea and electrolytes (U&Es), liver function tests (LFTs), bone 
profile, lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR) 
and C-reactive protein (CRP) to assess possible systemic adverse effects and 
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a change in generalised inflammation at W2, W4, M3, M6, M9 and M12 
compared to baseline. Serum would also be used to assess ELISA and IIF in 
order to detect any potential development of EB acquisita as a potential 
adverse effect of introducing   new   C7   expression   from   the   gene-
modified   autologous   fibroblasts. ELISPOT assay  for  detection  of  B-  and 
T-cell  responses  to  the  full length  C7  will  be performed at screening, W4, 
M3, M6, M12, M24 and M36. 
Local adverse effects should be assessed by clinical reviews, medical 
photographs of the biopsy site performed at each visit as well the review of 
diary cards completed by each patient during the study. Possible systemic 
effects will be assessed by physical examination and vital signs assessment 
performed by the clinician at each visit, review of diary cards and review of 
blood analysis indicating possible systemic immune response to the IMP.  
Patients will be followed up with study interventions for a 12 month period 
and then followed up quarterly for the second year and semi-annually for the 
third year as part of routine clinical care. Previous studies approved by GTAC 
in the past 5 years have usually requested a 36 month follow-up period in 
order to ensure safety data is accurately assessed with a particular concern 
regarding possible genotoxicity. As the number of gene therapy clinical trials 
continues to increase the likely necessity for prolonged assessment periods 
may be reduced.  
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7.4 Inclusion and Exclusion criteria 
Participants of either sex (over the age of 16) would be invited to participate 
if they had a diagnosis of RDEB, based on clinical and molecular findings. 
Patients with a history of a previous SCC would be excluded due to the risk 
of harvesting dysplastic epithelium. Criteria are listed in the table below. 
 
Inclusion criteria 
• Subjects with a clinical diagnosis of RDEB as confirmed by clinical 
characteristics and mutation in the COL7A1 gene 
• Subjects who have partial or complete absence of C7 on DIF 
• Subjects whom have at least 15cm2 of intact skin on the trunk and/or 
the extremities 
• Subjects who are aged ≥ 16  
• Subjects who have voluntarily signed and dated an informed consent 
form prior to the first study intervention 
• Subjects, who are, in the opinion of the investigator, able to 
understand the study, cooperate with the study procedures, and are 
willing to be available for all the required follow-up visits 
 
Exclusion criteria 
• Subjects who have received immunotherapy/chemotherapy within 90 
days of enrolment into this study 
• Subjects with a known allergy to any of the constituents of the product 
• Subjects with known or suspected malignancy, including cutaneous 
malignancy 
• Subjects with intolerance or allergy to additional study associated 
drugs/therapies (e.g. local anaesthetics, etc.) 
• Subjects who have taken systemic antibiotics within 7 days 
• Subjects taking immunosuppressive therapy including systemic 
steroids (e.g. oral prednisolone > 40 mg for more than 1 week) within 
the 30 days of the first treatment or planning immunosuppressive 
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therapy at any time during the study. Intranasal/inhaled steroids are 
acceptable 
• Subjects who have taken any other investigational product within 90 
days prior to screening or planned use of any other investigational 
product during the study period 
• Subjects who are pregnant, planning pregnancy and women of 
childbearing potential who are not abstinent or practicing an 
acceptable means of contraception, as determined by the investigator, 
for the duration of the treatment phase 
• Subjects with active infection requiring intravenous antibiotics at time 
of recruitment or administration of the IMP 
• Subjects with positive results for blood-borne pathogens (under 
2006/17/EC) : HIV, Hepatitis B surface antigen (HepBsAg), Hepatitis 
B core antibodies (HepBcAb), Hepatitis C IgG (HepCIgG), human T-
lymphotropic virus (HTLV) and Treponema pallidum serology for 
Syphilis 
• Subjects with a known history of poor adherence/compliance with 
medical treatment or follow-up 
• Subjects who are unable to understand the aims, objectives and 
follow-up treatment 
• Subjects with known alcohol or narcotic drug dependence. 
• Subjects who have who have an immune response to C7 as 
evidenced by both 
o positive serum antibodies to C7 confirmed by ELISA or 
ELISPOT and 
o positive IIF with binding to the base of salt split skin.   
7.5 Manufacture of the IMP 
7.5.1 Isolation of primary fibroblasts from skin biopsy using digestion 
method 
A 6 mm punch biopsy is taken from a limb. The biopsy is immediately placed 
in transfer medium (DMEM/10% FCS) in a sterile bottle, kept at 40C and 
transported to the laboratory within 12 hours. After the skin biopsy is 
delivered to the laboratory, it is immediately digested with neutral protease 
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for 30mins to remove the epidermis, followed by digestion with collagenase 
NB6 for 2 hours to isolate fibroblasts incubated at 37 degrees. Following 
digestion, the solution is centrifuged at 200G for 10 minutes and the 
supernatant removed carefully and resuspended in 3 mls cell culture media 
(Dulbecco Modified Eagle Media supplemented with 10% v/v FCS) and 
plated into two T75 flasks. 
7.5.2  Subculture and storage of primary fibroblasts 
The first passage of cells will take place approximately 14 days after initial 
seeding. Each flask is washed with PBS without calcium or magnesium and 
then supplemented with 5 mls of 0.05% Trypsin/EDTA and incubated at 37̊C 
until the cells are fully detached. Equal volumes of DMEM/FCS cell culture 
media are added and the cell suspension is transferred from the flask to a 
centrifuge tube. The cell pellet is replated in a new flask for continuing culture 
and transduction. 
7.5.3 Transduction of primary fibroblasts 
After no more than 4 cell passages, a total of 10x106 fibroblasts 2ill be  
subcultured in two T25 flasks. One flask is used for generating the patient’s 
gene-modified fibroblasts and another flask is used to generate non-modified 
fibroblasts. Twenty four – forty-eight hours after seeding, cells will undergo 
one round of transduction with pCCL-PGK-COL7A1 vector. The following 
day, the media is replaced with fresh culture medium. Both transduced and 
untransduced cells are then continuously cultured until reach 80% confluence 
(approximately 5-7 x 106 cells) which takes approximately 1-2 weeks. Cells 
are trypsinised and counted 2 to 3 weeks post-transduction. 1x10 cells are 
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taken from both transduced and untransduced cells for characterising gene 
modified fibroblasts.  The assays include pro-viral copy number and C7 
expression in cells.  
7.5.4 Cryopreservation of IMP 
Harvested cells are washed and resuspended in freezing media containing 
FBS/10% DMSO. 3 vials of transduced cells and 3 vials of untransduced cells 
are frozen with 2x10 cells/cryo-vial and stored in a controlled grade -80C 
freezer. 24 to 48 hours later, cells are transferred into the liquid nitrogen 
vessel linked to a temperature monitoring/alarm system. 
7.5.5 Thawing and dispatch of fibroblasts 
Frozen transduced and untransduced cells are thawed and washed with PBS. 
Cells are resuspended in PBS and counted.   After counting, cells are re-
pelleted, and resuspended in saline with approximately concentration of 3.2–
4.8 x106  live cells/ml   0.25 ml cell suspensions containing 0.8 -1.2 x 106 cell 
count live cells are packed into each 1ml syringe capped with luer-screw. 
Three syringes are packed with untransduced cells and three syringes are 
packed with transduced cells. All syringes are clear labelled and then packed 
into a transfer container for transport at ambient temperature. 
7.6 Discussion and update 
Based on my work with the GENEGRAFT project and protocols, there were 
a number of practical limitations and considerations which have delayed the 
regulatory applications and approvals, such that almost 6 years after the 
project was started we are yet to graft the first patient (November 2016). 
Running alongside my goal was to work on the LENTICOL-F project in order 
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to ensure a gene therapy protocol using gene corrected autologous fibroblasts 
administered intradermally could be delivered in the UK in a timely way. At 
the start of my research period, I had already been in discussion with Waseem 
Qasim and Adrian Thrasher at the Institute of Child Health regarding the 
project. Their group had viral vector platform that had been approved 
previously by the MHRA for another condition (Netherton syndrome) and 
already had a grant approval for the pre-clinical work.  My goal was to design 
the clinical trial protocol in anticipation of the safety data results in order to 
take forward into a clinical trial. Based on our experiences in the preparation 
for gene therapy clinical trials, it was clear waiting for the preclinical data 
before preparing the trial application would lead to significant delays. My 
work was critical for accelerating the launch of the phase 1 trial ensuring 
sufficient data for the MHRA application including the documents required 
for the trial protocol and Investigator’s Brochure (See supplementary 
material). I was able to take lessons learnt from my experience with the 
GENERGRAFT trial as well as the EBSTEM trial and work on the Netherton 
gene therapy trial to fast track this clinical trial, anticipating potential 
problems and therefore avoiding unnecessary delays. My period of research 
was completed in January 2015, but my work ensured that the MHRA 
application was completed on the 30th March 2015 (EudraCT 2014-00484-
19), GTAC meeting was on the 20th May 2015 and the first patient was 
screened in August 2015.  
7.7 Summary 
This chapter summarises the my work on the development of  the LENTICOL 
phase 1 clinical trial in terms of early protocol design including inclusion and 
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exclusion criteria, primary endpoints and trial design. In addition,my work 
included completing the Investigator Brochure detailing the specific IMP of 
autologous RDEB gene corrected fibroblasts. These documents facilitated the 
application for the trial to both GTAC and MHRA. 
Chapter 8 
Future perspectives 
8.1 Short term goals 
The pre-clinical data in Chapter 6 and clinical trial design in Chapter 7 have 
formed the basis for the successful application of the phase 1 study of 
autologous LV-COL7A1 corrected fibroblasts injected intradermally into 
adult patients with RDEB, LENTICOL-F (NCT0493816). Three patients  
have now been recruited and administered the IMP, with data regarding the 
subsequent follow-up biopsies still pending. Skin biopsy analyses are 
ongoing. Following on from this trial, the next logical step would be to design 
a clinical trial of a systemic therapy (intravenous or intrarterial 
administration) using either fibroblasts or MSCs corrected using the same 
vector platform. The benefits of systemic therapy would be the targeting of 
multiple chronic wounds simultaneously as well as the possible benefits in 
terms of mucosal involvement that would be otherwise impossible to achieve 
with grafting or intradermal therapies alone. Intravenous administration of 
both allogeneic fibroblasts and gene corrected fibroblasts have been shown to 
home to the skin and deliver C7 to the BMZ in murine skin (Woodley et al., 
2007). Interestingly only the corrected fibroblasts over-expressing C7, but not 
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uncorrected fibroblasts, led to increased rates of wound healing.  A small 
number of fibroblasts detected in foci of lung tissue in these mice raised a 
possible safety issue (although there were no pathophysiological sequelae in 
the murine models), hence a possible consideration for intrarterial 
administration of therapies. However, data recently published showing the 
safety of intravenous MSCs in both adults and children with RDEB (Petrof et 
al., 2015, El-Darouti et al., 2016) is supportive of this modality for 
administration, and considering the patient population would be less invasive 
and easier to perform. Furthermore, the assumption would be that in 
immunocompetent patients, cells migrated to unintended sites would be 
rapidly cleared (Woodley et al., 2007).  Data from the currently active phase 
I study of intravenous allogeneic MSCs in adults with RDEB (ADSTEM 
NCT02323789) will be critical in determining which cell type should be the 
next target for gene correction and systemic administration, as it is currently 
unclear which stem cell population would be able to show the greatest clinical 
benefit in RDEB. ADSTEM is a phase I clinical trial based at GSTT/KCL 
recruiting up to 10 adult patients with RDEB and administering 3 infusions 
of allogeneic MSCs over 14 days.  MSCs in particular have been shown to 
migrate to wounded sites and contribute to tissue regeneration while also 
confer immunomodulatory properties (Fathke et al., 2004b, Wang et al., 
2014). Currently systemic delivery of MSCs are being tested in clinical trials 
in a wide variety of systemic inflammatory and autoimmune conditions that 
affect the skin, such as systemic lupus erythematosus and graft versus host 
disease, and therefore there is a significant amount of safety data using this 
as an ATMP.  In fact recently Kühl et al. found that human MSCs express 
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C7 in vitro at approximately the same level as fibroblasts (Kuhl et al., 2015); 
and that in addition to secreting C7, they are able to mobilize myofibroblasts, 
ameliorate skin inflammation, and increase skin stability.  My hope would be 
to develop a further study, LENTICOL-M, using gene corrected MSCs, in 
patients with severe RDEB and chronic wounds.  
Other considerations for the use of gene corrected fibroblasts should be in the 
development of skin bio-equivalents and grafting. RDEB patients typically 
develop multiple sites of SCCs requiring surgical excision. Diseased 
fibroblasts such as those in RDEB have been shown to promote tumour 
progression, growth and metastasis by facilitating angiogenesis at the site 
highlighting the need for their removal (Flavell et al., 2008). Fibroblasts have 
also been shown to have a role in cancer at all stages including progression 
(Ronnov-Jessen et al., 1996), growth (Dvorak, 1986) and metastasis (Schedin 
and Elias, 2004). Therefore corrected fibroblasts introduced at graft site 
would compete with diseased fibroblasts and could theoretically benefit areas 
at high risk of further dysplasia. A clinically bioengineered scaffold similar 
to Apligraf® but containing autologous gene corrected fibroblasts overlayed 
with an autologous epidermal sheet could therefore be used to “fill” the 
wound following excision of SCCs. During my research period two of the 
nine recruited patients developed new SCCs requiring grafting, and therefore 
this option could be of significant benefit for them.  
Further goals in the field would be for the implementation of the 
GENEGRAFT study, and administration of the first gene-corrected skin 
equivalent graft for a UK patient with RDEB. The EU project has faced 
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multiple challenges during this time period since the initial kick off meeting 
in May 2010. There have been issues regarding the need for GMP facilities 
required for manufacture of the stem cell therapies.  Key components of GMP 
accreditation include: (a) performance of best-practice standard operating 
procedures when conducting research; (b) research staff being trained to a 
GMP standard; and (c) the building of an accredited GMP clean room where 
air pressure, temperature and sterility are monitored (Stephens et al., 2011). 
Up until 2012 GLP practices were used and the transition to GMP facilities 
would require complete redesign and refurbishment likely to take at least 5 
years to set up. This issue as well as inordinate volumes of pre-clinical safety 
data required to satisfy the EU regulatory bodies as well as conflicts within 
the multinational group led to changes to the site of manufacture of the IMP 
from Paris (INSERM), to Modena (Centre for Regenerative Medicine, 
UNIMORE) and finally now to Madrid (CIEMAT, Centro de Investigaciones 
Energeticas , Medioambientales y Technologicas). The need to ensure that 
the skin equivalent graft would be cultured and transduced in a GMP 
approved laboratory halted the initial plans for the IMP manufacture to be 
performed in Paris.  Each transition has required repeat GMP runs and 
development of SOPs relevant to each site. This has naturally led to 
significant delays in the delivery of this clinical trial, but I would still be 
hopeful for the data generated from Chapter 3 to form the basis for patient 
selection for the study and also to have helped developed SOPs for the patient 
pathway necessary for recruitment of patients from the UK. Regarding the 
applicability of gene corrected grafts for patients with RDEB, I do envisage 
them to have a role relevant for certain patients with localised disease, 
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particularly patients with RDEB-inversa with recalcitrant, chronic wounds. 
The Stanford group have recently published their data set for 4 patients (n=24 
grafts) grafted with autologous epidermal sheets but in one individual they 
have demonstrated that multiple sites can be treated simultaneously 
(Siprashvili et al., 2016). C7 expression at the DEJ was demonstrated on the 
graft sites by immunofluorescence microscopy in 9 of 10 biopsy samples 
(90%) at 3 months, in 8 of 12 samples (66%) at 6 months, and in 5 of 12 
samples (42%) at 12 months, including correct type VII collagen localization 
to anchoring fibrils. The decline in expression is different from the outcome 
described by Mavilio et al (2006) in their case report of a grafted patient with 
JEB, and may reflect a number of factors including the enrichment of stem 
cells in culture as well as the stem cells accrued from the harvest biopsy. The 
team have highlighted the importance of post-surgical procedures and 
variability according to graft site, as predicted by the GENEGRAFT project. 
Primary RDEB keratinocytes were transduced with the LZRSE-COL7A1 
retroviral vector containing full-length COL7A1 sequence and the long 
terminal repeat promoter with a mean of 70% efficiency and 0.8 pro-viral 
genome copies per cell. Interestingly that the wound beds were not induced 
and had been present for more than 5 years. The key important outcome was 
that no serious adverse safety events were reported, and particularly there was 
no evidence of a predisposition for the development of cutaneous SCCs, 
despite the inclusion of patients without a previous history of SCC. However, 
long term follow-up will be critical over the next 5 years to ensure a lack of 
oncogenic potential with this therapy. Immune response to the graft was not 
clinically relevant in all 4 of the treated patients, however all selected patients 
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expressed a non-functional truncated C7 protein containing the NC1 domain. 
Despite the lack of clinical sequalae, transient circulating antibodies were 
detected in 3 of the 4 patients using indirect immunofluorescence using 
patients’ serum. In fact, one patient had a previous positive IIF result (only 
detected retrospectively) highlighting again that a higher than expected 
number of patients who express non-functional C7 protein may have pre-
existing circulating antibodies but this may not necessarily lead to a negative 
clinical outcome.  
Professor Johan Bauer’s group in Austria have also demonstrated the 
applicability of grafting method in two patients with JEB (Murauer et al., 
2015). A patient with JEB was selected in Salzburg, a skin biopsy sent to 
Modena for transduction and culture. Five skin sheets each measuring 5 × 7 
cm, were grafted onto wounded areas on the patient’s thighs. The one year 
followup has yet to be published but initial data presented at DEBRA 
International 2015 showed normal appearing skin at the graft site with no 
reported adverse effects. One patient with JEB and coincidental 
Staphylococcus Scalded Skin Syndrome was also treated with widespread 
grafting of genetically corrected epidermal sheets under a Specials license, 
with an extremely favourable outcome although the long-term data has not 
been presented (J.Bauer, British Association of Dermatology meeting 2016). 
I strongly believe that as long as the long term safety data is assured, this 
approach will have an important role to play in the management of chronic 
wounds in a subset of patients with RDEB.  
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8.2 The future for cell and gene therapies for RDEB 
Gene therapy for RDEB is an expanding phase of development. Exciting 
advances in gene editing approaches, circumventing and minimising the 
theoretical risk of insertional mutagenesis. Furthermore, gene editing would 
also overcome the obstacle of delivering full length cDNA or potential 
complications arising from transgene over-expression that could contribute to 
C7 mediated fibrosis.  As the molecular tools available are still in their 
infancy one would expect significant advances to be made through increased 
efficiency and improved safety profile. 
The ultimate therapy for RDEB would be a combination of gene, cell, protein 
and drug therapies tailored according to the individual patient. Gene therapy 
clinical trials for RDEB have thus far focused on gene replacement using 
integrating viral vectors. Future directions will likely develop and build upon 
the current wave of phase 1 studies into phase II studies utilising cell types 





Figure 8-1 Combination therapy for RDEB 
Adapted from Wagner and Tolar, New England Journal of Medicine (2015). RV = 
retroviral vector, LV = lentiviral vector, ZFN = Zinc finger nucleases, TALEN = 
Transcription activator-like effector nucleases, CRISPR = Clustered Regularly 
Interspaced Short Palindromic Repeats 
Bone marrow transplant is still a consideration for patients with severe RDEB 
and reduced intensity conditioning regimens are continuing, particularly in 
the USA. Geyer et al (2015) published further data on 2 children with RDEB 
treated with a reduced intensity regimen using busulfan, fludarabine and 
alemtuzamab followed by HLA matched unaffected sibling-donor 
unmanipulated bone marrow haematopoietic progenitor cells (HPC) (Geyer 
et al., 2015). Although the regimen is safer than the full intensity approach, 
the duration of effect on skin fragility and blistering appeared to be short term 
in these cases and COL7A1 mRNA level levels were not sustained. 
Furthermore, the risks of giving allogeneic BM stem cells are still significant, 
particularly in a population with far higher premorbid state and with higher 
chances of developing severe, systemic infections. Recently there has one 
case of Toxic Epidermal Necrolysis (TEN) which developed following a 
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myeloablative allogeneic unrelated-donor 8/8 HLA-matched BMT and 
concurrent allogeneic marrow-derived MSC infusion (Boull et al., 2016). 
Given these risks, gene corrected autologous transplant of HPC should be the 
next approach.   
Further studies using placental based cell therapies are also underway. In fact, 
umbilical cord blood (UCB) has several potential advantages over bone 
marrow (BM), including decreased collection risk to the donor compared with 
the harvesting of BM, decreased risk of infection transmission from donor to 
patient, a need for less stringent human leukocyte antigen (HLA)-matching 
requirements and an overall lower risk of graft-versus-host disease (GVHD) 
(Nevala-Plagemann et al., 2015). Cord blood banks are increasingly available 
and more than 20,000 CB transplants have been carried out worldwide. 
However, comparison of umbilical cord cells versus BM stem cells in 
individuals with RDEB has shown better skin engraftment with a BM-derived 
population (Tolar and Wagner, 2012).  
An additional population of stromal stem cells that can be found in UCB are 
known as unrestricted somatic stem cells (USSCs) (Kogler et al., 2004). 
Recent, pre-clinical data have shown that unrestricted somatic stem cells can 
express C7 and accelerate wound healing, including improving the quality of 
wound healing, as evidenced by formation of new skin appendages (Liao et 
al., 2014).  
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8.3 Future gene editing strategies 
Since commencing this period of research the field of gene editing has 
accelerated with exciting developments. In particular, the ease with which 
CRISPRCas9 and TALENs can be configured to recognize new genomic 
sequences has driven a revolution in genome editing. Subsequent to this thesis 
there have been clinical trials using gene editing platforms. Tebas et al (2014) 
treated 12 patients with HIV in an open label study using a single dose of 
CCR5 ZFN modified autologous CD4 T cells. The infusion of autologous 
CD4 T cells in which the CCR5 receptor had been rendered dysfunctional by 
ZFNs targeting CCR5 were generally safe, with only one transfusion reaction 
noted.  
In addition targeted nucleases can be combined with viral vectors, such as 
AAV vectors, to mediate genome editing in situ. In vivo genome editing has 
recently enabled the restoration of dystrophin gene expression (DST) and the 
rescue of muscle function in mouse models of Duchenne muscular dystrophy.  
Despite these exciting advances there still are a number of hurdles to 
overcome, such as the development of methods that can facilitate nuclease 
delivery or expression to only diseased cells or tissues, and the development 
of new strategies that can enhance HDR in disease-associated postmitotic 
cells in vivo.  
8.4 Limitations and potential obstacles 
In the design and implementation of clinical trials, the demonstration of 
clinical need and pre-clinical supportive data may actual be the least of the 
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potential challenges. In rare diseases such as RDEB, one of the critical aspects 
is patient recruitment. Based on my experiences within the field, this is 
particularly applicable to the recruitment of adult patients. Within the UK 
there are only four tertiary centres with multidisciplinary teams dedicated to 
the care of adult patients with RDEB: Guys and St Thomas’ NHS Trust in 
London, Birmingham, Solihull and Edinburgh. Recruitment for studies 
requiring 5 or more patients may require involvement of multiple centres, and 
therefore requiring multiple Site Specific R+D applications. Identification of 
patients most suited for enrolment may also be problematic as in a number of 
cases mutation analysis and baseline skin biopsy specimens have either not 
been performed or had been archived. Access to patient data outside of GSTT 
would be prohibited and only available to those holding honorary contracts 
within each trust. Another challenge I had come across during patient’s 
selection studies has been patient engagement with clinical trials, and those 
involving gene therapy clinical trials in particular. Anecdotally, gene therapy 
was either poorly understood or terrifying for the individual and family. Cell 
therapies such as allogeneic fibroblast or MSC therapies were easier to 
conceptualise, and discussion of the theoretical unknown oncogenic potential 
of gene therapy to a cohort of patients with marked anxiety regarding the 
development of SCC was challenging. These experiences led to my desire to 
explore these opinions objectively and hence I conducted the survey detailed 
in Chapter 5. Interestingly over half of those questioned in the survey would 
consider taking part in a gene therapy clinical trial in the future and similar 
numbers would consider intradermal injections as well as a genetically 
corrected graft. This was wholly unexpected, in particular as these patients 
204 
 
have a chronic, debilitating disease which is characterised by hours of painful 
dressing changes required on a daily basis. One would assume that 
performing painful invasive procedures such as intradermal injections into 
chronic wounds or skin grafts would be intolerable. The unexpected 
enthusiasm in over 50% pf patients for these trials indicates the level of 
desperation and desire for a possible cure.  
Despite these findings, recruitment adult RDEB patients into clinical cell and 
gene therapy clinical trials using GSTT as the sole centre is challenging. 
Patients with RDEB have multiple medical issues and are often chronically 
sick. Adult patients also have far more complicated social issues that may 
limit involvement in clinical trials. The majority of the patients recruited to 
the EBGen study also live outside of London, and therefore the necessity for 
each study visit needs to be carefully considered, and where possible study 
visits need to be tied in with routine clinical care. Options for data collection 
via patient reported outcomes via electronic patient diaries should be used.  
There are also challenges within such a small cohort of patients as there may 
be more than one clinical trial occurring concurrently, with both the patient 
and researcher required to determine the most suitable patient for each study.   
The challenges faced in recruitment of adult patients has been in stark contrast 
to my experience within the EBSTEM study performed in a paediatric 
population, in which families were highly motivated and driven to take part. 
It could be argued that trials in children, before the irreversible contractures 
and scarring had occurred, should be the main focus for future studies.  
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Furthermore, the exclusion of patients with a previous squamous cell 
carcinoma depletes numbers of potential adult participants significantly. 
During the last year alone, seven diagnoses of SCC occurring in patients with 
no previous malignancy has been noted at GSTT. In my view the necessity 
for exclusion of these patients in phase 1 studies of gene therapy is still 
important. Perhaps the results of initial studies and assessments of off-target 
genomic analysis at graft sites would provide sufficient safety data to inclue 
those with a previous history of SCC, the difficulty then being for the clinician 
to identify suitable areas with no evidence of dysplasia for harvesting skin 
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Appendix 1. Results of open-ended questions from RDEB patient survey 
QUESTION RESPONSE 
BASED ON YOUR CLINICAL 
TRIAL EXPERIENCE, COULD 
YOU DEFINE WHAT IS A 
POSITIVE OR NEGATIVE 
CLINICAL TRIAL EXPERIENCE? 
“All I can remember is I’ve never had any result that actually helped me for future” 
“Positive: The researcher explaining the process clearly, but in line with the persons' intellect; don't speak 
down to anyone, but don't use language that only fellow scientists would understand. Build a rapport. If there 
will be pain as part of the trial, the patient needs to feel safe with you, and creating even a basic friendship 
will help that. When the treatment is being given, allow the patient to react as they need to. Don't laugh or 
scold, unless they are aiming curse words etc at you. Don't rush through administering the treatment, 
particularly if it involves pain. Allow time for the patient to take a breath, and ready themselves again. Keep 
them up to date on results from the trial. That is the experience I had, and it was wholly positive. A negative 
experience would simply be the opposite of the above to me. 
“Positive in the sense one always hopes that the trials will be of benefit to sufferers, whether that be me 
personally or others in the future” 
“positive would be constant contact throughout and for one month after it finishes to check if your still okay. 




“Wound healing is great but pain is unbearable while the injection. Although worth it would do it again.” 
CAN YOU EXPLAIN YOUR 
ANSWER (REGARDING 
PARTICIPATING IN GENE 
THERAPY CLINICAL TRIAL”AND 
GIVE REASONS WHY YOU 
WOULD OR WOULD NOT TAKE 
PART ? 
“I have had a lot skin grafts since i was a young child as i have had many hand surgery's. they took the skin 
graft from my thighs. as for genetically corrected cells, i have never had and to be honest i'm unsure of having 
that as i don't know much about it or have much experience with it” 
“I have wounds that are so painful, they directly inhibit my ability to live the best life I can. The life I used to 
have. Also, our researchers have worked so hard to reach this type of gene therapy, it would be folly to want 
treatment, but refuse to try them. Im more than happy to help find out if this would work, and how well.” 
“I would consider it as I want to try to heal myself and hopefully others with rdeb” 
“…I am keen and willing to support any initiatives that may be of benefit, be that for me 'today' or others in 
the future.” 
“I know it's not a cure yet but if one piece of skin is corrected maybe with more trials more of my affected 
skin can be corrected” 
“Having had my hand operated on and a skin graft done on my leg to provide the skin for my hand, I can see 
the negative effects the procedure can create on the donor site and also issues that can arise with the newly 
placed skin.” 
“It seems more invasive than the previous option I would like to know more about what this goes to achieve, 
if it's long-term” 
“I have already had a biopsy taken for this” 
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Appendix 2. RDEB patient survey on gene therapy 
This survey is about gene therapies for the condition Recessive Dystrophic Epidermolysis Bullosa. 
Considerable progress is being made in the search for effective treatments for EB, with early stage 
clinical trials in progress or planned for several therapies. Our department would like to find out about 
patients’ own understanding of gene therapy and willingness to take part in future related clinical 
trials and studies.  
The results will help clinical researchers design better clinical trials for RDEB that will hopefully lead 
to new and more effective treatments. 
The results of the survey will be confidential and anonymous. Your responses will not affect your 
regular clinical care. 
The survey should take no more than 10 minutes to complete. 
First a little bit about you... 
1.How old are you? 
a) 16-30 
b) 31-50 
c) > 50  
2.Are you male or female – please indicate below? 
a) Male 
b) Female 
3. Have you been diagnosed with Recessive Dystrophic Epidermolysis Bullosa? 
a) Yes 
b) No 
4. Have you ever taken part in a clinical trial? 
a) Yes 
b) No 
If Yes do you have any comments on your experience with the clinical trial, both positive and 
negative (Free text) 
4. Have you heard of a new treatment for RDEB called “gene therapy”? 
a) Yes 
b) No 




5. Gene therapy is the correction of a disease by genetic modification of a person’s own cells. This 
would be introducing a ‘good’ gene into the patient’s cells to treat the disease, but it won't change the 
chance that the disease will be passed on to the patient's children. A patients’ own skin cells would be 
first collected via a skin biopsy* and grown in a lab. After replacement with the missing gene, the 
skin cells can then be given back to the patient. There are a few methods of giving these cells back to 
the patient, such as an injection into the skin or even growing the skin cells into a sheet of skin which 
could be placed directly over a wound. 
(*) A skin biopsy is a procedure taking a small piece of skin the size of a 5p piece. This is done 
under a local anaesthetic so that the area is numbed beforehand. One stitch is usually all that is 
required to close the wound. 
6. Would you consider having a skin graft* of genetically corrected cells? 
(*) A skin graft is a piece of skin usually measuring 5 x 5 cm which can be attached to a wounded 




If not then why not? 
Free text 








9.Would you be willing to have a skin graft of an area of your body that was chronically 






10.Would you consider having an injection (*) of genetically corrected cells into a wound? 




11. If not then why not? 
c) Maybe 
12. Currently most planned clinical trials using gene therapy are able to treat localised areas 
rather than the whole body at once. Is there a specific wound or area that you would be keen to 
have treated first? 
a) Yes 
b) No 
If yes please list the areas and order of preference (top 3) 
13. As RDEB is a rare disease, many research centres are now collaborating in order to 
maximise the potential of treating patients. Would you be willing to travel abroad to receive a 
treatment such as an injection of cells into the skin or a skin graft? 
a) Yes 
b) No 
If so would you be willing to travel outside of the EU? 
a) Yes 
b) No 









Appendix 3. Birmingham Epidermolysis Severity Score  
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